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Due to reports of significant adverse events, the U.S. FDA placed a Boxed Warning on the opioid 
codeine in February 2013 – contraindicating its use in pediatric patients undergoing 
tonsillectomy and/or adenoidectomy.  Studies conducted in privately insured children showed a 
reduction in codeine prescribing and a slight increase in alterative opioid prescribing following 
the FDA warning, yet the extent to which the FDA warning impacted prescribing in publicly 
insured children is unknown. Using a quasi-experimental interrupted time series design, this 
study evaluated codeine and alternative opioid prescribing before and after the FDA warning in 
both publicly and privately insured children and compared prescribing between groups. Data on 
5603 children undergoing tonsillectomy and/or adenoidectomy at Oregon Health and Science 
University from 2010 – 2018 was analyzed via segmented regression analysis. Findings suggest 
codeine and alternative opioid prescribing decreased in both groups after the FDA warning and 
prescribing was comparable between groups. There was no difference in the mean level (p = 
0.664) or pre-post intervention slopes (p = 0.383) of codeine prescribing and no difference in the 
mean level (p = 0.103) or pre-post intervention slopes (p = 0.088) of alternative opioid 
prescribing between groups. Additional findings of interest included the effect of age, procedure 
 
 
indication and body habitus on opioid prescribing. Of these, young age appeared to influence 
opioid prescribing to the greatest degree. Results of this study indicate codeine and alternative 
opioid prescribing decreased after the FDA warning and prescribing did not appear to differ 
based on health insurance status, though clinical factors appeared to influenced prescribing. 
 
Keywords:  pediatric, tonsillectomy, FDA warning, codeine, opioids, health insurance, 
interrupted time series
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Chapter 1: Introduction 
 
Study and Chapter Overview 
 
The purpose of this study is to evaluate opioid prescribing in pediatric post-tonsillectomy 
and/or adenoidectomy patients before and after the U.S. Food and Drug Administration (FDA) 
Boxed Warning on the opioid codeine, formally published in 2013. This study will seek to assess 
the impact of the FDA warning on opioid prescribing behaviors in children who underwent 
tonsillectomy and/or adenoidectomy and examine if prescribing behaviors were influenced by 
health insurance status. Study results will assess the effect of the FDA warning on codeine 
prescribing, add additional knowledge on prescribing patterns of alternative/non-codeine 
containing opioids and help fill a gap in the literature concerning opioid prescribing behaviors in 
publicly and privately insured pediatric post-tonsillectomy and/or adenoidectomy patients.  
This chapter provides a brief background on opioid use in pediatric tonsillectomy and/or 
adenoidectomy patients and includes a statement of the problem. The study’s purpose and 
significance are summarized, followed by brief introductions to the study’s theoretical 
framework and methodology. Chapter one concludes with an overview of the remaining 
chapters. 
Background 
 
Tonsillectomy, with or without adenoidectomy, is one of the most commonly performed 
pediatric surgical procedures in the United States (U.S.), with more than 530,000 performed 
annually in children less than 15 years of age (Baugh et al., 2011). It represents the second most 
common and ninth most cumulatively expensive reason for care in U.S. children’s hospitals 
(Keren et al., 2012).  Though the procedure and care of a patient undergoing tonsillectomy 
 
 2 
and/or adenoidectomy is fairly routine, risks do exist – as summarized in Table 1. In particular, 
children who suffer from sleep-related breathing disorders have a higher preponderance of 
complications (De Luca Canto et al., 2015; Goldman et al., 2013; Mitchell et al., 2019). 
Obstructive sleep apnea (OSA) belongs to the continuum of sleep-related breathing disorders and 
is a common indication for tonsillectomy and/or adenoidectomy. In fact, of the 530,000 pediatric 
tonsillectomies performed annually, 75% are related to OSA (Patino, Sadhasivam, & Mahmoud, 
2013; Roland et al., 2011).  
Table 1 
Risks and Complications of Tonsillectomy and/or Adenoidectomy 
Operative Risks Postoperative Complications 
-Trauma to surrounding tissues (teeth, tongue, 
pharynx, soft palate, pharyngeal wall, carotid 
artery) 
-Infection 
-Airway fire/endotracheal tube ignition 
-Difficult intubation* 
-Laryngospasm 
-Laryngeal edema 
-Respiratory compromise** 
-Cardiac arrest 
-Death or anoxic brain injury** 
-Respiratory compromise/apnea*/** 
-Post-tonsillectomy bleeding/hemorrhage*** 
-Nausea/vomiting 
-Pain 
-Dehydration 
-Post-obstructive pulmonary edema 
-Aspiration pneumonitis 
-Death or anoxic brain injury** 
Note: *Higher in children with obesity. **Higher in children with OSA. ***Higher in children 
without OSA 
Information from: (Cote, Lerman, & Anderson. B., 2018; De Luca Canto et al., 2015; Goldman 
et al., 2013; Mitchell et al., 2019; Statham & Myer, 2010) 
 
OSA has become a major public health concern. Its incidence and severity in the 
pediatric population have increased, in large-part due to the rising rates of childhood obesity 
(Marcus et al., 2012; Patino et al., 2013). In the past, a ‘watchful waiting’ approach was taken for 
pediatric OSA management. However, when early tonsillectomy was compared with ‘watchful 
waiting’ care in randomized controlled trials (RCT), children receiving the surgical intervention 
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showed reduction of OSA symptoms, normalization of polysomnography (PSG) sleep-study 
indices and improved quality of life (Garetz et al., 2015; Goldstein et al., 2004; Marcus et al., 
2013). A recent Cochrane Database Systematic Review demonstrated high-quality evidence that 
early tonsillectomy improved PSG indices and moderate-quality evidence that OSA symptoms, 
quality of life and behavior are improved with early tonsillectomy (Venekamp et al., 2015). 
Currently, if a child meets criteria for OSA and does not have a contraindication for surgery, 
tonsillectomy is recommended as the first-line treatment (Marcus et al., 2012). If left untreated, 
the disorder can be associated with significant morbidity, including long-term cardiopulmonary 
sequela (Patino et al., 2013).   
The tandem rise in early surgical intervention and the growing number of children 
suffering from obesity and OSA has created the “perfect storm” where perioperative 
complications, particularly respiratory adverse events, are more likely to occur (Coté, Posner, & 
Domino, 2014; Marcus et al.,, 2012; Patino et al., 2013).  Many of these complications are 
related to medications that depress the respiratory drive, such as opioids. Opioids exert their 
action on the µ-receptors, which are located throughout the central nervous system and, to a 
lesser extent, in the periphery (Pathan & Williams, 2012). Agents that bind to these receptors 
cause analgesia – but also other unwanted effects, namely sedation and respiratory depression. In 
children with OSA, these effects are markedly increased due to greater opioid-related sensitivity 
(Marcus et al., 2012; Patino et al., 2013). Opioids exacerbate pharyngeal collapse, worsen OSA 
symptoms and can lead to significant complications, including respiratory adverse events or 
death (Coté et al., 2014). Such complications represent major limitations to the use of opioids in 
children with OSA. 
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Additionally, genetic variations in opioid metabolism further amplifies the risk of opioids 
in children undergoing tonsillectomy and/or adenoidectomy. The role of genetic phenotypes and 
polymorphisms are known to create noticeable differences in inter-individual drug metabolism. It 
is well established that pharmacogenetics was a contributing factor in several codeine-related 
adverse events, yet the extent to which pharmacogenetics play a role in the clinical response to 
other opioids is not fully elucidated (Parikh, Amolenda, Rutledge, Szabova, & Chidambaran, 
2019). Still, it appears as though there is interplay between genetic risk signatures and clinical 
risk factors in opioid-related adverse events in children undergoing tonsillectomy and/or 
adenoidectomy (Biesiada et al., 2014) – furthering the conditions that generate the “perfect 
storm” of complications. 
The safety of opioids in children undergoing tonsillectomy and/or adenoidectomy came 
under intense scrutiny after several unfortunate events and poor outcomes.  For decades, 
providers prescribed the opioid codeine for post-tonsillectomy and/or adenoidectomy pain – 
however, death and/or serious adverse events were reported after administration of codeine in 
some children (Cote et al., 2014). A review of cases reported to the U.S. Food and Drug 
Administration's (FDA) Adverse Event Reporting System between 1969 and 2012 identified 10 
deaths and 3 overdoses in children who had undergone tonsillectomy and/or adenoidectomy and 
were treated with codeine – 8 of which were attributed to OSA related opioid sensitivity and/or 
genetic variants leading to rapid metabolism of codeine (Coté et al., 2014; Kuehn, 2013; Tobias, 
Green, & Coté, 2016). Subsequently, the FDA contraindicated the use of codeine in all children 
undergoing tonsillectomy by placing a Boxed Warning – the FDA’s strongest warning – on the 
drug (Kuehn, 2013). Specifically, the 2013 FDA warning advised health care professionals “to 
prescribe an alternative analgesic [to codeine] for postoperative pain control in children 
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undergoing tonsillectomy and/or adenoidectomy” (U.S. FDA Drug Safety Communications, 
2013).  
Encouragingly, two recent analyses found a significant reduction in post-tonsillectomy 
and/or adenoidectomy codeine prescribing following the FDA warning, with a slight increase in 
prescribing of alternative opioids (Chua, Shrime, & Conti, 2017; Van Cleve, 2017). These 
authors, and others, have made meaningful contributions to the literature regarding post-
tonsillectomy codeine and opioid prescribing patterns – however, important gaps in knowledge 
remain. 
Gaps in Knowledge 
 
One considerable limitation to recent work in the field is the population of interest.  Rates 
of tonsillectomy and/or adenoidectomy are similar for children insured by Medicaid compared 
with those insured by private sources (Boss, Marsteller, & Simon, 2012) – though, to date, all 
relevant studies have examined post-tonsillectomy and/or adenoidectomy codeine and opioid 
prescribing in privately insured children. Knowledge of post-tonsillectomy prescribing practices 
in publicly insured children is unaccounted for. Though it is difficult to tell whether patients with 
different types of insurance are treated equally, differences in the medical treatment of publicly 
insured children and/or those of low socioeconomic status (SES) versus privately insured 
children are suggested (Alexander & Currie, 2017; Boss et al., 2015; Canino et al., 2010; 
Sabharwal, Zhao, McClemens, & Kaufmann, 2007). Specifically, differences in opioid 
prescribing in publicly versus privately insured children are documented. A recent study showed 
pediatric patients with public insurance were more likely to receive an opioid after surgery than 
those with private insurance (Donohoe, Zhang, Mensinger, & Litman, 2019). However, other 
studies demonstrate that children with private insurance were prescribed more opioids than their 
 
 6 
publicly insured counterparts in non-surgical settings (Groenewald, Rabbitts, Gebert, & Palermo, 
2016; Tomaszewski, Arbuckle, Yang, & Linstead, 2018). Though the evidence is mixed, these 
findings suggest it is plausible that codeine and/or opioid prescribing differs between publicly 
and privately insured children undergoing tonsillectomy and/or adenoidectomy.  
The reasons underlying potential prescribing differences in post-tonsillectomy children 
are likely subtle and complex. Prescribing decisions may be related to potential implicit or 
explicit bias based on certain patient characteristics (Donohoe et al., 2019; Sabin & Greenwald, 
2012). These attitudes and beliefs may subtly and unintentionally contribute to disparities in 
prescribing practices. Prescribing decisions may also be explained from a clinical perspective. 
Providers may prescribe less opioids in publicly insured children due to the higher prevalence of 
certain comorbid conditions in this patient population. Children of lower SES (viewed as a proxy 
for public insurance) have an increased prevalence of obesity and sleep-related breathing 
disorders, such as OSA (Boss et al., 2012; Dudley & Patel, 2016). Given the dangers of the 
combination of opioids, obesity and OSA, it is reasonable to hypothesize that providers are more 
cautious in prescribing opioids (e.g. prescribe less opioids) to a population of children with a 
higher prevalence of these disorders. On the other hand, there is a negative association between 
SES and pain prevalence in pediatric post-tonsillectomy children, where those with lower SES 
appear to have a higher pain prevalence. This is evidenced by higher rates of emergency room 
revisits for pain after tonsillectomy in children with decreasing median incomes (Bhattacharyya 
& Shapiro, 2014). To avoid increased health care utilization (emergency room revisits), 
providers may prescribe more opioids to those with public insurance.  
The combination of recent studies documenting differences in opioid prescribing in 
publicly and privately insured children, potential provider biases and clinical explanations for 
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prescribing differences give reason to believe codeine and/or opioid prescribing may differ in 
public and private pediatric post-tonsillectomy patients.  
Problem Statement 
 
Due to its well-documented safety issues, the opioid codeine is contraindicated in all 
children undergoing tonsillectomy. It appears that as a result of the FDA warning, codeine 
prescribing rates have fallen in privately insured U.S. children, with a slight (non-significant) 
increase in alternative opioid prescriptions. Yet, it is unknown to what extent the FDA warning 
impacted codeine and alternative opioid prescribing rates in publicly insured children – and if 
prescribing rates differ between publicly and privately insured children.   
Study Purpose and Research Questions 
 
The purpose of this study is to investigate the relationship between the FDA warning and 
codeine/alternative opioid prescribing in publicly and privately insured children who underwent 
tonsillectomy and/or adenoidectomy at Oregon Health and Science University (OHSU) between 
2010 – 2018. Successful completion of this study will help clarify the impact of the FDA 
warning and compare prescribing rates of codeine and alternative opioids between publicly and 
privately insured children. This study will seek to answer two questions:  
(1) What is the relationship between the FDA warning and codeine/alternative opioid 
prescribing in children who underwent tonsillectomy at Oregon Health and Science 
University (OHSU) between January 2010-December 2018?  
(2) Does the relationship between codeine and/or alternative opioid prescribing in 
pediatric post-tonsillectomy children who underwent tonsillectomy at OHSU between 
January 2010 and December 2018 vary by health insurance status? 
Study Significance 
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 This study examines the significant clinical dilemma of opioid prescribing in children 
undergoing tonsillectomy and/or adenoidectomy. The study will illuminate the impact of the 
FDA warning on codeine and alternative opioid prescribing rates in pediatric tonsillectomy 
and/or adenoidectomy patients and generate new knowledge by evaluating the problem in the 
context of an understudied population. Publicly insured children, who share similar rates of 
tonsillectomy and/or adenoidectomy as their privately insured counterparts, have largely been 
left out of the body of relevant research. Inclusion of health insurance status as an indicator of 
opioid prescribing rates is substantiated by recent work in the field where certain subgroups of 
patients, including publicly insured children, were more likely to be prescribed opioids after 
surgery (Donohoe et al., 2019). Importantly, this study will contribute a meaningful comparison 
of prescribing rates in publicly versus privately insured post-tonsillectomy children – an analysis 
that has not been undertaken to date. 
Finally, this study advances the body of research in that the implications of codeine 
substitution remain unclear. In the ‘no-codeine’ era, prior studies demonstrated a slight, non-
significant increase in alternative opioid prescribing (Chua, Shrime, & Conti, 2017; Van Cleve, 
2017). Because clinical and genetic risk factors may play a role in both codeine and non-codeine 
opioid related adverse events (Biesiada et al., 2014), it is important to further the understanding 
of codeine-substitution and alternative opioid prescribing rates.  
Introduction to Theoretical Framework 
 
The Donabedian model will serve as the theoretical framework for the study.  
Donabedian’s landmark article proposed three domains in which the quality of medical care can 
be assessed – structure, process and outcome (Donabedian, 1966/2005). The assumption of the 
model is that “good structure increases the likelihood of good processes, and good processes 
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increase the likelihood of good outcomes” (Donabedian, 1988, p.1145). In this study, the 
structure arm of the triad will be the FDA warning; the process arm will be codeine/alternative 
opioid prescribing practices before and after the FDA warning and the outcome will be the 
number of codeine/alternative opioid prescriptions prescribed.  
Emphasizing the need to account for a patient’s environmental and/or personal 
characteristics, Donabedian’s model was later modified by Coyle & Battles (1999) to include 
antecedent conditions. Antecedent conditions are individuals’ personal and environmental factors 
that may influence outcomes of care.  Socioeconomic factors, including health insurance status, 
have been described as pertinent antecedents to quality health care (Coyle & Battles, 1999) –
providing justification to include health insurance status as antecedent in this study.  
The linkage in this study is: The FDA warning (structure) will lead to a change in 
prescribing practices (process) and influence the number of codeine and alternative opioid 
prescriptions (outcome). Health insurance status (antecedent) may affect the number of codeine 
and alternative opioid prescriptions. The theoretical model and linkage will be further explored 
in Chapter Two. 
Assumptions 
 
The primary assumption in this study is that prescribing providers are aware of the FDA 
Boxed Warning on codeine. This assumption can be justified by reviewing the study site’s drug 
formulary, which clearly restricts the use of codeine in children < 18 years of age (Lexicomp 
Drug Formulary, n.d.). There is also an underlying assumption that the FDA warning for codeine 
in tonsillectomy and/or adenoidectomy will remain in effect. Given the well-described dangers 
of codeine in children and the various worldwide agencies recommending against the use of 
codeine in children (FDA, American Academy of Pediatrics, World Health Organization 
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(WHO), United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA) 
European Medicines Agency (EMA) and Health Canada (Tobias et al., 2016)), this assumption 
can be justified. It is also assumed that no opioid-drug shortages occurred during the study 
period.  
Delimitations 
 
The time-frame of this study is limited to 2010-2018. The starting year (2010) is 
consistent with prior studies (Chua et al., 2017; Van Cleve, 2017) and will provide data for three 
consecutive years prior to the 2013 FDA Boxed Warning on codeine. In addition, the data source 
(discussed below) is expected to yield complete, electronic data for the entire study interval. 
Next, the study sample includes those children who receive care at OHSU and have public or 
private insurance. Given federal, state and/or organizational medical assistance programs, very 
few children undergo surgery uninsured at OHSU. In 2016, the proportion of uninsured children 
in the U.S. was < 5% and in the state of Oregon this percentage is even lower at 3% (Child 
Trends, 2017; Oregon Health Authority, 2017). Because inclusion of uninsured children would 
lead to substantially unequal study groups, uninsured children will not be included in the 
statistical analysis of the health insurance subgroup. Also, children who require post-
tonsillectomy and/or adenoidectomy inpatient admissions (planned or unplanned) will be 
excluded from the study. An inpatient admission allows for greater patient monitoring 
capabilities (e.g. pulse oximetry and regular, prescribed bedside monitoring by staff), which may 
increase the propensity for a provider to prescribe post-tonsillectomy and/or adenoidectomy 
opioids.  
A Brief Overview of Methodology  
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Research design 
 
This study will employ a quasi-experimental, interrupted time-series design with data 
analyzed via segmented regression analysis. Interrupted time-series analyses are the standard for 
evaluation of policy actions and segmented regression analyses allow for pre-and post-
intervention comparisons (Polit & Beck, 2017). Because this study aims to assess the impact of 
the FDA warning on pre-and post-FDA warning prescribing practices, this analysis is ideal to 
address the research questions.  
Summary of data source 
 
Data from this study will be extracted from OHSU’s electronic health record (EHR) 
EPIC Hyperspace® platform. The outpatient EPIC Hyperspace® platform was fully integrated 
into OHSU in 2008. Thus, the data source is expected to yield full and accurate data.  
Definition of Terms 
 
• Child/children: An individual under the age of 18 years of age (Oregon Laws Legal 
Dictionary, 2017). 
• Food and Drug Administration Boxed Warning: Denotes labelling on prescription drugs that 
have serious or life-threatening risks; also known as a “Black Box” warning (U.S. Food and 
Drug Administration, 2012). 
• Health insurance: An aggregated category that includes: Private health insurance, Medicare, 
Medicaid, Children’s Health Insurance Program, Department of Defense, and Department of 
Veterans Affairs. These plans provide insurance against medical losses to eligible individuals 
and/or families and may directly provide medical care (Center for Medicare and Medicaid 
Services, n.d.). 
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• Obstructive Sleep Apnea: “A disorder of breathing during sleep characterized by prolonged 
partial upper airway obstruction and/or intermittent complete obstruction that disrupts normal 
ventilation during sleep and normal sleep patterns” (American Thoracic Society, 1995, p. 
898). 
• Opioid: A group of drugs that bind to opiate receptors in the central and peripheral nervous 
systems to elicit analgesia (Pathan & Williams, 2012).  
• Otolaryngologist/otolaryngology: A physician that provides medical and/or surgical therapy 
for disease, disorders and/or injuries of the “ears, nose, sinuses, throat, respiratory, and upper 
alimentary systems, face, jaws, and the other head and neck systems”; may also be known 
known as ear-nose-throat (ENT) physician (American Medical Association, n.d.). 
• Tonsillectomy and/or adenoidectomy: A surgical procedure that completely removes the 
tonsil, including its capsule, by dissecting the peritonsillar space between the tonsil capsule 
and the muscular wall; may be performed with or without removal of the adenoids; also 
known as adenotonsillectomy (Mitchell et al., 2019). 
• Private health insurance: Includes health insurance plans marketed by the private-health 
industry; often employer-connected, but may be purchased on the free market. In private 
health insurance, premiums are paid to traditional managed care, self-insured health plans 
and indemnity plans (Center for Medicare and Medicaid Services: Glossary, n.d.). 
• Public health insurance: A program run by U.S. federal, state, or local governments where 
healthcare costs for individuals and/or families are paid for by the government. In the state of 
Oregon, the Oregon Health Plan comprises Medicaid and the state children’s health 
insurance program (SCHIP), both of which provide low or no-cost health coverage to eligible 
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children (Center for Medicaid and Medicare Services, n.d.). Medicare (coverage for 
individuals >65 years) is not pertinent to this study. 
Chapter Summary 
 
Chapter One provided a background on codeine and opioid use in pediatric tonsillectomy 
and/or adenoidectomy patients. It also highlighted opioid prescribing disparities in publicly 
versus privately insured children and pointed to a knowledge gap in opioid prescribing patterns 
in pediatric tonsillectomy and/or adenoidectomy patients. The Donabedian model with relevant 
antecedents was introduced and the study’s methodology was overviewed.   
The remaining manuscript includes Chapter Two – Chapter Five. Chapter Two provides a 
comprehensive review of the literature and fully explores the theoretical underpinnings for the 
study. Chapter Three describes the study’s methodology, including research design, study 
variables, study sample and data analysis plan. Chapters Four and Five include results of the 
study and discussion of study findings. 
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Chapter 2: Literature Review 
 
Chapter Overview 
 
 This chapter reviews literature pertaining to opioid use in pediatric post-tonsillectomy 
and/or adenoidectomy patients. The chapter begins by defining pain and postoperative pain, 
offers a historical perspective on pediatric surgical pain management, discusses the current state 
of post-tonsillectomy and/or adenoidectomy opioid use and identifies factors that contribute to 
poor outcomes in pediatric tonsillectomy patients. The research gap is identified, followed by 
study aims & hypotheses. A detailed discussion of the Donabedian framework as it relates to the 
study is also included.    
Background 
 
Definition of pain  
 
 Pain has been defined in many ways, though the definition set forth by The Taxonomy 
Committee of International Association for the Study of Pain (IASP) offers the most widely 
accepted designation: “An unpleasant sensory and emotional experience associated with actual 
or potential tissue damage or described in terms of such damage” (International Association for 
the Study of Pain (ISAP), 1994/2017). Pain is a multi-dimensional phenomenon that can be 
further classified by the pathophysiological mechanism, duration, etiology and anatomic location 
of pain (World Health Organization (WHO), 2012; IASP, 1994/2017), as discussed in Table 2. 
Table 2 
Classification and Characteristics of Pain 
Classification of 
Pain 
Characteristics of Pain  
Pathophysiologic 
Mechanism 
• Nociceptive: arises from tissue injury, tends to be time-limited and 
responsive to opioids. Nociceptive pain can be further differentiated 
by the location of activated nociceptors: 
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- Somatic: activation of nociceptors in either surface tissues (skin, 
mucosa of mouth, etc.) or in deeper structures (bone, joint, 
muscle and connective tissue) 
- Visceral: activation of nociceptors located in the internal viscera 
(thoracic, abdominal organs, etc.) 
• Neuropathic: arises from nerve cell damage or dysfunction in the 
peripheral or central nervous systems; tends to be longer lasting and 
has a less robust response to opioids. 
• Mixed: nociceptive and neuropathic pain that coexists 
• Idiopathic: inability to find an underlying cause; may be termed 
psychogenic pain 
Duration • Acute: onset of pain is sudden and immediately felt following 
injury; the intensity is generally severe but short in duration 
• Chronic: continuous or recurrent pain that persists beyond the 
expected normal time of healing  
• Episodic/Recurrent: pain that occurs intermittently over a long 
period of time 
Etiology • Based on the underlying disease and generally classified as malignant 
or non-malignant  
Anatomic 
Location 
• Can be classified by body location (e.g. head, back or neck) or the 
anatomic function of the affected tissue (e.g. myofascial, rheumatic, 
skeletal, neurological and vascular) 
Note: Information from: WHO 2012; IASP, 1994/2017 
 
Postoperative pain 
 
Postoperative pain is considered a form of acute pain due to surgical trauma, resulting in 
an inflammatory reaction and a cascade of nociceptive activation (Gupta et al., 2010; WHO, 
2012). Different surgical procedures involve specific organs and surrounding tissues, creating 
various patterns of somatic and/or visceral nociception activation during surgery (IASP, 2017). 
The quality, anatomic location and severity of postoperative pain is largely a result of this 
nociceptive activation, though it is also influenced by autonomic, endocrine, metabolic and 
psychological responses to pain (Brennan, 2011; Gupta et al., 2010). Treatment of acute 
postoperative pain relies on therapies that modulate pain transmission; the mainstay of 
postoperative pain therapy in many settings is opioids (Garimella & Cellini, 2013). Effective 
postoperative pain control is an essential need of any individual undergoing surgery. 
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Historical perspective on pediatric postoperative pain 
 
 The understanding of postoperative pain in children has advanced considerably over the 
last several decades. Long held assumptions that children are more tolerant of pain, are incapable 
of pain perception or that provision of pain relief is more harmful than the pain itself, are no 
longer scientifically or ethically justifiable (Unruh & McGrath, 2014). In the late 19th and early 
20th centuries, clinicians believed pediatric patients tolerated postoperative pain well and seldom 
required medication for the relief of pain after surgery (Unruh, 1992). A classic document by 
Eland & Anderson (1977) assessed disparities in postoperative pain management between 
children and adults and noted that postoperative pain in children was vastly undertreated. Though 
the study was not rigorous, it represented a landmark study highlighting the extreme differences 
and inadequacy in surgical pain management between children and adults (McGrath, 2011; 
Unruh, 1992). Several publications followed, including an early systematic study showing a 
dramatic increase in pediatric pain publications in the 1980’s – implying a heightened interest in 
the field around this time (Guardiola & Banos, 1980; McGrath, 2011). Since then, the 
conceptualization and treatment of pediatric surgical pain has advanced to appreciate the 
developmental neurobiology of pain and the importance of adequate analgesia in children 
(McGrath, 2011; Schechter, 2014). 
 Disparities in treatment of pediatric pain led organization such as the Agency for Health 
Research and Quality (AHRQ) and the American Pain Society (APS) to provide guidelines for 
pediatric pain management (Cote, Lerman, & Anderson, 2018). The AHRQ’s 1993 Clinical 
Practice Guideline for Acute Pain Management in Infants, Children and Adolescents: Operative 
Procedures (archived and no longer intended to guide medical practice), recommended opioids 
such as codeine to be used after minor pediatric surgical procedures. The APS Task Force on 
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Pain in Infants, Children and Adolescents (2001) endorsed early treatment of postoperative pain 
with non-opioids and opioids, providing a specific recommendation only to avoid the opioid 
meperidine. These guidelines and recommendations, crafted with the best available evidence at 
the time, served as a platform for safe opioid prescribing practices in children.  
Additionally, the World Health Organization (WHO) created initial (1986) and revised 
(1996) guidelines on pain relief, based on the well-known “analgesic ladder.” As shown in 
Figure 1, the traditional ladder advocates a three-step treatment process, where the first step 
centers on non-opioids, the intermediate step relies on weak opioids, such as codeine and 
tramadol, and the final step supports use of stronger opioids, such as morphine (Gray, Collins, & 
Milani, 2013). Some authors have since devised more recent iterations of the ladder, including a 
fourth step of interventional approaches (e.g. nerve blocks) for treatment of persistent pain 
(Cuomo, Bimonte, Forte, Botti, & Cascella, 2019; Vargas-Schaffer, 2010). Creation of the WHO 
analgesic ladder was significant in that it established the concept of a grading approach to opioid 
prescribing. Though the WHO analgesic ladder was not specifically intended for the pediatric 
population nor for postoperative pain, these guidelines have been broadly applied to many 
patients requiring analgesic therapy – including both pediatric and postoperative patients 
(Ballantyne, Kalso, & Stannard, 2016; Cartabuke, Tobias, Taghon, & Rice, 2014; Gray et al., 
2013; Vargas-Schaffer, 2010). 
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Figure 1. WHO Analgesic Ladder for Pain. Adapted from: (Vargas-Schaffer, 2010; World 
Health Organization, 2012) 
 
Impact of pediatric postoperative pain  
 
As the understanding of pediatric pain improved, so did the ability to appropriately 
measure and treat pediatric pain. One of the most notable advances in pediatric pain medicine 
was the recognition that untreated or undertreated surgical pain leads to short and long-term 
consequences, including detrimental psychological and physiological effects (McGrath & Craig, 
1986; Verghese & Hannallah, 2010). Acute postoperative pain causes fear, distress, behavioral 
disturbances, disrupted eating and sleeping cycles and harmful neuroendocrine and inflammatory 
responses (Cote et al., 2018; Lauder & Emmott, 2014). Additionally, the psychological and 
physiological responses to pain may predispose children to develop chronic pain as adults 
(Finley, Chorney, & Campbell, 2014). Children experience and process acute postoperative pain, 
making provision of adequate postoperative pain control a priority.   
Perspective on pediatric post-tonsillectomy pain  
 
Pain following tonsillectomy and/or adenoidectomy is very common, representing a 
major cause of post-surgical morbidity (Baugh et al., 2011; Mitchell et al., 2019). Post-
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tonsillectomy and/or adenoidectomy pain is thought to be due to inflammation and irritation of 
pharyngeal nerve endings and pharyngeal muscle spasms; it often exhibits a bimodal pattern, 
with pain and functional limitations lasting for up to 7-10 days (Lauder & Emmott, 2014; 
Rodríguez, Villamor, & Castillo, 2016). Untreated post-tonsillectomy and/or adenoidectomy 
pain leads to dehydration, nausea/vomiting, dysphagia, weight loss and unplanned hospital 
readmissions (Lauder & Emmott, 2014; Mitchell et al., 2019). Because the majority of 
tonsillectomies and/or adenoidectomies are performed on an outpatient basis, pain control is 
required following hospital discharge. Though non-opioid analgesic regimens may be optimal, 
opioids are still commonly used, with 6 in 10 post-tonsillectomy children filling a prescription 
opioid in the perioperative period (Chua et al., 2019).   
Codeine in Pediatric Tonsillectomy  
 
Codeine is a weak opioid widely used in the management of mild-moderate pain (He, 
Lardieri, & Morgan, 2018). It was historically the primary analgesic agent for post-tonsillectomy 
pain, though it has fallen out of favor due to the risk of serious opioid-related adverse events 
(Coté et al., 2014).  A review of basic opioid pharmacology is offered below, followed by 
specific information pertaining to codeine analgesia.  
Basic opioid pharmacology  
 
Opioids produce their analgesic action by activating opioid receptors, which are located 
in the central nervous system (brain and spinal cord) and, to a lesser extent, in peripheral tissues 
(Pathan & Williams, 2012; Trivedi, Shaikh, & Gwinnut, 2008). Three classic types of opioid 
receptors have been identified: mu, kappa and delta opioid receptors (Hemmings & Egan, 2019). 
Opioids have a higher affinity for mu-receptors than the kappa or delta receptor subtypes, though 
all receptor subtypes have important physiological effects (Andrzejowski & Carroll, 2016). 
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When opioid receptors are activated, a spectrum of physiological effects occur, as shown in 
Table 3. Notably, respiratory depression and sedation are characteristic of mu-opioid receptor 
activation. 
Table 3 
Physiological Effects of Opioid Receptors   
 Mu Kappa Delta 
Spinal & supraspinal 
analgesia 
Yes Yes Yes 
Respiratory 
depression 
Yes, marked No Possibly, minimal  
Sedation Yes, marked No Possibly, minimal 
Gastrointestinal 
effects 
Yes No Yes 
Genitourinary effects Yes No Yes 
Euphoria  Yes No Possibly, minimal 
Dysphoria 
(restlessness/agitation) 
No Yes No 
Abuse potential Yes No Yes 
Note: Adapted from: (Flood, Rathmell, & Shafer, 2015; Hemmings & Egan, 2019; Trescot, 
Datta, Lee, & Hansen, 2008) 
 
Both endogenous and exogenous substances interact with opioid receptors to elicit a 
physiological response. Opioid receptors are normally stimulated by endogenous peptides 
(endorphins, enkephalins, and dynorphins) that are produced in response to noxious stimulation  
(Trescot, Datta, Lee, & Hansen, 2008). Exogenous substances are naturally occurring, semi-
synthetic or synthetic opioid compounds that bind to any subpopulation of the opioid receptor, 
mimicking the action of endogenous substances (Flood et al., 2015). Activation of the mu-opioid 
receptor by an exogenous agonist is thought to be the major mechanism in opioid-induced 
analgesia (Pathan & Williams, 2012).  
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Morphine, a mu-receptor opioid agonist, is considered the prototypical opioid analgesic 
to which all others are compared (Hemmings & Egan, 2019; Pathan & Williams, 2012). Many 
commonly used semisynthetic or synthetic opioids are created by chemical modification or 
synthesis from the morphine molecule (Flood et al., 2015; Pathan & Williams, 2012). Each 
modification of the morphine molecule yields a derivative with differing, but “morphine-like”, 
properties (Flood et al., 2015). One particular property that differs among opioid derivatives is 
analgesic potency. As shown in Table 4, opioids were traditionally classified based upon this 
property (Trivedi et al., 2008). The designation of opioids based on potency is the basis for the 
WHO’s analgesic ladder and grading approach to opioid prescribing.  
Table 4 
Opioid Classification Based on Potency 
 
Strong Intermediate Weak 
Morphine 
Meperidine 
Fentanyl 
Alfentanil 
Remifentanil 
Sufentanil 
Buprenorphine 
Butorphanol 
Nalbuphine 
Codeine 
Tramadol 
Note: Adapted from: Trivedi et al., 2008 
 
Codeine overview 
 
 Codeine received U.S. FDA approval in 1950 and has been a commonly used analgesic 
for postoperative pain in adults and children for more than 50 years (Andrzejowski & Carroll, 
2016). In 2011, codeine-containing prescriptions were prescribed to more than 18 million 
children under 11 years of age – making it the most prescribed opioid at that time (Cartabuke et 
al., 2014; Chidambaran, Sadhasivam, & Mahmoud, 2017). Codeine is a naturally occurring 
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alkaloid compound, acting as an agonist at the mu-opioid receptor (Pathan & Williams, 2012). 
When compared to morphine, it possesses a 200-fold weaker affinity for the mu-opioid receptor 
– hence its status as a “weak” opioid (Chidambaran et al., 2017; Hansen, Shah, & Benzon, 2016).  
Oral codeine is rapidly absorbed, reaching plasma concentration levels within 1 hour of 
administration in adults and slightly longer in children (Andrzejowski & Carroll, 2016). The 
half-life of codeine is approximately 3-3.5 hours and therapeutic effects of codeine are similar in 
adults and children, generally lasting for 4-6 hours (Andrzejowski & Carroll, 2016; Cote et al., 
2018).  Common side effects of codeine are listed in Table 5. Codeine is eliminated by either 
direct renal excretion or following metabolism via the cytochrome (CYP) 450 system in the liver 
(Chidambaran et al., 2017). 
Table 5 
Common Side Effects of Codeine 
Airway and 
Breathing 
Effects 
Cardiovascular 
Effects 
Central Nervous 
System Effects 
Gastrointestinal 
Effects 
Other 
Effects 
-Shortness of 
breath 
-Respiratory 
depression 
-Decreased 
cough 
-Flushing -Drowsiness 
-Sedation 
-Dizziness 
-Light-
headedness 
-Nausea 
-Vomiting 
-Constipation 
-Sweating 
 
Note: Adapted from: (FDA, 2010; Andrzejowski & Carroll, 2016)  
 
Codeine is a pro-drug, requiring conversion of the drug into its active form to produce 
analgesia (Chidambaran et al., 2017; Fortenberry, Crowder, & So, 2018; He, Lardieri, & 
Morgan, 2018). As shown in Figure 2, the drug has three major metabolic pathways: 70-80% of 
codeine is metabolized by the enzyme UDP-glucuronosyltransferase-2B7 (UGT2B7) into 
codeine-6-glucuronide (active drug); 5-10% is metabolized by the cytochrome P450 (CYP) 3A4 
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enzyme into norcodeine (inactive); 10% of the drug undergoes O-demethylation via CYP 2D6 
enzyme to morphine (active) (Biesiada et al., 2014; Chidambaran et al., 2017; Fortenberry et al., 
2018). The greatest degree of analgesia is produced from the active metabolite morphine 
(Chidambaran et al., 2017). 
 
Figure 2. Codeine Metabolism  
Note: Adapted from Fortenberry et al., 2008 
 
Background on codeine use in pediatric tonsillectomy 
 
For decades, codeine analgesia was the primary agent for outpatient analgesia after 
tonsillectomy and/or adenoidectomy in children (Constant et al., 2014; Lauder & Emmott, 2014; 
Tobias et al., 2016). Otolaryngologists prescribe codeine at greater rates than dentists, 
pediatricians and general/family practice physicians (Chidambaran et al., 2017). Codeine 
analgesia was favored by otolaryngologists for post-tonsillectomy and/or adenoidectomy pain for 
numerous reasons, as outlined in Table 6.  
Table 6 
Reasons for Codeine Use in Post-tonsillectomy Pediatric Patients  
Favorable characteristics of 
codeine 
Rationale for use in post-tonsillectomy 
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Can be administered orally via a 
liquid or tablet  
Oral opioids can be initiated and continued after 
discharge from the hospital  
Is a step-2 analgesic in the WHO 
analgesic ladder  
 
Was thought to be effective for mild-moderate post-
tonsillectomy pain  
Is considered a ‘weak’ opioid  Is weaker than morphine and was thought to have a good 
safety profile  
Causes less postoperative nausea 
and vomiting than morphine  
Nausea/vomiting is a common problem after 
tonsillectomy and/or adenoidectomy, with an incidence 
ranging from 15-80%  
Greater ease of prescribing   Codeine co-formulated with acetaminophen is the only 
opioid analgesic classified as a Schedule III controlled 
substance, allowing for verbal and facsimile prescribing 
to pharmacies as well as refills with the original 
prescription; also, the drug did not require triplicate 
prescription forms in many states 
Is relatively inexpensive  Represented a cost-effective therapy option for post-
tonsillectomy and/or adenoidectomy pain 
Note: Information from: (Chidambaran et al., 2017; Constant et al., 2014; Cote et al., 2018; 
Garimella & Cellini, 2013; Hansen et al., 2016; Lauder & Emmott, 2014; Semple et al., 1999; 
WHO, 2012) 
 
Current state of codeine use in pediatric tonsillectomy 
 
 The favorable characteristics of codeine have since been outweighed by its association 
with significant adverse events, including deaths and near deaths. In 2009, a fatality occurred in a 
healthy 2-year-old boy who was given codeine after adenotonsillectomy (Ciszkowski & Madadi, 
2009). This was followed in 2012 by three additional deaths and two cases of respiratory 
insufficiency in children who underwent adenotonsillectomy (Kelly et al., 2012). In 2013, three 
additional codeine-related deaths occurred in children aged 4-10 years who were prescribed the 
recommended weight-based dose of codeine (Friedrichsdorf, Nugent, & Strobl, 2013).  
These reports of deaths and near deaths in children receiving standard doses of oral 
codeine prompted the FDA and international regulatory agencies to review the safety of the drug 
in children undergoing tonsillectomy and/or adenoidectomy. Subsequently, the FDA, WHO, 
European Medicines Agency (EMA), the UK Medicines and Healthcare Products Regulatory 
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Agency (MHRA) and Health Canada made formal recommendations against the use of codeine 
containing products in all children undergoing tonsillectomy and/or adenoidectomy. Figure 3 
depicts the progression of the ‘codeine-ban’ in children: It was first recommended that codeine 
be avoided in any child undergoing tonsillectomy and/or adenoidectomy; this has been followed 
by more recent guidelines to avoid codeine-containing cough elixirs in all children <18 years of 
age.  
 
 
 
 
 
 
 
 
 
Figure 3. Depiction of the Codeine Ban. Information from (European Medicines Agency, 2013, 
2015; Health Canada, 2016; U.S. Food and Drug Administration, 2013, 2018; UK Medicines and 
Healthcare Products Regulatory Agency, 2013, 2015; World Health Organization Expert 
Committee, 2011) 
 
Contributing Factors in Post-tonsillectomy Deaths and/or Adverse events 
 
Though codeine plays a major role in post-tonsillectomy deaths and/or adverse events, it 
is not solely to blame. Rather, several factors have been implicated in the “perfect storm” of 
post-tonsillectomy complications including comorbid conditions, opioid sensitivity, genetic 
polymorphisms in opioid metabolism, and other factors (Coté et al., 2014; Cote et al., 2018).  
Comorbid conditions 
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Obesity  
 
Defined by the Center for Disease Control (CDC) as a body mass index >95th percentile 
for age and gender, obese children are more likely to suffer from a number of comorbid 
conditions including cardiovascular disease (hypertension, dyslipidemia), respiratory disorders 
(OSA, asthma), endocrinopathies (diabetes, metabolic syndrome), renal and liver dysfunction 
(Cote et al., 2018).  Obesity presents challenges during the perioperative period and increases the 
risk of poor outcomes. In a large study of post-tonsillectomy morbidity and mortality, obesity 
was the second most common predisposing factor for perioperative adverse events (Goldman et 
al., 2013). Obese children have a higher incidence of adverse respiratory events during and after 
surgery when compared with normal-weight children (Mortensen, Lenz, Abildstrøm, & 
Lauritsen, 2011). Increased tissue mass, alterations in respiratory mechanics, reduction in lung 
capacities and airway narrowing are thought to contribute to the heightened risk profile of obese 
children (Mortensen et al., 2011; Patino et al., 2013). In 2009, researchers found that obese 
children represented 21% of all children undergoing tonsillectomy (Nafiu et al., 2009). A decade 
later, it is likely this percentage has increased.  
Obstructive sleep apnea 
 
Over 75% of children presenting for tonsillectomy suffer from OSA (Patino et al., 2013). 
OSA is a sleep-related breathing disorder that is characterized by intermittent cessation of air 
exchange that disrupts normal ventilation and sleep patterns (American Thoracic Society, 1996). 
It is further defined as central (lack of respiratory effort due to a central defect), obstructive 
(upper airway obstruction) or mixed (central and obstructive problems) and is diagnosed via 
clinical assessment or polysomnography (PSG) sleep study (Cote et al., 2018; Marcus et al., 
2012). Symptoms of OSA include obstructed breathing, snoring, paradoxical chest wall motion, 
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increased respiratory effort, apneas/hypopneas, hypercarbia and oxygen desaturation. The 
spectrum of OSA ranges from mild to severe, based on the total number of obstructive episodes 
and oxygen desaturations during sleep (Cote et al., 2018; Patino et al., 2013). OSA occurs in 
about 2-5% of all children and can afflict a child of any age, but is more common in children 
aged 3-7 years (Marcus et al., 2012). It affects boys and girls equally, though the disorder has a 
greater prevalence in African American and Hispanic children when compared with Caucasian 
children (Dudley & Patel, 2016).  
The incidence of pediatric OSA and sleep-disordered breathing has risen dramatically – 
in large part due to the rise in childhood obesity (Marcus et al., 2012; Patino et al., 2013).  
Though pediatric OSA is a multifactorial disease, obesity is a predisposing factor – leading to a 
higher prevalence of the disorder and exacerbating the symptoms of OSA (Cote et al., 2018; 
Patino et al., 2013). OSA is reported in 14-59% of obese children, compared to 1-2% in non-
obese children, and the degree of OSA parallels the degree of obesity (Cote et al., 2018; Verhulst 
et al., 2008). In general, children with obesity suffer from the obstructive-type of OSA, where 
increased resistance to air flow and airway obstruction are characteristic of the disorder (Patino 
et al., 2013).  
Tonsillectomy and adenoidectomy is recommended as the initial treatment in children 
with OSA, yet the presence of OSA significantly increases the odds for post-tonsillectomy 
complications (Cote et al., 2018). A recent meta-analysis demonstrated differences in the 
distribution of post-tonsillectomy complications between children with OSA and those without. 
Canto et al. (2015) showed children with OSA have a 5-fold increase in the odds for 
perioperative respiratory events when compared to children without OSA. Also, several recent 
studies reported unexpected deaths and/or near deaths following tonsillectomy and/or 
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adenoidectomy related to suspected or confirmed sleep apnea (Coté et al., 2014; Goldman et al., 
2013). The risk of complications related to OSA appears to be due to a confluence of factors 
including impaired hypoxic and hypercarbic ventilatory responses, pharyngeal collapse leading 
to airway obstruction, opioid sensitivity with exaggerated respiratory depression, and improper 
post-operative monitoring (Collins, 2015; Coté et al., 2014; Cote et al., 2018; Goldman et al., 
2013; Mortensen et al., 2011). Notably, though tonsillectomy and/or adenoidectomy is 
considered to be an effective treatment for OSA, the symptoms of OSA may become worse 
during the immediate post-operative period (Marcus, et al., 2012) – making it a particularly 
vulnerable time.  
Opioid sensitivity  
 
Due to the intermittent airway obstruction during sleep that is characteristic of OSA, 
children with OSA experience recurrent episodes of nocturnal desaturation and hypoxemia (Cote 
et al., 2018). Although the molecular basis for the effect of nocturnal hypoxemia on opioid 
receptors is not fully understood, research shows that exposure to nocturnal hypoxemia increases 
the density of mu-opioid receptors in respiratory-areas of the central nervous system (Johnson & 
Netzer, 2015; Lam, Kunder, Wong, Doufas, & Chung, 2016). This effect is observed in both 
animals and humans. In experimental rat pup models, exposure to recurrent hypoxia was linked 
to upregulated opioid receptors in the brainstem and greater respiratory sensitivity to opioids 
(Moss, Brown, & Laferrière, 2006; Wu, Li, Wu, & Chen, 2015). Clinical studies are consistent 
with this finding where children with OSA had a higher incidence of apnea at uniform doses of 
opioids and required less opioid analgesia following tonsillectomy (Brown, 2009; Waters, 
McBrien, Stewart, Hinder, & Wharton, 2002). The altered mu-opioid receptor response to 
opioids results in patients with OSA being analgesic at lower blood levels of opioids (Coté, 
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2015). Thus, children with OSA require less opioids than their non-OSA counterparts and a 
normal dose of opioid is a relative overdose in a child with OSA (Coté et al., 2014). 
Genetic polymorphisms affecting opioid metabolism 
 
 Genetic polymorphisms that contribute to individual variability in opioid-metabolism 
have been implicated in post-tonsillectomy deaths and near deaths (Andrzejowski & Carroll, 
2016; Chidambaran, et al., 2017) . Codeine is particularly affected by genetic polymorphisms 
and will be discussed following a general overview of drug metabolism.   
General overview of drug metabolism 
 
In general, drug metabolism occurs in the liver and is classified as either a Phase I or 
Phase II reaction, where the former is an oxidative, reduction or hydrolysis reaction and the latter 
are conjugation reactions (Hemmings & Egan, 2019). Often drugs undergo both phases of 
metabolism, first undergoing a Phase I reaction to increase the drug’s polarity followed by a 
Phase II reaction to conjugate the drug to a water-soluble compound for subsequent excretion 
(Flood et al., 2015).  Both Phase I and II metabolic pathways involve enzyme systems. Phase I 
reactions rely primarily on the CYP 450 system, which is a large family of membrane-bound 
hemeproteins that catalyze the metabolism of endogenous or exogenous compounds (Flood et al., 
2015; Hemmings & Egan, 2019). Numerous CYP proteins have been identified and different 
CYP 450 pathways are classified by similar gene sequences; they are first assigned a family 
number (e.g. CYP2), then a sub-family letter (e.g. CYP2D) and are differentiated by a number 
for the specific enzyme (e.g. CYP2D6) (McDonnell & Dang, 2013). The CYP 450 system plays 
a key role in the metabolism many drugs, including opioids.  
Codeine 
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 As discussed above and illustrated in Figure 2, codeine follows three major metabolic 
pathways to produce active and inactive forms of the drug. The primary analgesic effect of 
codeine is its conversion to morphine via the CYP450 system, specifically the CYP2D6 enzyme 
(Chidambaran et al., 2017; Fortenberry et al., 2018; Kirchheiner et al., 2007). The potential 
dangers of codeine lie primarily in genetic polymorphisms of this enzyme.  
Variability in the clinical response to codeine prompted inquiries into the role of genetic 
polymorphisms of the CYP2D6 enzyme on codeine-related adverse events. The CYP2D6 
enzyme is encoded by a gene located on chromosome 22 at 22q.13.1; more than 100 
polymorphisms of CYP2D6 have been identified, leading to a broad range of phenotypic activity 
of the enzyme (Andrzejowski & Carroll, 2016; Chidambaran et al., 2017). Depending on which 
maternal and paternal alleles an individual inherits, the metabolism profile of codeine varies 
from poor to ultra-rapid metabolism, drastically affecting the clinical response to codeine 
(Andrzejowski & Carroll, 2016; Chidambaran et al., 2017; Kirchheiner et al., 2007). The major 
polymorphisms of CYP2D6, as shown in Table 7, alter the clinical response to codeine by 
significantly reducing or augmenting the conversion of codeine to morphine (Crews et al., 2012; 
Fortenberry et al., 2018).  This corresponds with either reduction in its intended therapeutic 
effect or heightened therapeutic effect with the potential for significant morphine toxicity (Crews 
et al., 2012; Lam et al., 2014).  
Table 7 
Major Polymorphisms of CYP2D6 Enzyme 
Phenotype Enzyme 
Activity Score 
Genotype Incidence Codeine 
Analgesic 
Effect 
Poor metabolizer 0 Two non-
functioning alleles 
5-10% Very little 
analgesic effect 
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Intermediate 
metabolizer 
0.5 One non-
functioning allele 
& one decreased-
functioning allele 
2-11% Reduced 
analgesic effect 
Normal 
metabolizer 
1-2 Two normally 
functioning alleles 
77-92% Expected 
analgesic effect 
Ultra-rapid 
metabolizer 
2 Gene duplication 
of normally 
functioning alleles 
1-2% ‘Overdose’ 
analgesic effect 
Information from: (Andrzejowski & Carroll, 2016; Chidambaran et al., 2017; Coté, 2015; Crews 
et al., 2012; Dean, 2012) 
 
Genetic testing is available for common CYP2D6 variants (~30 alleles) (Dean, 2012). 
Both maternal and paternal variant alleles, known as diplotypes, are reported; then an activity 
score is assigned to each allele in the diplotype, as shown in Table 7 (Andrzejowski & Carroll, 
2016; Chidambaran et al., 2017). Though available, the practicality, payer coverage and 
affordability limit routine preoperative genetic phenotyping (Chidambaran et al., 2017).  
Genetic testing has been undertaken in post-mortem analysis of codeine-related fatalities. 
In 2009, a 2-year-old toddler with OSA suffered fatal respiratory arrest after tonsillectomy and 
adenoidectomy; post-mortem analysis revealed a serum morphine concentration of 32 nanograms 
per milliliter (ng/mL) (therapeutic range = 4.5 + 2.1 ng/mL) and duplicate CYP2D6 alleles, 
indicating ultra-rapid metabolizer status (Ciszkowski & Madadi, 2009). Similar cases have since 
been reported: a 4-year-old boy and a 3-year-old girl with OSA and a 5-year old boy without 
OSA – post-mortem morphine concentrations in these children were 17.6, 17 and 30ng/mL, 
respectively; all were found or predicted to have duplicate or mutant CYP2D6 alleles (Kelly et 
al., 2012).  In all cases, the prescribed dose of codeine was appropriate, based on the child’s 
weight, and the reported dose administered by the caregivers were within the boundaries of the 
prescribed dose.   
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Limited prospective work has evaluated the role of genetic variations on opioid 
metabolism. In 2007, Kirchheiner and colleagues administered codeine to 16 individuals with 
known CYP2D6 gene alterations and found that those with CYP2D6 genotypes predicting ultra-
metabolism (gene duplication) had a 50% higher plasma morphine concentration than those 
without gene duplication (Kirchheiner et al., 2007).  Biesiada and colleagues (2014) conducted a 
prospective study (n=273) to evaluate genetic variants associated with respiratory depression in 
children undergoing tonsillectomy and adenoidectomy with morphine analgesia. The researchers 
found inter-individual differences in morphine-related post-operative respiratory depression, 
where certain genetic alleles helped discriminate between low and high risk for post-operative 
respiratory depression (Biesiada et al., 2014).  
Presently, there are no diseases or conditions known to be linked to CYP2D6 variants – 
however there is increasing evidence of ethnic variations in cytochromes responsible for drug 
metabolism (Andrzejowski & Carroll, 2016; Cote et al., 2018). Populations that exhibit ultra-
rapid metabolism include Ethiopians (30%), North Africans/Arabs (16-30%), 
Italians/Greeks/Spaniards/Portuguese (10%) and Caucasians (1-10%) and poor metabolizer 
populations include Chinese (30%) and Caucasians (5-10%) (Andrzejowski & Carroll, 2016; 
Chidambaran et al., 2017). However, CYP2D6 cannot be predicted based on ethnicity alone; the 
only definitive means of knowing genetic signatures is via enzyme mapping (Chidambaran et al., 
2017). 
Other opioids 
 
 The role of genetic polymorphisms affecting codeine metabolism is well documented, 
however the extent to which pharmacogenetics influences the metabolism of other opioids is 
evolving. Other mild-moderate opioids, such as tramadol, oxycodone and hydrocodone were 
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thought to be a safer alternative to codeine – though these drugs may exhibit similar inter-
individual genetic variations in metabolism because they are, in part, metabolized by CYP2D6  
(Andrzejowski & Carroll, 2016; Chidambaran et al., 2017; Crews et al., 2012). Tramadol and, to 
a lesser extent, hydrocodone and oxycodone may not be good alternatives to codeine because 
their metabolism is affected by CYP2D6 activity (Crews et al., 2012; Dean, 2012).  
 Tramadol is metabolized by two pathways in the liver: moderate metabolism via 
CYP3A4 and extensive metabolism via CYP2D6. CYP3A4 metabolizes tramadol into an 
inactive compound, N-desmethytramadol, whereas CYP2D6 metabolizes tramadol into an active 
compound, O-desmethyltramadol (Fortenberry et al., 2018). The active metabolite has a 200-fold 
greater affinity for the mu-opioid receptor than the parent drug and is predominantly responsible 
for the drug’s analgesic effect (Crews et al., 2012). A prospective, double blind RCT found 
tramadol was safer than codeine/acetaminophen in pediatric tonsillectomy and/or adenoidectomy 
patients, with tramadol causing less respiratory depression and sedation (Friedrichsdorf et al., 
2015). However, there is evidence for decreased efficacy of tramadol in poor metabolizers and 
case reports of respiratory distress and near fatalities in ultra-rapid metabolizers – indicating 
genetic polymorphisms play a role in the clinical response to tramadol (Crews et al., 2012; 
Elkalioubie et al., 2011; Poulsen, Arendt-Nielsen, Brøsen, & Sindrup, 1996; Stamer et al., 2007). 
One recent report highlights a case of severe tramadol-related respiratory depression in a child 
with OSA undergoing tonsillectomy and adenoidectomy (Orliaguet et al., 2015). As a result, the 
FDA also took a stance on tramadol administration in pediatric tonsillectomy and/or 
adenoidectomy patients. In 2017, a Boxed Warning and labeling change to avoid tramadol in 
pediatric tonsillectomy and/or adenoidectomy patients < 18 years of age was announced (U.S. 
Food and Drug Administration, 2017). 
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Oxycodone is also metabolized by CYP34A and CYP2D6, though the metabolic profile 
differs from tramadol in that CYP34A is the predominant metabolic pathway and CYP2D6 plays 
a relatively minor role (Chidambaran et al., 2017). The byproducts of CYP34A and CYP2D6 
metabolism are noroxycodone, a metabolite with weak analgesic properties, and oxymorphone, 
which possesses 14 times more potency than the parent drug (Chidambaran et al., 2017; Lauder 
& Emmott, 2014). Current understanding of oxycodone’s pharmacogenetics is limited, 
particularly in pediatrics. In a randomized crossover double-blind study of 10 healthy adult 
volunteers, oxycodone pharmacodynamics differed depending on CYP2D6 polymorphisms, 
where ultra-rapid metabolizers experienced increased effects (Samer et al., 2010). Stamer and 
colleagues (2013) later demonstrated the number of functionally active CYP2D6 alleles had an 
impact on oxycodone metabolism in adult postoperative patients, causing variation in clinical 
response to oxycodone. At least one case has been reported where a non-fatal toxicity occurred 
in an adult patient with impaired CYP2D6 metabolism (Foster, Mobley, & Wang, 2007). There 
is no FDA contraindication on oxycodone, though more data is required to understand the impact 
of pharmacogenetics on oxycodone metabolism in children. 
Hydrocodone is partially metabolized via CYP3A4 and CYP2D6 into hydromorphone 
and norhydrocodone, respectively (Chidambaran et al., 2017). Hydromorphone is the active 
compound and has a 10-to 33-fold greater affinity for mu-opioid receptors as compared with 
the parent drug (Crews et al., 2012). Again, the pharmacogenetic data for hydrocodone is 
limited and no pediatric data exists. There is some evidence that hydromorphone is generated 
at substantially different rates in adults depending on CYP2D6 genotype and that poor 
metabolizers may have a limited analgesic effect to hydrocodone (Otton et al., 1993; Stauble 
et al., 2014) – yet there is insufficient data to understand whether ultra-rapid metabolizers 
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have an increased risk of hydrocodone related toxicity (Crews et al., 2012). No hydrocodone 
fatalities related to CYP2D have been reported and no FDA warnings have been placed on 
the drug in the context of pediatric tonsillectomy and/or adenoidectomy. 
The differing associations of CYP2D6-related variation in metabolism of codeine and 
tramadol as compared with oxycodone and hydrocodone may be related to the relative roles of 
the parent drug and circulating metabolites (Crews et al., 2012; Dean, 2012). Based on 
pharmacogenetics data, oxycodone and hydrocodone may be less prone to unintended sedation 
when compared with codeine and tramadol. However, it critical to consider clinical risk factors, 
such as obesity and OSA, along with genetic risk signatures – as both play a role in opioid-
induced adverse events.   
Other factors 
 
 In addition to comorbid conditions and genetic risk factors, other factors implicated in 
post-tonsillectomy deaths and/or adverse events include inadequate preoperative assessment for 
OSA, performing outpatient surgery in high-risk populations and lack of appropriate post-
operative monitoring in the hospital or home setting (Coté, 2015; Coté et al., 2014; Patino et al., 
2013). These, in addition to opioid therapy, are expressed as preventable factors in post-
tonsillectomy deaths and/or adverse events (Coté et al., 2014).  
Opioid Prescribing in the Post-codeine Era 
 
 There is strong evidence against the use of codeine and evolving evidence that 
substitution of other opioids may be unsafe in pediatric tonsillectomy and/or adenoidectomy 
patients. Since the FDA Boxed Warning on codeine, two large-scale and one single-center 
observational study analyzed the impact of the FDA warning on codeine and opioid prescribing 
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in pediatric tonsillectomy and/or adenoidectomy patients. These studies are described below and 
summarized in Table 8. 
Table 8  
Summary of Relevant Literature 
Study Population & 
Sampling Frame 
Outcome 
Measures 
Results Limitations 
Chua et 
al. (2017) 
Post-tonsillectomy 
and/or 
adenoidectomy 
children < 18 years 
(n=362,992); 
Truven MarketScan 
Commercial Claims 
and Encounters 
database, years 
2010 – 2015. 
> 1 prescription 
fill for codeine or 
other opioids 
within 7 days of 
surgery. 
Significant 
reduction in 
codeine dispensed 
from 2010 to 2015 
in children with 
and without OSA. 
Non-significant 
increase in other 
opioids dispensed. 
Privately insured 
children only. 
Claims data 
captures opioids 
dispensed, not 
opioids prescribed. 
Unable to discern 
type of providers 
who prescribed 
opioids. 
Van 
Cleve 
(2017) 
Post-tonsillectomy 
and/or 
adenoidectomy 
children < 18 years 
of age (n=230,744); 
Truven MarketScan 
Commercial Claims 
and Encounters 
database, years 
2010 – 2015. 
Opioids 
dispensed from 2 
weeks prior until 
2 days following 
tonsillectomy & 
14-day 
postoperative 
rates of 
emergency 
department (ED) 
visits. 
Significant 
reduction codeine 
dispensed from 
2010 to 2015; 
Non-significant 
increase in other 
opioids dispensed; 
No change in 14-
day ED visit rates. 
Demographics not 
presented. Privately 
insured children 
only. Claims data 
captures opioids 
dispensed, not 
opioids prescribed. 
Unable to discern 
type of providers 
who prescribed 
opioids. 
Goldman 
et al. 
(2018) 
Post-tonsillectomy 
and adenoidectomy 
children aged 2-12 
years; Medical 
record data, years 
2010 – 2015. 
Post-operative 
opioids 
prescribed by 
academic and 
non-academic 
otolaryngologists.  
Significant 
reduction in 
codeine prescribed 
by academic and 
non-academic 
otolaryngologists; 
No change in post-
operative ED visit 
rates.  
Single center study. 
Health insurance 
status not reported. 
Post-operative 
prescribing time 
parameters unclear. 
Did not define 
“other narcotics”. 
 
 Using the Truven MarketScan Commercial Claims and Encounters database, Chua and 
colleagues (2017) identified 362,992 privately insured children who underwent tonsillectomy 
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and/or adenoidectomy between 2010 – 2015. The researchers measured the occurrence of >1 
codeine or alternative opioid (hydrocodone, oxycodone and other opioids) prescription fill within 
7 days of surgery and made pre-and post-FDA warning comparisons. The monthly rate of change 
in codeine prescribing following the FDA warning was significant and negative (-13.3; 95% CI = 
[-14.5 to -12.1]), where codeine prescribing fell from 30.1% in 2010 to 5.1% in 2015 (Chua et 
al., 2017). Changes in alternative opioid prescribing were found to be slight and non-significant, 
with 31.7% fills in 2010 and 46.1% in 2015.  
 Van Cleve (2017) also studied the impact of the FDA warning on opioid prescribing in 
pediatric post-tonsillectomy patients. Using the same commercial insurance database as Chua et 
al. (2017), data on 230,477 pediatric tonsillectomies between 2010 – 2015 were analyzed. 
Acetaminophen-codeine, acetaminophen-hydrocodone, oxycodone or ‘other’ prescription fills 
from two weeks prior until two days post-surgery were identified and classified as pre-or post-
FDA warning. Van Cleve (2017) found a significant reduction in post-FDA warning codeine 
prescribing, where the relative risk (RR) of receiving a codeine-containing prescription in the 
post-FDA warning period was RR=0.31 (95% CI, = [0.31-0.32]). The RR of receiving a 
hydrocodone or oxycodone-containing prescription in the post-FDA warning period was slightly 
increased, though not significant.    
 The Goldman et al. (2018) study added additional knowledge by comparing prescribing 
practices in academic and non-academic otolaryngologists. Though a significance level was not 
reported, the researchers noted that academic otolaryngologists’ prescribing reached zero faster 
than the non-academic otolaryngologist group (Goldman, Ziegler, & Burckardt, 2018).  The 
researchers also found an overall 5% reduction in postoperative opioid use by both academic and 
non-academic otolaryngologists (p < .001). However, aside from noting hydrocodone was the 
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most frequently prescribed post-FDA warning opioid (accounting for 91% of such prescriptions), 
the study did not report which other opioids were substituted for codeine.  
Goldman et al. (2018) did not report granular information on “other narcotics”, but both 
Chua et al. (2017) and Van Cleve (2017) found an increase in alternative opioid prescribing after 
the FDA warning on codeine. Though these results were non-significant, this data still provides 
useful trends on which non-codeine containing opioids are substituted for codeine. As shown in 
Table 9, Chua and colleagues (2017) present detailed information on which alternative opioids 
have seen the greatest substitution since the FDA warning on codeine.  Van Cleve (2017) and 
Goldman et al. (2018) also found hydrocodone to be the opioid most frequently prescribed in the 
post-FDA warning era.  
Table 9 
Substitution Trends of Alternative Opioids 
 2010  2015 
CODEINE 46.8 % 9.1 % 
HYDROCODONE 48.4 % 72.7 % 
OXYCODONE 3.8 % 17.4 % 
OTHER OPIOID 0.1 % 0.8 % 
 
Research Gaps in Post-tonsillectomy Opioid Prescribing 
 
The literature to date contributed beneficial knowledge on the impact of the FDA 
warning on codeine and opioid prescribing in pediatric tonsillectomy and/or adenoidectomy 
patients, though important gaps remain. As introduced above, both Chua et al. (2017) and Van 
Cleve (2017) analyzed the same commercial insurance database – Truven MarketScan 
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Commercial Claims and Encounters database. This database reports de-identified, patient-level 
data for over 50 million employee-sponsored insured Americans annually (Truven Healthcare 
Analytics, 2017). Utilizing this dataset is good for generalizability to other similarly insured U.S. 
children, though it leaves a segment of the childhood population underrepresented: publicly 
insured children. Van Cleve (2017) lists this as a “major limitation” to his work (p. 1052) and 
Chua et al. (2017) note the generalizability of the results to other commercially insured children 
and to publicly insured children is unclear. Goldman et al. (2018) did not specify insurer status in 
their work, rather focused on academic versus non-academic prescribing providers. Collectively, 
no study has evaluated the impact of the FDA warning on publicly insured post-tonsillectomy 
children, nor has any study compared opioid prescribing between publicly and privately insured 
post-tonsillectomy children. Children enrolled in Medicaid constitute an important population to 
study, given an estimated 40% of US children have health insurance coverage by Medicaid 
(Kaiser Family Foundation, 2018). Additionally, tonsillectomy rates in publicly and privately 
insured children are similar with rates of 81.5 and 80.6 per 10,000 U.S. children, respectively 
(Boss et al., 2012) – making post-tonsillectomy opioid prescribing relevant and important in both 
subsets of children. The extent to which publicly and privately insured children may be treated 
differently is a source of controversy (Alexander & Currie, 2017) and will be examined below. 
Further, both the Chua et al. (2017) and Van Cleve (2017) studies analyzed prescription 
opioids filled (e.g. dispensed by the pharmacy), rather than opioids prescribed (e.g. written by 
the provider). Earlier work suggests there is a difference between prescribed and dispensed 
medications, with high rates of non-dispensing in medications prescribed by general practice 
providers (Gardner, Dovey, Tilyard, & Gurr E, 1996; Lars, Nilsson, & Johansson, 1995).  More 
recent studies share similar findings where many prescribed medications are not actually 
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dispensed. Fischer et al. (2010) conducted an analysis of 195,930 electronic prescriptions and 
found 28% of new medications prescribed by primary care providers were not dispensed. 
Similarly, another study demonstrated that 31.3% of primary care patients never filled an initial 
prescription (Tamblyn, Eguale, Huang, Winslade, & Doran, 2014).  Though no literature exists 
on perioperative opioid prescribing versus dispensing, these studies in primary care illuminate 
the value of assessing opioids prescribed rather than dispensed. Measuring opioids dispensed 
may underestimate actual prescribing.  
Finally, there is a dearth of research evaluating the impact of the FDA warning on 
codeine or opioid prescribing beyond the year 2015. Both the Chua et al. (2017) and Van Cleve 
(2017) analyses are encouraging in that codeine prescribing fell as a result of the FDA warning -
however, in 2015 residual post-FDA codeine prescribing was shown in both studies, despite the 
drug’s well documented dangers. In 2017, codeine prescribing in pediatric post-tonsillectomy 
patients was 3.3% - however this reflects only one year of prescribing data (2016-2017) and does 
not assess longer-term trends (Chua et al., 2019). The longer-term trend of codeine prescribing is 
an important gap to fill in that the impact of FDA warnings may demonstrate erosion over time. 
In a study evaluating the 2004 FDA warning on antidepressants in children, the effects of the 
FDA warning differed in the early-and late-post FDA warning periods. In the years immediately 
following the FDA warning, a statistically significant decline in antidepressant use was found, 
but the prevalence of antidepressant use returned to pre-FDA warning levels 5 years later 
(Kafali, Progovac, Shu-Yeu Hou, & Lê Cook, 2018). This suggests the impact of FDA warnings 
may fade in the long-run and more frequent reinforcement of drug safety warnings may be 
necessary. It is currently unknown if the effects of the FDA warning on codeine resulted in a 
sustained or further reduction in codeine use and/or if alternative opioid prescribing practices 
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have changed since 2015. The present study will add additional information on codeine and 
opioid prescribing up to the year 2018.  Overall, the current study addresses multiple gaps in the 
literature by assessing post-tonsillectomy opioid prescribing in public and privately insured 
children, evaluating opioids prescribed rather than dispensed and extending the study period to 
understand the longer-term impact of the FDA warning. 
Influence of Health Insurance on Medical Treatment 
 
 The influence of health insurance on medical treatment is complex. A review of opioid 
prescribing based on insurance status and the medical treatment of publicly versus privately 
insured children is presented below.   
Introduction 
 
In 2017, the CDC’s National Center for Health Statistics reported 54.7% children were 
privately insured and 41.8% of children were publicly insured (Center for Disease Control, 
2017). Public insurance for children via government funded programs includes Medicaid or 
Children’s Health Insurance Plans (CHIP), which are based on income standards expressed as 
the federal poverty level (Kaiser Family Foundation, 2018). Because only low-income families 
and children are eligible for public insurance programs, children in economically disadvantaged 
groups are the most likely to have government health insurance (Child Trend, 2017). Race and 
ethnicity in children covered by Medicaid/CHIP tends to differ based on U.S. geography, though 
in 2010 36.5% were White, 24.5% were Black, 35.7% were Hispanic and 4.3% were other/non-
Hispanic children (Coyer & Kenney, 2013). Private health insurance refers to plans marketed by 
the private-health industry as opposed to government run insurance programs; it is primarily 
provided via employee sponsored programs (Center for Medicaid & Medicare Services, n.d.). In 
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2017, non-Hispanic White and Asian children were most likely to have private health insurance 
whereas Hispanic children were least likely (Berchick, Hood, & Barnett, 2018). 
Differences in the treatment of publicly insured versus privately insured children are 
documented across many venues, including prescribing practices, access to specialty care, 
hospital admissions/readmissions and healthcare utilization. Literature pertaining to opioid 
prescribing practices in publicly versus privately insured children, emphasized below, is scant 
and mixed; additional information on the differences in medical treatment of publicly versus 
privately insured children is summarized in Table 10.  
Opioid prescribing based on insurance status 
 
A recent study from a large academic pediatric hospital assessed trends in postoperative 
opioid prescribing in pediatric post-surgical patients. Donohoe and colleagues (2019) conducted 
a retrospective evaluation of 65,190 pediatric outpatient surgical encounters from 2013 to 2017 
and measured the rate of post-surgical opioid prescribing and duration of therapy. The 
researchers found the rate of prescribing remained stable throughout the study period, though the 
duration of therapy declined (p < 0.001). Certain subgroups of patients had a greater likelihood 
of receiving an opioid prescription, including females (p < 0.0001) and those with public 
insurance (p < 0.05). Opioids were also more likely to be prescribed in patients who did not 
disclose their ethnicity and those of non-white descent (p < 0.0001). Additionally, the odds of 
receiving an opioid prescription were greater for otolaryngology procedures compared with all 
other procedure types (p < 0.0001). This study gives reason to believe that opioid prescribing 
patterns in children undergoing tonsillectomy may differ between publicly and privately insured 
children.  
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However, other studies reveal that opioid prescribing is actually decreased in publicly 
insured children. A cross-sectional analysis of 69,152 pediatric emergency department (ED) 
patients was undertaken to evaluate factors associated with opioid prescribing. Those using 
Medicaid as their primary payment method had a significantly lower likelihood of being 
prescribed an opioid (OR = 0.74, 95% CI = [0.67-0.81]) compared with those using private 
insurance (Tomaszewski et al., 2018). This study also revealed that white patients were more 
likely to be prescribed an opioid (OR 1.34, 95% CI = [1.19-1.50]) compared with nonwhite 
patients. However, this study was not conducted in the perioperative setting, limiting its 
generalizability to post-tonsillectomy children. 
Additionally, Fortuna and colleagues (2010) assessed prescribing rates of controlled 
substances (opioids) for injury and non-injury related visits in adolescents and young adults 
across multiple settings, including outpatient clinics and emergency departments. Using National 
Hospital Ambulatory Medical Care Survey data from 2005 to 2007, this study showed uninsured 
patients were consistently prescribed controlled substances at higher rates than those with private 
insurance (p < 0.001) (Fortuna, Robbins, Caiola, Joynt, & Halterman, 2010). Though this study 
does not address post-operative opioid prescribing, it further highlights prescribing differences 
based on health insurance status. 
Though inconsistent, the general body of knowledge indicates there are variations in 
opioid prescribing patterns and one factor associated with these variations appears to be 
insurance status. Plausible explanations for differences in opioid prescribing in pediatric post-
tonsillectomy patients may be related to implicit or explicit biases based on certain patient 
characteristics or clinical reasoning, as discussed in Chapter 1.  
Medical treatment based on insurance status 
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Additional evidence illustrates that publicly insured children may be treated differently 
than their privately insured counterparts. These studies, summarized in Table 10, collectively 
represent treatment differences that may be, in part, based on insurance status.   
Table 10 
Treatment Differences in Publicly versus Privately Insured Children 
Study Design & Subjects Measures Conclusions 
(Alexander 
& Currie, 
2017) 
Retrospective review 
of children between 3 
months and 13 years 
of age who presented 
at a New Jersey 
hospital ED between 
2006 and 2012  
Likelihood of 
hospital admission 
during high flu-
weeks 
Likelihood of hospital admission 
favored privately insured children 
for admission, especially when 
hospitals are capacity constrained 
(Boss et 
al., 2015) 
Retrospective review 
of outpatient 
otolaryngology clinic 
children with a new 
diagnosis of sleep-
disordered breathing 
and without a PSG 
sleep study (n=136) 
Days from initial 
evaluation to sleep 
study & days from 
initial evaluation to 
adenotonsillectomy 
Children with OSA who had 
public insurance had longer 
intervals from initial evaluation 
to sleep study (p = 0.001) or 
surgery (p = 0.001) 
(Bisgaier 
& Rhodes, 
2011) 
Prospective study of 
two paired phone 
calls separated by 1 
month to 273 
randomly selected 
specialty pediatric 
medical clinics in one 
Midwest county  
Ability to make an 
appointment at a 
specialty clinic 
(eight specialty 
clinics 
investigated)  
Significant differences in 
provider acceptance of 
Medicaid/CHIP versus private 
insurance. Average wait time for 
publicly insured children was 22 
days longer (p < 0.005); 66% of 
publicly insured children were 
denied an appointment compared 
with 11% of privately insured 
children (p < 0.0001) 
(Chang et 
al., 2014) 
Retrospective cohort 
study evaluating 
Medicaid (n=6,435) 
& commercially 
(n=4592) insured 
children who newly 
started asthma 
treatment 
Total number of 
asthma 
prescriptions  
Total number of asthma 
prescriptions possessed by 
Medicaid children were higher 
compared with privately insured 
children (29.5% vs 12.8%; p < 
0.01) 
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(Sabharwal 
et al., 
2007) 
Retrospective evaluation 
of children < 18 years 
with an extremity injury 
requiring orthopedic 
consultation after 
visiting the ED (n= 125) 
Time from 
initial 
presentation to 
time until 
orthopedic 
consultation 
52% of children with private   
insurance received orthopedic 
care within 24 hours compared 
with 22% with public insurance 
(p = 0.013) 
    
 
The complexity of health and health care invites many alternative explanations for these 
findings, including delay/avoidance of health care due to low-literacy, limited health-related 
knowledge, perceptions of health care and transportation, cost or other access barriers (Arpey et 
al., 2017; Smith et al., 2018; Polit & Beck, 2017). Still, health insurance status seems to 
influence some aspects of health and health care, including prescribing patterns. 
Theoretical Framework 
 
The following section details the theoretical underpinnings of the study and applies the 
theoretical constructs within the context of the study.  
Introduction 
 
Defining the quality of healthcare is challenging. Many problems stem from the notion 
that quality is inherently difficult to define. The Institute of Medicine (IOM) initially defined 
quality as “the degree to which health services for individuals and populations increases the 
likelihood of desired health outcomes and are consistent with current professional knowledge” 
(Institute of Medicine, 1990, p.21). Later, the IOM presented a new conceptualization of quality 
to include six domains of quality healthcare – care that is safe, timely, patient-centered, effective, 
equitable and efficient (Institute of Medicine, 2001).   
Quality of care is a central matter in this study. Evaluating codeine and opioid prescribing 
in publicly and privately insured pediatric post-tonsillectomy patients aligns with the IOM’s 
quality conceptualizations of safety (halting codeine prescribing) and equity of care (in all 
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children, regardless of health insurance status). The Donabedian model will serve as a 
framework to define how quality will be measured in this study. 
The Donabedian model 
 
In pursuit of evaluating quality in healthcare, Avedis Donabedian worked to define and 
develop techniques to measure the quality of healthcare; his research contributed an influential 
body of work on the theory and practice of quality in healthcare  (Ayanian & Markel, 2016). As 
shown in Figure 4, Donabedian’s landmark article proposed three domains in which the quality 
of healthcare can be assessed – structure, process and outcome (S-P-O) (Donabedian, 
1966/2005). The assumption of the model is “good structure increases the likelihood of good 
processes, and good processes increases the likelihood of good outcomes” (Donabedian, 1988, 
p.1145). It is integral to note that structure, process and outcome do not themselves constitute 
elements of quality – rather they are vehicles by which quality can be assessed. The following 
narrative will describe each arm of Donabedian’s triad.  
 
Figure 4. The Donabedian Model  
 
Shi & Singh (2015) describe structure as the foundation of quality healthcare.  The 
structure of care relates to the organization of health care delivery and can be viewed at the 
system, organizational or individual level (Kleinman & Dougherty, 2013). The structure arm of 
the triad refers to characteristics or attributes of the setting in which care occurs and 
instrumentalities that produce care within those settings (Donabedian, 1966/2005). Facility 
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resources, qualifications of providers/organizations, administrative structure, governance systems 
and fiscal components are aspects of Donabedian’s structure arm. Structure may also include 
administrative and related processes that support and direct the provision of care (Shi & Singh, 
2015; Donabedian, 1966/2005). The assumption, as delineated by Donabedian (1966/2005), is 
“given the proper settings and instrumentalities, good medical care will follow” (p. 695).   
Another approach to quality assessment is to evaluate the process of care itself. The 
process arm of the triad represents what is actually done in giving and receiving care and 
includes all components of delivered care (Donabedian, 1988). Performance of the healthcare 
provider can be assessed by both technical and interpersonal aspects. Best practice, or the 
process that is “known or believed to produce the greatest improvement in health”, is used to 
judge the goodness of technical performance or effectiveness of delivered care (Donabedian, 
1988, p. 1743).  Interpersonal aspects of care comprise effective provider-patient communication 
based on dignity, respect, compassion and concern (Shi & Singh, 2015). Again, the assumption 
by Donabedian (1966/2005) is when “good” medical care has been applied, “good” outcomes 
will follow.  Processes can be evaluated by means of appropriateness of medical care, technical 
competence, coordination of care, acceptability of care and interpersonal performance 
(Donabedian, 1966/2005). Process measures are actionable (e.g. can modify a process to reflect 
best practice) and can be directly targeted to improve quality (Glance, Neuman, Martinez, 
Pauker, & Dutton, 2011). 
Finally, the outcome of medical care is a frequently used indicator to evaluate quality of 
care. It denotes the effect of care on the health status of the patient and population; its evaluation 
may broadly encompass recovery, restoration of function and survival (Donabedian, 1988; 
Donabedian, 1966/2005). Shi & Singh (2015) describe outcomes as final results comprising 
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health status, recovery/improvement, mortality, iatrogenic illnesses, re-hospitalization, disease 
incidence and prevalence and patient satisfaction. Because outcomes are relatively concrete, 
valid, widely accepted and amenable to precise measurement, using outcomes as indicators of 
quality is common and advantageous – so long as the outcomes are clearly defined and relevant 
(Donabedian, 1966/2005). Outcomes “by and large, remain the ultimate validators of the 
effectiveness and quality of medical care” (Donabedian, 1966/2005, p. 694). 
The components of Donabedian’s triad were discussed distinctly to provide information 
on each domain in which quality can be assessed. Yet, this approach to quality assessment is 
only possible “because good structure increases the likelihood of good processes, and good 
processes increase the likelihood of good outcomes” (Donabedian, 1988, p. 1145). Thus, a 
unidirectional relationship exists among these elements. This relationship between S-P-O makes 
Donabedian’s model a useful framework to evaluate the influence of structural and process-
related factors on outcomes. As shown in Table 11, this triad has been widely adopted and used 
extensively to evaluate the quality of healthcare. 
Table 11 
Donabedian’s Model Applied to Evaluate the Quality of Healthcare 
Study Design/Population  Structure Process Outcome 
(Hannan et 
al., 2001) 
Retrospective 
review of patients 
undergoing carotid 
endarterectomy 
(CE) 
(n = 3644)  
 
n/a Surgical approach 
and/or medication 
administration in 
patients 
undergoing CE 
Death or stroke 
(Gardner, 
Gardner, & 
O’Connell, 
2014) 
Mixed methods 
study evaluating 
nurse practitioner 
(NP) services using 
stakeholder surveys 
(n=36) and in-
Settings for NP 
services (6 
service 
settings) 
Clinical services 
provided by NP’s 
(technical 
competence and 
scope of practice) 
Quality of care 
(safety and patient 
satisfaction) 
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depth interviews 
(n=24) 
(Liu, 
Singer, 
Sun, & 
Camargo, 
2011) 
Retrospective 
review of patients 
boarded in an 
emergency 
department 
Overflow of 
boarded 
patients to the 
hallway 
Delays or errors 
in diagnosis or 
treatment 
Quality of care 
(length of stay, 
patient satisfaction, 
adverse outcomes) 
(Moore, 
Lavoie, 
Bourgeois, 
& 
Lapointe, 
2015) 
Retrospective 
review of patients 
treated in 57 
trauma systems (n= 
63, 971) 
Trauma 
accreditation 
reports 
Conformity to 
established 
clinical processes 
Mortality, length of 
stay, unplanned 
readmissions, 
complications 
(Profit et 
al., 2010) 
Synthesis of 
various 
frameworks of 
quality of care to 
form composite 
indicators for 
quality of care 
Nurse-to-
patient ratio, 
intensivist in-
house 24 hours 
per day 
Medication safety 
practices, central 
line and ventilator 
assisted 
pneumonia 
processes  
Infection rates, 
pneumonia rates, 
mortality   
(Tsai, 
Joynt, 
Orav, 
Gawande, 
& Jha, 
2013) 
Retrospective 
review of Medicare 
patients discharged 
after 
hospitalization for 
six indexed 
procedures (n= 
479, 471) 
Hospital size, 
teaching status, 
region 
Adherence to 
surgical process 
measures 
Hospital 
readmission rates  
 
Application of Donabedian’s model  
 
This study explores the linkage of Donabedian’s S-P-O constructs, as illustrated in Figure 
5, where the FDA warning (structure) will lead to a change in prescribing practices (process) and 
influence the number of codeine and alternative opioid prescriptions (outcome). An adaptation to 
the model includes health insurance status, where health insurance status (antecedent) may affect 
the number of codeine and alternative opioid prescriptions.  
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Figure 5. Application of Donabedian’s Structure-Process-Outcome model  
 
In this study, the structure arm of the triad is viewed at the system level, where the FDA 
warning is an administrative/regulatory process that supports and directs the provision of care. 
Prescribing practices are consistent with actual care rendered, fitting within Donabedian’s 
process arm. Outcomes, or final results, are the actual number of codeine/opioid prescriptions 
received by pediatric post-tonsillectomy and/or adenoidectomy patients.   
The Donabedian model was modified by Coyle & Battles (1999) to include antecedent 
conditions, or factors that may significantly influence the outcomes of care. Antecedent 
conditions account for the patient’s environmental and/or personal characteristics – the former 
includes cultural, social, political and physical aspects and the latter includes genetics, socio-
demographics, health attitudes, beliefs and preferences (Coyle & Battles, 1999). Health 
insurance status is described as a pertinent socio-demographic antecedent to quality health care 
in Coyle & Battles’ (1999) adaptation of the model, providing justification to include health 
insurance status as antecedent in this study.  
Research Aims and Hypotheses 
 
Aim 1: Evaluate post-tonsillectomy codeine prescribing in publicly and privately insured 
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the 2013 
FDA warning on codeine. 
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Hypothesis one (H1): In publicly and privately insured post-tonsillectomy and/or adenoidectomy 
children at OHSU, rates of codeine prescribing (level and/or trend) decreased following the 2013 
FDA warning on codeine. 
Aim 2: Compare post-tonsillectomy codeine prescribing in publicly and privately insured 
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the 2013 
FDA warning on codeine. 
Hypothesis two (H2): There is a difference in codeine prescribing (level and/or trend) between 
publicly and privately insured post-tonsillectomy and/or adenoidectomy children at OHSU.   
Aim 3: Examine all other post-tonsillectomy opioid prescribing (oxycodone, hydrocodone) in 
publicly and privately insured children who underwent tonsillectomy at OHSU before and after 
the 2013 FDA warning on codeine. 
Hypothesis three (H3): In publicly and privately insured post-tonsillectomy and/or 
adenoidectomy children at OHSU, rates of alternative opioid prescribing (level and/or trend) 
increased following the 2013 FDA warning on codeine. 
Aim 4: Compare post-tonsillectomy other opioid prescribing in publicly and privately insured 
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the FDA 
warning on codeine. 
Hypothesis four (H4): There is a difference in other opioid prescribing (level and/or trend) 
between publicly and privately insured post-tonsillectomy and/or adenoidectomy children at 
OHSU.   
Chapter Summary  
 
 Post-tonsillectomy adverse events result from a variety of factors including opioids, 
comorbid conditions and genetic risk signatures. Codeine, and potentially other opioids, should 
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be avoided in all post-tonsillectomy and/or adenoidectomy children due to the risk significant 
adverse events. Studies have evaluated the impact of the FDA warning on codeine and opioids in 
privately insured children, but no study has done so in publicly insured children. Though the 
evidence is mixed, studies suggest insurance status may influence prescribing patterns. The 
purpose of this study is to fill the research gap of codeine/opioid prescribing in publicly insured 
post-tonsillectomy and/or adenoidectomy children and compare prescribing rates between 
publicly versus privately insured children.  
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Chapter 3: Methodology  
Chapter Overview 
 
The purpose of this study is to examine the impact of the FDA warning on codeine/opioid 
prescribing in children undergoing tonsillectomy and/or adenoidectomy at Oregon Health and 
Science University (OHSU) and to evaluate if prescribing practices vary based on health 
insurance status. The previously described Donabedian model provides the theoretical 
framework to inform the study. Donabedian’s constructs of structure, process and outcome will 
guide operationalization of study variables and evaluation of study data. 
Chapter Three describes the study’s research methodology, including research design, 
population, and sampling information. A detailed description of the study’s variables, discussion 
of the data source, overview of data collection procedures and a summary of the data analysis 
plan is presented. This section concludes with an account of the validity of research design. 
Research Design 
 
 This study will evaluate the impact of the FDA warning on opioid prescribing in pediatric 
post-tonsillectomy patients by employing a quasi-experimental, interrupted time series (ITS) 
study design. An ITS design provides understanding of patterns of change over time and 
evaluates the effects of a planned or unplanned intervention (Velicer, Hoeppner, & Goodwin, 
2012). The ‘time series’ represents repeated observations of a particular event collected over 
time in a defined population and the ‘interruption’ signifies the intervention (Polit & Beck, 
2017). The most common ITS design includes two segments where the first comprises rates of 
the event prior to the intervention or policy change and the second represents the rates after the 
intervention or policy change (Penfold & Zhang, 2013). Series of observations on the same 
outcome can test immediate and gradual effects of the intervention or policy change (Taljaard, 
McKenzie, Ramsay, & Grimshaw, 2014). This study design is particularly useful when the 
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investigator does not have control over the implementation of an intervention, when 
randomization is not feasible and when a control group is lacking (Penfold & Zhang, 2013; Polit 
& Beck, 2017). Time series designs can be prospective or retrospective, or a combination of both 
(Polit & Beck, 2017). This study will employ a retrospective design and obtain data from the 
health system’s electronic health record (EHR).  
An ITS design is an appropriate methodology for this study for several reasons. First, ITS 
designs are the standard for evaluating the impact of policy changes, public health interventions 
or quality improvement programs (Bernal, Cummins, & Gasparrini, 2017; Penfold & Zhang, 
2013; Ray, 1997). The design is particularly suited to assess interventions/policies that are 
instituted at a population level over a defined period of time (Bernal et al., 2017). The ITS 
methodology aligns with the current study’s aim of evaluating the effects of a policy/regulatory 
change (FDA warning) on repeated outcomes (prescribing practices) in a defined population 
(pediatric post-tonsillectomy patients). Next, this study contains a naturally occurring 
intervention (FDA warning) that represents the ‘interruption’ in the ITS design. This feature 
allows for clear differentiation of pre-and post-intervention periods and repeated pre-and post-
intervention measures. Additionally, similar studies utilized the ITS study methodology to 
evaluate opioid prescribing practices, as summarized in Table 12. Finally, it would not be 
feasible nor ethical to randomize participants to intervention and control arms within the context 
of the FDA warning on codeine; this warning applied nationally to all post-tonsillectomy 
children immediately after the warning was announced. 
Table 12 
Interrupted Time Series Methodology in Opioid-prescribing Studies 
Study Objective Data Source Time series comparisons 
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(Bohnert, Guy, 
& Losby, 2018) 
If release of the 2016 CDC 
Guidelines for Prescribing 
Opioids for Chronic Pain* 
corresponded to declines in 
opioid prescribing practices 
in U.S. adults 
Retail pharmacy 
data from 2012-
2017 
Compared pre-and post-
CDC guideline monthly 
prescribing measures 
(dosage, supply, 
opioid/benzodiazepine 
overlap) 
(Boyle et al., 
2019) 
If sharing individual 
provider prescribing data 
with other providers* 
impacted the rates of opioid 
prescriptions written for 
adult patients discharged 
from the ED 
Single center 
community hospital 
EHR data from 
2015-2016 
Compared pre-and post-
intervention number of 
discharge prescriptions 
written by each clinician 
(Chua et al., 
2017) 
If the FDA Boxed Warning* 
on codeine resulted in a 
reduction in codeine and/or 
opioid prescribing in 
children who underwent 
tonsillectomy 
Prescription data 
from the Truven 
MarketScan 
Commercial Claims 
Encounters 
database from 
2012-2015 
Compared pre-and post-
FDA warning codeine and 
opioid prescribing rates  
(Fernandes et 
al., 2016) 
If the national clinical 
practice guidelines* and/or 
drug policy interventions* 
impacted opioid prescribing 
rates or opioid-toxicity 
hospitalizations in Canadian 
citizens  
Prescription data 
from the Ontario 
Drug Benefit 
database from 
2003-2014 
Compared pre-and post- 
intervention rates of 
prescribing, dose of opioid 
prescribing and opioid-
related ED visits and 
hospitalizations 
(Meisenberg, 
Grover, 
Campbell, & 
Korpon, 2018) 
If a multilevel opioid 
intervention* reduced 
opioid prescribing in 
inpatient and outpatient 
adult patients 
Single center 
community hospital 
EHR data from 
2016-2018 
Compared pre-and post-
intervention morphine 
milligram equivalents 
(MME) per month, MME 
per prescription and rates 
of opioid prescriptions  
(Ranapurwala, 
Carnahan, 
Brown, 
Hinman, & 
Casteel, 2019) 
If Iowa’s prescription 
monitoring program* 
(PMP) reduced opioid 
prescribing patterns in 
adults 
Iowa’s private 
health insurance 
claims database 
from 2003-2014 
Compared pre-and post 
PMP daily MME dosage, 
MME per prescription, 
supply of opioids and 
overall prescribing rates 
(Van Cleve, 
2017) 
If the FDA Boxed Warning* 
on codeine resulted in a 
reduction in codeine and/or 
opioid prescribing in 
pediatric post-tonsillectomy 
patients 
Prescription data 
from the Truven 
MarketScan 
Commercial Claims 
Encounters 
database from 
2012-2015 
Compared pre-and post-
FDA warning 
codeine/opioid prescribing 
rates and ED visits. 
*I = “Interruption” in the design  
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Data Source 
 
 The data source for this study is OHSU’s EHR platform, EPIC Hyperspace®. The 
outpatient EPIC Hyperspace® platform was fully integrated into OHSU in 2008. Thus, the data 
source is expected to yield complete, electronic data from 2010-2018. Data will be extracted by 
the OHSU Pharmacy Informatics team; information regarding data collection is detailed below. 
Population and Sample 
 
Target population & accessible population 
 
The target population for this study is U.S. pediatric patients up to 18 years of age 
undergoing tonsillectomy and/or adenoidectomy on an outpatient basis. The accessible 
population is children up to 18 years of age who presented to OHSU between January 2010 
through December 2018 for outpatient tonsillectomy and/or adenoidectomy. 
Sampling strategy 
 
In retrospective evaluation of EHR data, sampling refers to the method by which cases or 
records are selected from the accessible population or database. A convenience sampling method 
is the most common method for selecting cases or records from an EHR over a specific time 
frame (Worster & Haines, 2004). In this study, the EHR represents the sampling frame and the 
sampled population will be all eligible patients who underwent tonsillectomy and/or 
adenoidectomy at OHSU between January 2010 through December 2018.  The number of cases 
in the sample will be limited to the number of cases performed at OHSU. This convenience 
sampling strategy is expected to produce adequate data, as OHSU otolaryngology surgeons 
perform nearly 300-400 such cases annually.  
Eligibility criteria 
 
 Inclusion and exclusion criteria are presented and justified in Table 13, below. 
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Table 13 
Inclusion and Exclusion Criteria 
 Criteria Justification 
Inclusion  Male or female 
patient presenting for 
outpatient 
tonsillectomy and/or 
adenoidectomy at 
OHSU 
The FDA warning applies to all children undergoing 
tonsillectomy and/or adenoidectomy, regardless of 
demographic characteristics or indication for 
tonsillectomy. 
Age 0-18 years The FDA warning applies to all children < 18 years of 
age.  
Public or private 
insurance 
No study has compared post-tonsillectomy opioid 
prescribing in publicly versus privately insured children. 
Research suggests insurance status may impact opioid 
prescribing practices (Donohoe et al., 2019). 
Exclusion  Date of surgery 
between February 
2013 – March 2013 
The month the FDA warning was announced (February 
2013) plus the month after (March 2013) will be 
excluded. Exclusion of the month/month after accounts 
for a “wash out” effect (Polit & Beck, 2017). 
A combined 
procedure of any type 
A combined procedure of any type may influence post-
operative pain severity may increase the likelihood of a 
post-operative opioid prescription (Donohoe et al., 2019.; 
Fortuna et al., 2010). 
Inpatient admission 
following 
tonsillectomy 
Inpatient admission allows for greater patient monitoring 
capabilities, which may increase the likelihood a 
provider would prescribe post-tonsillectomy and/or 
adenoidectomy opioids. 
Uninsured children Due to federal and state initiatives, the percentage of 
uninsured children in Oregon is < 3%. This low rate of 
uninsured children would lead to inadequate observations 
per time period and unbalanced study groups.  Uninsured 
children will not be included in the statistical model for 
the health insurance stratified analysis. 
 
Power analysis 
 
 In ITS, power is a function of a variety of factors including the number of time points, the 
distribution of time points before and after the intervention, the degree to which data are 
correlated across time (autocorrelation), expected effect size and the presence of confounders 
(Bernal et al., 2017). As a result, there are no fixed limits regarding the number of time points –  
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though it has been suggested that studies with few time points and small effect sizes may be 
underpowered (Bernal et al., 2017; Zhang, Wagner, & Ross-Degnan, 2011). Time points are 
defined as a continuous sequence of observations on a population, taken repeatedly at equal 
intervals over time; there is no standard measurement interval – weekly, monthly and yearly time 
points are described in health policy literature (Bernal, Cummins, & Gasparrini, 2018; Hudson, 
Fielding, & Ramsay, 2019). In ITS, power increases with the number of time points and/or if the 
number of time points before and after the intervention are equally distributed. The latter is 
rarely practical whereas former is imperative, as a sufficient number of time points are required 
to properly analyze time-series data (Bernal et al., 2017; Wagner, Soumerai, Zhang, & Ross-
Degnan, 2002). Power also increases when autocorrelation is small, when effect size is large and 
when changes in both the regression slope and level is expected; all of these values are often 
difficult to establish a priori (Zhang et al., 2011). 
Using simulated-based power calculations, Zhang et al. (2011) described acceptable 
methods for calculating power in health policy time-series research designs. With a significance 
level of alpha (a) = 0.05, models with greater than 80% power to detect moderate effect sizes 
require 24 or more time points. Samples as small as 12 time points should be used with caution 
as unreliable power estimates and Type II error may be introduced (Wagner et al., 2002; Zhang 
et al., 2011). In addition to a sufficient number of time points, ITS requires an adequate number 
of observations at each time point (Hawley, Ali, Berencsi, Judge, & Prieto-Alhambra, 2019). 
There appears to be no distinct minimum number of observations at each time point, though 
>100 is desirable to achieve an acceptable level of variability at each time point (Wagner et al., 
2002). Table 14 details the components of power analysis considered for this study.  
Table 14 
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Components of Power Analysis 
Anticipated effect size Small. Based on conservative estimates from the 
literature (Chua et al., 2017; Van Cleve, 2017) 
Anticipated autocorrelation Unknown. If autocorrelation is unknown, using a range 
of 0.1 and 0.5 is recommended. This is consistent with 
previous policy evaluation time-series studies (Zhang et 
al., 2011) 
Anticipated change in level and 
slope 
Based on previous studies, both a level and slope change 
are anticipated, with a greater change in the level when 
compared with the slope (Chua et al., 2017) 
N= Total number of time points 
(time points = months) 
Pre-intervention: 31 time points (January 2010 – July 
2012) 
Post-intervention: 69 time points (April 2013 – 
December 2018) 
Total N = 100 
n = Total number of observations 
at each time point (observations = 
number of tonsillectomies per time 
point) 
25-30, assuming 300-400 tonsillectomies per year 
Balance of design Unbalanced. The post-intervention period includes a 
greater distribution of time points. Pre- and post-
intervention periods in health policy research are often 
unbalanced (Bernal et al., 2017) 
Confounders Seasonal variation in rate of tonsillectomies may 
influence power 
 
 The relatively low number of observations at each time point, unbalanced design, small 
effect size and potential seasonal variation may be offset by the sufficiently long sampling period 
and adequate number of time points (Polit & Beck, 2017; Wagner et al., 2002).  Power is also 
enhanced in this study due to population-level repeated measures of the outcome over an 
extended period of time, a well-defined pre-and-post health policy change period and equally 
spaced observation intervals (Hawley et al., 2019). Based on Zhang’s et al. (2011) simulated 
power analysis, the estimated power for a model with both a slope and level change, a small 
effect size, unbalanced pre-and post-intervention periods, autocorrelation range between 0.1-0.5 
and a= 0.05, power is expected to be 0.76 – 0.99. Thus, this study is appropriately powered. 
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Data Collection 
 
The tool used to collect data in this study will be the OHSU health system’s EHR. An 
EHR is unbiased (non-reactive) and inexpensive way to collect data (Polit & Beck, 2017). EHR’s 
collect longitudinal, electronic data during routine delivery of health care and generally include 
demographic, administrative, claims (medical and pharmacy), clinical, and patient-centered data 
(Cowie et al., 2017). Collecting data via the EHR is an appropriate method given this study aims 
to evaluate clinical, demographic, medical and pharmacy data that has been collected over time 
during routine tonsillectomies and/or adenoidectomies.  
Variables and Measures 
 
Table 15 shows study variables that will be collected and their associated measurement. 
In this study the predictor variables are the intervention (FDA Warning) and time (months pre-
and post-FDA warning). The outcome variables include rates of codeine and other post-
tonsillectomy opioid prescribing. Additional demographic (age, gender, race) and clinical (OSA 
status, body mass index [BMI] percentile) variables will be collected to assess group 
comparability and to evaluate if prescribing is influenced by demographic or clinical factors; 
health insurance payer information will be collected to assess if prescribing varies by insurance 
status. Procedural data and date of surgery will be collected for each child. Note: International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Procedure 
Codes (ICD-10-PSC), International Classification of Diseases, Tenth Revision, Clinical 
Modification (ICD-10-CM) and Procedure Codes (ICD-10-PCS) and Current Procedural Codes 
(CPT) are further detailed in Appendix A.  
Table 15 
Study Variables and Measurement 
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Variable Collected Measurement Type of Variable 
Sleep related 
breathing disorder 
and/or OSA 
diagnosis  
ICD-9-CM* codes: 327.23 and/or 780.57 
within 90 days of DOS 
ICD-10-CM* codes: G47.33 and/or G47.30 
within 90 days of DOS 
Categorical [OSA/no 
OSA] 
Tonsillectomy 
and/or 
adenoidectomy 
surgical procedure 
CPT codes: 42820, 42821, 42825, 42826, 
42830, 42831 and/or 42835, 42836 on DOS 
ICD-9-PCS codes:28.2, 28.3 and/or 28.6 on 
DOS 
ICD-10-PCS codes: 0CTP0ZZ, 0CTPXZZ, 
0CTQ0ZZ, 0CTQXZZ, 0C5P0ZZ, 0C5PXZZ, 
0C5Q0ZZ, 0C5QXZZ, 0CBP0ZZ, 
0CBPXZZ, 0CBQ0ZZ and/or 0CBQXZZ on 
DOS 
n/a – all children 
included in the study 
underwent 
tonsillectomy and/or 
adenoidectomy 
Time Date of service (month/year) associated with 
CPT and/or ICD-9/10-PCS code(s) for 
tonsillectomy and/or adenoidectomy  
Continuous   
FDA Boxed 
Warning 
Measured using the date of the FDA warning 
(February 2013) to denote pre-FDA warning 
or post-FDA warning periods 
Categorical [pre or 
post-FDA warning 
period] 
Age Age at DOS; obtained via demographic 
information  
Continuous variable, 
collapsed into 
categorical variables  
Gender Male or female gender; obtained via 
demographic information  
Categorical 
[male/female] 
Height Height in meters Continuous 
Weight Weight in kilograms Continuous 
Body Mass Index 
[BMI] 
Weight in kilograms divided by the square of 
height in meters 
Categorical 
[underweight, normal 
weight, overweight, 
obese] 
Race Race (as defined by the CDC’s revised race 
standards); obtained via demographic 
information 
Categorical [0 = 
American Indian, 
Alaskan Native, Native 
Hawaiian or Other 
Pacific Islander, 1= 
Asian, 2= Black, 3= 
White] 
Health insurance 
status 
Payer information; obtained via 
administrative claims 
Categorical 
[private/public] 
Post-tonsillectomy 
codeine prescribed 
(0-2 days) 
 
 
If prescribed:   
Prescription data; obtained from pharmacy 
claims 
 
 
Dose (milligram/kilogram [mg/kg]) of codeine 
prescribed 
Continuous [rates of 
codeine** prescribing, 
expressed in %] 
 
Continuous  
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Post-tonsillectomy 
alternative opioid 
prescribed (0-2 
days) 
 
If prescribed: 
Prescription data; obtained from pharmacy 
claims 
 
 
 
Dose (milligram/kilogram [mg/kg]) of alternative 
opioid prescribed 
Continuous [rates of 
other*** opioid 
prescribing, expressed 
in %] 
 
Continuous  
*ICD-9-CM and PCS effective until 10/1/2015; ICD-10-CM and PCS effective 10/2/2015 -
present 
**Codeine = Includes codeine alone or any codeine-containing drug – the most common being 
codeine with acetaminophen 
***Other opioids = Hydrocodone, oxycodone, tramadol  
  
Data management 
 
All data will be extracted from OHSU’s EHR, exported to Microsoft® Excel and entered 
into the IBM® Statistical Package for the Social Sciences (SPSS) statistical software. 
Confidentiality of the data will be maintained through use of a password protected, encrypted 
OHSU issued laptop. Any hard copies of subject information will be stored in a locked cabinet 
and made accessible only to those directly involved in the study. Study records (electronic and/or 
hard copy) will be made available for review only to those directly involved in the study and the 
Institutional Review Boards (IRB) of OHSU and Virginia Commonwealth University (VCU).  
Protection of Human Subjects 
 
This study collects secondary data from the medical record, does not require consent and 
represents no more than minimal risk to subjects. Subject information will be recorded in a 
manner that the identity of the human subjects cannot readily be ascertained directly or 
indirectly. Subject identifiers will be treated as confidential per the Health Insurance Portability 
and Accountability ACT (HIPAA) of 1996; identifiers will not be used in published information 
or disseminated otherwise.  
Children are a vulnerable population addressed in the federal regulations of research 
conduct (45 CFR 46 Subpart D; 21 CFR 50 Subpart D). From a regulatory perspective, this study 
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falls into the “minimal risk” category and no additional protection is required beyond that of 
appropriate IRB approval from OHSU and VCU, and abiding by the ethical standards of research 
conduct (Welch et al., 2015).  
Data Analysis 
 
Data cleaning 
 
After data extraction, the variables will be named and data will be cleaned using 
procedures described by Tabachnick and Fidell (2013). First, descriptive statistics will be 
evaluated for accuracy of data input, including assessment of normality, out-of-range values and 
outliers. Next, missing data will be assessed; if data is missing, a missing value analysis will be 
performed to identify the extent and pattern of missing data. Linearity between the independent 
(time) and dependent (prescribing rates) variables within each regression segment will be assess 
via residual plots (Wagner et al., 2002). Autocorrelation will be assessed and, if present, will be 
dealt with via adjustment of standard errors as suggested by Tabachnick and Fidell (2013).    
Descriptive statistics 
 
Descriptive statistics will be generated to describe the characteristics of children 
undergoing tonsillectomy at OHSU between January 2010 – December 2018. For each study 
year the following will be reported:  Sample size, gender (% male and female), age (% 0-4.9 
years, 5-9.9 years, 10-18 years) weight status (% underweight, normal weight, overweight or 
obese), race (% American Indian, Alaskan Native, or Other Pacific Islander, Asian, Black or 
African American and White), health insurance status (% public and private) and OSA status (% 
with and without OSA).  
Time-series analysis 
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Segmented regression analysis is a statistical method for modelling ITS data and will be 
used in this study to assess the impact of the FDA warning on codeine and opioid prescribing in 
post-tonsillectomy children. This is a well-established method to test the hypothesis that an 
intervention caused a significant change in the outcome over time (Valsamis, Ricketts, Husband, 
& Rogers, 2019; Wagner et al., 2002). Segmented regression is an adaptation of linear regression 
where separate regressions are performed for periods before and after an intervention 
(Tabachnick & Fidell, 2013; Valsamis et al., 2019). The regression coefficients of the model 
estimate the pre-intervention slope, the level change at the intervention point and the slope 
change from pre-intervention to post-intervention (Kontopantelis, Doran, Springate, Buchan, & 
Reeves, 2015). Figure 6 further describes the slope and level changes within the context of an 
ITS design. 
 
Figure 6. Slope and Level Changes in Interrupted Time Series Designs. Information from: 
(Kontopantelis et al., 2015) 
 
The two segments in this study will be defined as the pre-FDA or post-FDA warning 
periods and the intervention, or ‘interruption’, will be the FDA warning. Segmented linear 
regression will quantify changes in the level and slope in the pre-and post-FDA warning periods, 
then estimate if the differences are statistically significant. The level and trend estimates will 
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provide information on the immediate (level change) and/or gradual (trend or slope change) 
effects of the FDA warning. The segmented regression equation that will be used for this study, 
adapted from Wagner et al. (2002), is: Yt= b0 + b1*timet + b2*interventiont + b3*time after +et 
Where Y = mean number of prescriptions in month t 
time = time in months at time t from the start of the observation period 
intervention = time t occurring before or after the FDA warning 
time after = number of months after the FDA warning at time t 
b0 = baseline level of number of prescriptions per month at time zero 
b1 = change in the mean number of prescriptions that occurs with each month pre-
FDA warning 
b2 = level change in the mean number of monthly prescriptions immediately after 
the FDA warning 
b3 = trend change in the mean number of monthly prescriptions after the FDA 
warning, compared with the monthly trend before the FDA warning 
et = error term at time t represents variation not explained by the model  
 
The first regression model will evaluate codeine prescribing in publicly and privately 
insured post-tonsillectomy children at OHSU, addressing hypothesis one (H1). The second 
regression model will evaluate alternative opioid prescribing in publicly and privately post-
tonsillectomy children at OHSU, addressing H3. The impact of health insurance on codeine (H2) 
and alternative opioid (H4) prescribing will be assessed using an additional regression model. 
This model will test whether associations vary among children with public versus private 
insurance. To accomplish this, interaction terms between the covariate of interest (health 
insurance status) and the three ITS components relating to the pre-intervention slope, level 
change, and change in slope will be evaluated (Kontopantelis et al., 2015). For all statistical tests, 
p-values and confidence intervals will be reported; two-sided p-values of £ 0.05 will be 
considered clinically significant. Data will also be presented graphically via time series plots. 
Assumptions and Threats 
 
The key study design assumption is that without the intervention (FDA warning), pre-
intervention prescribing trends would continue unchanged into the post-intervention period and 
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no external factors systematically affect the trends (Kontopantelis et al., 2015; Tabachnick & 
Fidell, 2013). To evaluate external factors that could bias the results, the FDA’s Drug Shortages 
Database (https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm) will be searched to 
assess for shortages of codeine, oxycodone, hydrocodone or tramadol. Also, the literature will be 
examined for other interventions (known as co-interventions) that may confound the results. The 
aforementioned will address the threat of history bias. Next, time series designs may exhibit 
seasonal fluctuation due to cyclic variation in illnesses, preferences or clinical practice (Bernal et 
al., 2018; Wagner et al., 2002). Seasonality in this study may occur related to varying rates of 
tonsillectomies per month, however a sufficiently long sampling period reduces this threat.  
Statistically, segmented regression assumes data are collected regularly over time at 
equally spaced intervals. This assumption will be met, as the observation points in this study will 
be collected at regular, monthly intervals. Also, analysis of time-series data requires that 
correlation of the data points across time is accounted for (Tabachnick & Fidell, 2013; Zhang et 
al., 2011). Statistical procedures will be performed to account for data points that are close 
together in time and tests for autoregulation will be reported. If autocorrelation is present, it will 
be controlled for statistically by adjusting the standard errors, as described by Tabachnik and 
Fidell (2013). These procedures, along with an appropriate power analysis, distinct pre-and post-
intervention periods and accurate measurement tools, enhance the statistical conclusion validity 
of this study. 
Convenience sampling increases the external validity of this study, though threatens 
internal validity (Polit & Beck, 2017). However, because this study observes a single population 
(pediatric post-tonsillectomy patients) over an extended period of time, threats due to between-
group differences, such as selection bias or unmeasured confounders, are minimized (Bernal et 
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al., 2018). Additionally, because ITS designs model the baseline trend, within-group 
characteristics that randomly fluctuate or slowly change over time are controlled for (Bernal et 
al., 2018; Kontopantelis et al., 2015). Still, demographic information (age, gender, race) will be 
collected and accounted for statistically if group differences are significant.  
Measurement error is a potential threat in this study. This concern is reduced as no 
changes in the measurement of the variables and/or data collection methods will occur. 
Additionally, due to institutional and regulatory oversight, opioid prescribing is tightly-
controlled and generally free of errors. It is possible that early in the study period paper/written-
prescriptions, versus current electronic prescriptions (e-prescriptions), were prescribed. 
However, all paper prescriptions were required to be entered into the EHR, minimizing this 
concern. Finally, an outlier assessment will be conducted to evaluate for inconsistent data points 
that may constitute measurement error. 
Internal validity is also threatened due to lack of a control group. However, it is infeasible 
to select a group that was not exposed to the FDA warning on codeine, as this warning applied 
nationally to all children undergoing tonsillectomy. Though a control group leads to stronger 
inferences, an ITS design without a control group represents a valid quasi-experimental design 
(Polit & Beck, 2017).  
Temporal sequencing does not pose a threat in this study as the timing of the FDA Boxed 
Warning is distinct (February 2013). Pre-FDA warning outcomes (prescribing practices) will be 
measured to serve as a reference point and change in the level and/or slope of the outcome in the 
post-FDA warning is evidence to support temporality (Polit & Beck, 2017). The month of the 
FDA warning (February 2013) and the month following (March 2013) will be excluded as a 
“wash out” period.  
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Chapter Summary 
 
This chapter presented the methodological details for the study, including a description of 
the planned ITS research design and data analysis methods that will be used to evaluate the 
impact of the FDA warning on codeine/opioid prescribing in pediatric-post-tonsillectomy 
patients at OHSU. Information regarding the sampling method, eligibility criteria, variables, data 
collection and management was presented. The chapter concluded with a discussion of study 
assumptions and threats to study validity. Chapter Four will present results of the study. 
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Chapter 4: Results 
 
Chapter Introduction 
 
The dangers of codeine in children undergoing tonsillectomy and/or adenoidectomy are 
well documented. Codeine prescribing should be avoided in all pediatric post-tonsillectomy 
and/or adenoidectomy patients, regardless of demographic or clinical characteristics. The 
purpose of this study was to examine the impact of the FDA warning on codeine/other opioid 
prescribing in children undergoing tonsillectomy and/or adenoidectomy at OHSU and to evaluate 
if prescribing practices vary based on health insurance status. 
This study evaluated the impact of the FDA warning on opioid prescribing in pediatric 
post-tonsillectomy patients by employing a quasi-experimental, interrupted time series (ITS) 
design. This design provided understanding of opioid prescribing patterns over time and 
evaluated the effects of the FDA warning on codeine and other opioid prescribing. This chapter 
describes data preparation and statistical analyses that were employed to accomplish the study’s 
aims. The chapter begins with a review of data extraction procedures, including a description of 
study exclusion criteria, followed by an overview of data cleaning/preparation and statistical 
assumption testing. Descriptive analysis and statistical modeling are presented. The chapter 
concludes with a summary of the study findings. 
Review of Data Extraction  
 
After IRB approval from OHSU and VCU, the data was extracted from OHSU’s EHR 
platform (EPIC Hyperspace®), deidentified and coded with unique patient identifiers by the 
OHSU Pharmacy Informatics team. The data was transferred via email in a xls.doc (Microsoft 
Excel®) following OHSU data-security protocols. Greater than 99% of opioid prescribing 
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occurred within 0-2 days after tonsillectomy and therefore this prescribing interval was used. 
Insurer information was confirmed for all children on the day of procedure plus two days. 
The initial dataset contained 108 months (January 2010-December 2018). When the unit 
of time for analysis equaled month, the total number of cases at each observation interval was 
small (n < 20), potentially introducing error into the analysis and threatening validity of 
inferences. Rather than monthly observations, data was grouped into 4-month observation 
intervals to assure adequate observations per unit of time. Appendix B displays the months 
included in each observation interval. To accommodate for the ITS analysis and to have clear 
differentiation between the pre-and post-FDA warning periods, the first and last months of data 
(months 1 and 108, respectively) were removed. Two months of data in time period 25 were 
excluded due to outlier values, as discussed below. The month the FDA warning was issued 
(February 2013) and the following month (March 2013) were excluded. Figure 7 depicts the 
study exclusions. A total of 26 observation intervals were included in the analysis; observation 
intervals 1-9 comprised the preintervention period and 10-26 were the postintervention period. 
 
 
 71 
 
Figure 7. Study Exclusion Flow Chart 
 
 
Data Preparation 
 
The data was cleaned and coded using SPSS. Study variables were coded as shown in 
Table 16. Study months were ordered chronologically and coded as pre-or post-FDA warning 
period. Gender was categorized as males and females. Age was collapsed into three categories 
(0-4.9, 5-9.9 and 10-18 years) for clinical relevance and to approximate even groups. Though 
race was recorded as White (81.3%), Multiracial (8.4%), Black (3.3%), Asian (2.4%), American 
Indian (1.3%), Other Pacific Islander (0.2%) or unknown (0.1%), for analyses it was categorized 
as White, Non-white or missing. Insurer was classified as public, private or self. The OHSU 
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Otolaryngology billing department was consulted to assist in classifying insurers into respective 
categories. Health care programs for military personnel (Tricare, ChampVA, VA Community 
Outsource) represented < 2% of the sample and were included in the private insurer group. See 
Appendix C for a list of insurers included in each category. Body Habitus was derived from BMI 
percentile (based on age, gender, height and weight) and collapsed into normal, non-normal 
(underweight, overweight or obese) or missing BMI percentile. Procedure indication denoted the 
primary diagnosis associated with the procedure CPT code and was categorized as OSA versus 
non-OSA. Non-OSA indications included tonsillar or/or adenoidal hypertrophy, tonsillitis, 
adenoiditis and other. Opioids prescribed indicated whether a child did (yes) or did not (no) 
receive an opioid prescription within 0-2 days post-tonsillectomy and/or adenoidectomy. Opioid 
type included codeine-containing products or other opioids. Other opioids were non-codeine 
containing products (oxycodone or hydrocodone-containing products); no children in the study 
were prescribed the opioids tramadol, morphine or hydromorphone and therefore they were not 
included in the variable. 
Table 16 
Study Variables and Coding 
Variable Coding 
Study months (time) Ordered chronologically and coded as  
0: Pre_FDA  
1: Post_FDA  
Gender 0: Males 
1: Females 
Age 0: 0-4.9 years 
1: 5-9.9 years 
2: 10-18 years 
Race 0: White 
1: Non-White 
Insurer 0: Public 
1: Private 
2: Self 
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Body Habitus 0: BMI percentile Normal 
1: BMI percentile Non-Normal 
2: BMI percentile Missing 
Procedure Indication 0: OSA 
1: Non-OSA 
Opioids Prescribed  0: Yes 
1: No 
Opioid Type 0: Codeine Containing Opioid 
1: Other Opioids (Oxycodone or hydrocodone containing opioid) 
 
Assumption Testing  
 
Histograms with normal curve overlays for each variable were examined and are 
illustrated in Appendix D. The normalized plot of residuals for each dependent variable were 
inspected via Kernel Density plots and the data satisfactorily met the assumption of normality 
(See Appendix E). Linearity of the preintervention trends was checked via visualization of 
scatter plots. Data on the variable ‘other opioids’ met the assumption of linearity. The ‘codeine’ 
variable exhibited a somewhat irregular pattern in the pre-intervention period; transformations on 
the variable did not markedly improve linearity. Therefore, the data was left in its original form 
to retain the metrics for purposes of interpretation. Time series data inherently violate the 
assumption of independence of residuals because of autocorrelation over time (Tabachnik & 
Fidell, 2013). Autocorrelation of errors at various lags were examined via the Cumby-Huizinga 
test for autocorrelation. Autocorrelation was present at lag 1 but not any higher order lags and, 
therefore, lag(1) was included in the models. Newey-West standard errors were used in each 
model to handle autocorrelation and possible heteroskedasticity. Visual inspection of time series 
plots did not reveal a seasonal pattern in opioid prescribing. 
The time-series plots were examined for outliers. Discrepant cases were found in time 
period 25 (T25), which contained months April-July 2018. The discrepant cases were attributed 
to May and June 2018, where zero opioids were prescribed during those months. Data for T25 
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was re-extracted by the Pharmacy Informatics team to confirm accuracy of data extraction. The 
otolaryngology surgical group verified there were no co-interventions during that time and the 
pharmacy team did not find evidence of opioid shortages. The Information Technology 
department confirmed an EPIC Hyperspace upgrade during that time. Given the magnitude of 
discrepancy and a plausible technological fault, the outliers were dealt with via exclusion. The 
remaining observations in T25 (April and July 2018) were used to populate opioid prescribing 
for the observation interval. A sensitivity analysis was conducted where data from T24 was 
carried forward to replace the T25 observation interval. No changes to the model occurred, 
confirming the robustness of findings. 
A missing values analysis was conducted. Data was complete for all variables with the 
exception of race and body habitus (BMI). Because the variable race had only 3.1% missing data 
and was not a critical variable for hypothesis testing, the variable was not altered. The BMI 
variable contained 15% missing values. Missing values for BMI were attributed to missing 
height information from the EHR. The majority of missing values occurred in the first two study 
years with 65.7% and 36.3% missing in 2010 and 2011, respectively. Missingness continued to a 
lesser extent throughout the remaining study years (range 4.7-12.8%). The frequency of missing 
BMI percentile data is presented in Table 17. Younger children, those who were self-insured, 
and children with a primary diagnosis of non-OSA tended to have higher percentages of missing 
BMI percentile data. Little MCAR test was conducted on the BMI variable and showed the data 
were not missing at random (Chi2 = 24.4, df =1, p = 0.00). The missing data was dealt with via 
multiple imputation. Multiple imputation makes no assumptions about the type of missing data 
(random or non-random) and can be applied to time-series data (Tabachnik & Fidell, 2013). 
Therefore, multiple imputation was used (5 imputations) to estimate BMI from variables that 
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were complete and known to predict BMI (age, gender and weight). The missing data was 
replaced with the pooled results of the imputations. 
Table 17  
 
Frequency of Missing BMI Percentile Data 
 
  Missing  
N (%) 
Gender M= 467 (15.6) 
F= 374 (14.4) 
Age 0-4.9 = 458 (22.2) 
5-9.9 = 284 (11.5) 
10-18 = 99 (9.3)  
Race White = 705 (15.6) 
Non-White= 121 (13.2)  
Missing = 15 (8.8) 
Insurance 
Status 
Public= 422 (14) 
Private= 396 (15.8) 
Self = 23 (24) 
Primary 
Diagnosis 
OSA = 481(11.3) 
Non-OSA = 360 (26.7) 
 
 
Descriptive Analysis 
 
Descriptive statistics were generated for demographics, clinical characteristics and opioid 
prescribing for each study year as summarized in Tables 18-20. A total of 5603 children 
underwent tonsillectomy and/or adenoidectomy during the study period. On the whole, the 
number of procedures increased over time. Male and female patients underwent the procedure at 
similar rates. Tonsillectomy and/or adenoidectomy was most often performed in children age 5-
9.9 years. A greater proportion of the sample were White children. Children with public or 
private insurance appeared to undergo the procedure at comparable rates. Most children had a 
normal body habitus. The percentage of opioid prescribing decreased over time and the trend in 
the type of opioid prescribed changed with time (see Figure 8). Hydrocodone was the most 
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commonly prescribed opioid in the early study period (years 1 and 2) whereas oxycodone was 
more commonly prescribed in subsequent years. Codeine prescribing was low throughout the 
study period, ranging from 0-3.6%. Demographic and clinical composition of the study groups 
(pre-and post-FDA warning groups) will be discussed below.  
 
Figure 8. Histogram of Study Year by Opioid Type 
 
Table 18 
 
Yearly Demographic Characteristics of the Sample 
 2010* 2011 2012 2013** 2014 2015 2016 2017 2018*** 
Sample 
size 
493 521 474 475 695 732 749 862 602 
Gender  
Males  
N (%) 
262 
(53.1) 
274 
(52.6) 
262 
(55.3) 
254 
(53.5) 
377 
(54.2) 
378 
(51.6) 
403 
(53.8) 
473 
(54.9) 
319  
(53) 
Females  
N (%) 
231 
(46.9%) 
247 
(47.4) 
212 
(44.7) 
221 
(46.5) 
318 
(45.8) 
354 
(48.4) 
346 
(46.2) 
389 
(45.1) 
283  
(47) 
Age 
(years) 
 
0-4.9 
N (%) 
175 
(35.5) 
219 
(42) 
177 
(37.3) 
189 
(39.8) 
280 
(40.3) 
250 
(34.2) 
271 
(36.2) 
301 
(34.9) 
202 
(33.6) 
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5-9.9 
N (%) 
220 
(44.6) 
227 
(43.6) 
206 
(43.5) 
194 
(40.8) 
274 
(39.4) 
335 
(45.8) 
328 
(43.8) 
400 
(46.4) 
286 
(47.5) 
10-18 
N (%) 
98 
(19.9) 
75 
(14.4) 
91 
(19.2) 
92 
(19.4) 
141 
(20.3) 
147 
(20.1) 
150 
(20) 
161 
(18.7) 
114 
(18.9) 
Race  
White 
N (%) 
406 
(82.4) 
434 
(83.3) 
391 
(82.5) 
394 
(82.9) 
567 
(81.6) 
601 
(82.1) 
605 
(80.8) 
667 
(77.4) 
450 
(74.8) 
Non-white 
N (%) 
84  
(17) 
81 
(15.5) 
78 
(16.5) 
73 
(15.4) 
110 
(15.8) 
107 
(14.6) 
112 
(15) 
152 
(17.6) 
118 
(19.6) 
Missing 
N (%) 
3  
(0.6) 
6  
(1.2) 
5  
(1.1) 
8  
(1.7) 
18  
(2.6) 
24  
(3.3) 
32  
(4.3) 
43  
(5) 
34  
(5.6) 
Insurer  
Public  
N (%) 
242 
(49.1) 
300 
(57.6) 
251 
(53) 
255 
(53.7) 
346 
(49.8) 
381 
(52) 
411 
(54.9) 
475 
(55.1) 
349  
(58) 
Private  
N (%) 
249 
(50.5) 
219 
(42) 
222 
(46.8) 
220 
(46.3) 
302 
(43.5) 
312 
(42.6) 
336 
(44.9) 
385 
(44.7) 
253  
(42) 
Self-Pay 
N (%) 
2  
(0.4) 
2  
(0.4) 
1  
(0.2) 
0 
 
47  
(6.8) 
39  
(5.3) 
2  
(0.3) 
2  
(0.2) 
0  
*Excludes January 2010 
**Excludes February & March 2013 
***Excludes May, June & December 2018 
Table 19 
 
Yearly Clinical Characteristics of the Sample 
 2010* 2011 2012 2013** 2014 2015 2016 2017 2018*** 
Body 
Habitus 
         
Original  
Normal  
N (%) 
83 
(16.8) 
162 
(31.1) 
212 
(44.7) 
227 
(47.8) 
325 
(46.8) 
391 
(53.4) 
389 
(51.9) 
422 
(49) 
300 
(49.8) 
Non-Normal 
N (%) 
86 
(17.4) 
170 
(32.6) 
223 
(47) 
200 
(42.1) 
281 
(40.4) 
303 
(41.4) 
325 
(43.4) 
397 
(46.1) 
266 
(44.2) 
Missing 
N (%) 
324 
(65.7) 
189 
(36.3) 
39  
(8.2) 
48 
(10.1) 
89 
(12.8) 
38  
(5.2) 
35  
(4.7) 
43  
(5) 
36 
(6) 
Imputed  
Normal 
N (%) 
352 
(71.4) 
319 
(61.2) 
245 
(51.7) 
268 
(54.6) 
400 
(57.6) 
423 
(57.8) 
420 
(56.1) 
460 
(53.4) 
331 
(54.9) 
Non-Normal 
N (%) 
141 
(28.6) 
202 
(38.8) 
229 
(48.3) 
207 
(43.6) 
295 
(42.4) 
309 
(42.2) 
329 
(43.9) 
402 
(46.6) 
271 
(45.1) 
Procedure 
Indication 
         
OSA 
N (%) 
180 
(36.5) 
391 
(75) 
371 
(78.3) 
388 
(81.7) 
543 
(78.1) 
590 
(80.6) 
594 
(79.3) 
710 
(82.4) 
490 
(81.4) 
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Non-OSA  
N (%) 
313 
(63.5) 
130 
(25) 
103 
(21.7) 
87 
(18.3) 
152 
(21.9) 
142 
(19.4) 
155 
(20.7) 
152 
(17.6) 
112 
(18.6) 
*Excludes January 2010 
**Excludes February & March 2013 
***Excludes May, June & December 2018 
Table 20 
 
Yearly Opioid Prescribing in the Sample  
 2010* 2011 2012 2013** 2014 2015 2016 2017 2018*** 
Opioid 
Prescribed 
         
Yes 
N (%) 
490 
(99.4) 
515 
(98.8) 
462 
(97) 
445 
(93.7) 
605 
(87.1) 
651 
(88.9) 
655 
(87.4) 
741 
(86) 
499 
(82.9) 
No 
N (%) 
3  
(0.6) 
6  
(1.2) 
12 
(3) 
30 
(6.3) 
90 
(12.9) 
81 
(11.1) 
94 
(12.6) 
121 
(14) 
103 
(17.1) 
Type of Opioid          
Acetaminophen 
w/ codeine  
N (%) 
6  
(1.2) 
5   
(1) 
12  
(2.5) 
17  
(3.6) 
18  
(2.6) 
21  
(2.9) 
1 
(0.1) 
5  
(0.6) 
3  
(0.4) 
Hydrocodone/ 
acetaminophen  
N (%) 
457 
(92.7) 
428 
(82.1) 
188 
(39.7)
  
114 
(24) 
42  
(6) 
35  
(4.8) 
39  
(5.2) 
2  
(0.2) 
0 
Oxycodone 
N (%) 
27  
(5) 
82 
(15.7) 
262 
(55.3) 
314 
(66.1) 
544 
(78.3) 
595 
(81.3) 
615 
(82.1) 
733 
(85) 
496 
(68.4) 
Oxycodone/ 
acetaminophen  
N (%) 
0 0 0 0 1  
(0.1) 
0 0 1 
(0.1) 
0 
*Excludes January 2010 
**Excludes February & March 2013 
***Excludes May, June & December 2018 
 
Table 21 shows the demographic summaries of children in the pre-and post-FDA warning 
periods. A total of 1527 tonsillectomy and/or adenoidectomy cases were performed in the pre-
FDA warning period and 4076 were performed in the post-FDA warning period. Pearson chi-
square tests for independence were used to assess for group differences in the categorical 
variables of gender, age, race, insurance status, body habitus and procedure indication. There 
were no differences in gender (p = 0.945), age (p = 0.110), race (p = 0.421) or insurance status (p 
= 0.209) in the pre-and post-FDA periods. The distribution of body habitus and procedure 
indication differed between the pre-and post-FDA warning periods. Compared with the pre-FDA 
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warning period, more children had a procedure indication of OSA in the post-FDA period (p < 
0.001).  Also, children in the post-FDA warning period had a greater frequency of having a non-
normal BMI percentile (p < 0.001). Therefore, stratified analyses were conducted on the 
subgroups of body habitus and procedure indication. 
Table 21 
 
Characteristics of the Sample in the Pre-and Post-FDA Warning Periods 
  Pre-FDA (N=1527) 
 
N (%) 
Post-FDA (N=4076) 
 
N (%) 
P-value 
Gender M=817 (53.5) 
F= 710 (46.5) 
M=2185 (53.6) 
F=1891 (46.4) 
0.945 
Age 0-4.9 = 591 (38.7) 
5-9.9 = 668 (43.7) 
10-18 = 268 (17.6) 
0-4.9 = 1473 (36.1) 
5-9.9 = 1802 (44.2) 
10-18 = 801(19.7) 
0.100 
Race White = 1268 (83) 
Non-White = 245 (16.1) 
Missing = 14 (0.9) 
White = 3247 (79.7) 
Non-White= 670 (16.4) 
Missing = 159 (3.9) 
0.421 
Insurance 
Status 
Public = 811 (53.1) 
Private = 711 (46.6) 
Self = 5 (0.3) 
Public= 2199 (53.9) 
Private= 1787 (43.8) 
Self = 90 (2.2) 
0.209 
Body Habitus  Normal = 939 (61.6) 
Non-Normal= 586 (38.4) 
Normal= 2277 (55.8) 
Non-Normal= 1798 (44.2) 
< 0.001* 
Procedure 
Indication  
OSA = 970 (63.4) 
Non-OSA = 557 (36.6) 
OSA = 3287 (80.6) 
Non-OSA = 789 (19.4) 
< 0.001* 
*Chi2 analysis, two tailed p-value set to a significance of 0.05 
 
 
Additional comparisons were made during descriptive analysis to assess baseline opioid 
prescribing in the pre-FDA warning periods. As shown in Table 22, opioid prescribing did not 
appear to differ by demographic or clinical characteristics in the pre-FDA warning period. Based 
on visual inspection of simple time series line plots (see Figures 9a-c), age, procedure indication 
and body habitus appeared to influence opioid prescribing. Additional analytical models were 
conducted to explore the impact of the FDA warning in these subgroups.  
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Table 22 
 
Opioid Prescribing in the Pre-FDA Warning Period 
Pre-FDA 
Warning 
Opioid Y  
(N= 1504) 
Opioid N 
(N=23) 
P-value 
Gender 
Male 
Female 
 
802 (98.2) 
702 (98.9) 
 
15 (1.8) 
8 (1.1) 
 
0.256 
Age 
0-4.9 years 
5-9.9 years 
10-18 years 
 
580 (98.1) 
658 (98.5) 
266 (99.3) 
 
11 (1.9) 
10 (1.5) 
2 (0.7) 
 
0.462 
Race 
White 
Non-White 
 
1249 (98.5) 
241 (98.4) 
 
19 (1.5) 
4 (1.6) 
 
0.779 
Insurance 
Public 
Private  
 
803 (99) 
696 (97.9) 
 
8 (1) 
15 (2.1) 
 
0.073 
Procedure 
Indication 
OSA 
No OSA 
 
 
957 (98.7) 
547 (98.2) 
 
 
13 (1.3) 
10 (1.8) 
 
 
0.428 
Body Habitus 
BMI Normal 
BMI Non-Normal 
 
927 (98.6) 
577 (98.3) 
 
13 (1.4)  
10 (1.7) 
 
0.669 
*Chi2 analysis, two tailed p-value set to a significance of 0.05 
 
 
 
  
 
 
Figure 9a. Simple Time Series Plots of Opioid Prescribing in All Children & Subgroup Gender 
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Figure 9c. Simple Time Series Plots of Opioid Prescribing in Subgroups Age, Procedure 
Indication & Body Habitus 
 
  
 
Figure 9b. Simple Time Series Plots of Opioid Prescribing in Subgroups Gender & Insurance Status 
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Statistical Analysis 
 
Data was imported from SPSS into Stata and analyzed in Stata using the itsa command. 
An ITS analysis using segmented linear regression was used to compare opioid prescribing 
before and after the FDA warning. Time periods 1-9 comprised the preintervention segment and 
time periods 10-26 were the postintervention segments. The rate (percentage) of opioid 
prescribing (codeine or other opioids) was used as the outcome measure. The rate of prescribing 
was calculated as the number of prescriptions per time period divided by the total number of 
cases per time period. Statistical models were analyzed to assess level or slope changes in opioid 
prescribing over time. Additional estimates were generated from the posttrend command in 
Stata. Posttrend provides estimates of the postintervention trend (b1 + b3), considering both the 
preintervention trend (b1) and the difference in pre-and post-intervention trends (b3). The 
posttrend estimate shows the average percentage of opioid prescribing at each interval after the 
FDA warning. The coefficients of the models were estimated by ordinary least-squared 
regression. The regression equation used was: 
Yt= b0 + b1*timet + b2*interventiont + b3*time after +et 
 
Where Y = mean number of prescriptions in month t 
time = time in months at time t from the start of the observation period 
intervention = time t occurring before or after the FDA warning 
time after = number of months after the FDA warning at time t 
b0 = baseline level of number of prescriptions per month at time zero 
b1 = change in the mean number of prescriptions that occurs with each time period pre-FDA 
warning (preintervention trend) 
b2 = level change in the mean number of monthly prescriptions immediately after the FDA 
warning 
b3 = trend change in the mean number of monthly prescriptions after the FDA warning, 
compared with the monthly trend before the FDA warning 
et = error term at time t represents variation not explained by the model  
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Separate ITS models were conducted for hypothesis testing. First, codeine and other 
opioid prescribing in the pre-and post-FDA warning periods was assessed for the entire sample 
(all children undergoing tonsillectomy and/or adenoidectomy), then subgroups were analyzed. 
Subgroup analyses included insurance status, age, procedure indication and body habitus. These 
subgroups were included based on the aims of the study and findings during descriptive analysis.  
Opioid Prescribing in All Children 
 
Prior to subgroup analyses, data were analyzed for opioid prescribing in all children 
undergoing tonsillectomy and/or adenoidectomy during the study period. Two models were 
performed: (1) Codeine prescribing (2) Other opioid prescribing in all children. Prescribing was 
expressed in percentages where the number of opioid prescriptions (codeine or other opioids) per 
time period was divided by the total number of cases per time period. Results are presented and 
discussed below.  
Codeine Prescribing in All Children 
 
 
Figure 10. Time Series Graph of Codeine Prescribing in All Children 
 
As shown in the Table 23, the starting level of codeine prescribing in all children 
undergoing tonsillectomy and/or adenoidectomy was estimated at 0.97%. Codeine prescribing 
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did not significantly change in the time periods prior to the FDA warning (p = 0.139). In the first 
time period of the FDA warning, there was not a significant decrease in codeine prescribing (p = 
0.275). The difference between the pre-and post-intervention slopes was significant (p = 0.004, 
CI = [-.66, -.15]). The postintervention trend in codeine prescribing was significant and negative 
(p = 0.001, CI = [-0.33, -0.14]. Figure 10 illustrates the time series graph for codeine prescribing 
in all children. The predicted codeine prescribing line in the pre-intervention period did not 
appear to fit the observed data well. Additional models were generated including a Newey-West 
model with a linear smoother (itsa smoother) and a generalized linear model (itsa Prais). Results 
were comparable and therefore the original model was retained.  
These results indicate the FDA warning did not have an abrupt (level) effect on codeine 
prescribing. However, a significant slope change suggests a treatment effect over time, or a 
gradual downward trend in codeine prescribing after the FDA warning. After introduction of the 
FDA warning, codeine prescribing decreased every time period in the post-intervention period at 
a rate of 0.23%. 
Other Opioid Prescribing in All Children 
 
 
Figure 11. Time Series Graph of Other Opioid Prescribing in All Children 
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As shown in the Table 23, the starting level of other opioid prescribing in all children 
undergoing tonsillectomy and/or adenoidectomy was estimated at 98.8%. Other opioid 
prescribing appeared to decrease every time period prior to the FDA warning by 0.5% (p = 
0.019, CI = [−0.92, -0.09]). In the first time period of the FDA warning, there was a significant 
decrease in other opioid prescribing by 5.9% (p = 0.019, CI = [-10, -.1.0]). The difference 
between the pre-and post-intervention slopes was not significant (p = 0.35). The postintervention 
trend in other opioid prescribing was significant and negative (p = 0.05, CI= [-0.6, -0.01]). 
Figure 11 illustrates the time series graph for other opioid prescribing in all children. 
These results indicate an abrupt intervention effect (level change) rather than a gradual 
treatment effect. Immediately after the FDA warning, other opioid prescribing in all children 
undergoing tonsillectomy and/or adenoidectomy decreased by 5.9%. Opioid prescribing 
continued to decrease by 0.31% each time interval following the FDA warning.  
Table 23 
 
Regression Table for Codeine and Other Opioid Prescribing in All Children 
Variable Coefficient Estimates t-statistic P-value 95% Confidence 
Interval 
Codeine 
Prescribing 
[All children] 
b0 (Intercept)* 0.97 2.14 0.043 0.03, 1.9 
b1 (Pre-Slope) 0.17 1.53 0.139 -0.06, 0.4 
b2 (Level change) 0.98 1.12 0.275 -0.83, 2.8 
b3 (Slope change) -0.40 -3.25 0.004** -.66, -.15 
b1 + b3 (Post-Slope) -0.23 -5.02 0.001** -0.33, -0.14 
      
Other Opioid 
Prescribing 
[All children] 
b0 (Intercept) 98.8 142.2 0.000 97.3, 100.2 
b1 (Pre-Slope) -0.51 -2.53 0.019 -0.92, -0.91 
b2 (Level change) -5.95 -2.50 0.02* -10.8, -1.02 
b3 (Slope change) 0.19 0.95 0.354 -0.23, 0.63 
b1 + b3 (Post-Slope) -0.31 -2.12 0.045** -0.61, -0.01 
* The intercept represents the start of the data series; the p-values and/or confidence intervals are 
not useful in interpretation. 
**significance p £ 0.05 
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Opioid Prescribing Based on Insurance Status 
 
To accomplish the study’s aims, ITS models were performed to evaluate opioid 
prescribing in publicly and privately insured children. Self-insured children were not included in 
the statistical models. Prescribing was expressed in percentages where the number of opioid 
prescriptions (codeine or other) in each group per time period was divided by the total number of 
cases in each group per time period. For example, codeine prescribing in publicly insured 
children was expressed as: Total # of codeine prescriptions in publicly insured children per time 
period (numerator) / Total # of cases in publicly insured children per time period (denominator). 
Models were performed to evaluate codeine and other opioid prescribing in each group, 
addressing H1 and H3. Additional models compared codeine (H2) and other opioid (H4) 
prescribing between groups. 
H1: Codeine Prescribing in Publicly and Privately Insured Children  
 
The first aim of this study evaluated codeine prescribing in publicly and privately insured 
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the 2013 
FDA warning on codeine and tested the following hypothesis (H1): In publicly and privately 
insured post-tonsillectomy and/or adenoidectomy children at OHSU, rates of codeine prescribing 
(level and/or trend) decreased following the 2013 FDA warning on codeine. Separate single 
group ITS analyses were performed for codeine prescribing in publicly and privately insured 
children, as presented below. 
 
 
 
 
 
 
 
 
 
 87 
Codeine Prescribing in Publicly Insured Children 
 
 
Figure 12. Time Series Graph of Codeine Prescribing in Publicly Insured Children 
 
 
As shown in Table 24, the starting level of codeine prescribing in publicly insured 
children undergoing tonsillectomy and/or adenoidectomy was estimated at 0.8%. Codeine 
prescribing did not appear to change significantly in time periods prior to the FDA warning (p = 
0.058). In the first time period of the FDA warning, there was no significant change in codeine 
prescribing (p = 0.146). The difference between the pre-and post-intervention slopes was 
significant (p = 0.003, CI = [-0.81, -0.2]). The postintervention trend in codeine prescribing was 
significant and negative (p = < 0.001, CI= [-0.46, -0.15]). Figure 12 illustrates the time series 
graph for codeine prescribing in publicly insured children. 
These results indicate the FDA warning did not have an abrupt (level) effect on codeine 
prescribing in publicly insured children. However, the slope of the regression line changed 
significantly after the FDA warning, suggesting a change in the trend of codeine prescribing in 
the post-FDA period. After the introduction of the FDA warning, opioid prescribing decreased 
every time period in the post-intervention period at a rate of 0.3%. These results indicate a 
gradual downward trend in codeine prescribing in publicly insured children. 
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Codeine Prescribing in Privately Insured Children 
 
 
Figure 13. Time Series Graph of Codeine Prescribing in Privately Insured Children 
 
As shown in Table 24, the starting level of codeine prescribing in privately insured 
children undergoing tonsillectomy and/or adenoidectomy was estimated at 1.2%. Codeine 
prescribing did not appear to change significantly in time periods prior to the FDA warning (p = 
0.394). In the first time period of the FDA warning, there was not a significant change in codeine 
prescribing (p= 0.611). The difference between the pre-and post-intervention slopes was 
significant (p = 0.034, CI = [-0.64, -0.03]). The postintervention trend in codeine prescribing was 
significant and negative (p = 0.006, CI= [-0.30, -0.09]). Figure 13 illustrates the time series graph 
for codeine prescribing in privately insured children. The predicted codeine prescribing line in 
the pre-intervention period did not appear to fit the observed data well. Additional models were 
generated including a Newey-West model with a linear smoother (itsa smoother) and a 
generalized linear model (itsa Prais). Results were comparable and therefore the original model 
was retained. 
The findings in privately insured children were similar to that of publicly insured 
children. There was not an immediate (level) change in codeine prescribing in publicly insured 
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children, but a significant slope change indicated a gradual reduction in codeine prescribing after 
the FDA warning. The trend of the time series after the FDA warning demonstrated that codeine 
prescribing decreased in privately insured children every time period in the post-intervention 
period at a rate of 0.14% and the decrease was significant.  
Table 24 
 
Regression Table for Codeine Prescribing in Publicly and Privately Insured Children 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Codeine 
Prescribing 
[Publicly 
insured] 
b0 (Intercept) 0.78 2.44 0.023 0.12, -1.4 
b1 (Pre-Slope) 0.2 2.00 0.058 -0.01, 0.41 
b2 (Level change) 1.32 1.5 0.147 -0.5, 3.1 
b3 (Slope change) -0.50 -3.41 0.003* -0.81, -0.2 
b1 + b3 (Post-Slope) -0.304 -3.96 < 0.001* -0.46, -0.15 
      
Codeine 
Prescribing 
[Privately 
insured] 
b0 (Intercept) 1.2 1.61 0.121 -0.35, 2.7 
b1 (Pre-Slope) 0.135 0.87 0.394 -0.19, 0.46 
b2 (Level change) 0.653 0.52 0.611 -1.96, 3.27 
b3 (Slope change) -0.33 -2.26 0.034* -0.64, -0.03 
b1 + b3 (Post-Slope) -0.19 -4.02 0.006* -0.30, -0.09 
*significance p £ 0.05 
 
The hypothesis was supported. Rates of codeine prescribing decreased in the post-FDA 
warning period in publicly and privately insured children. The change in codeine prescribing was 
not abrupt in either group, rather both groups demonstrated a more gradual downward trend in 
codeine prescribing. There was a significant slope change in codeine prescribing and significant 
downward (negative) slope of the postintervention trend in both groups, indicating codeine 
prescribing decreased after the FDA warning. 
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H2: Codeine Prescribing in Publicly versus Privately Insured Children  
 
 
Figure 14. Time Series Graph of Codeine Prescribing in Publicly versus Privately Insured 
Children   
 
The second aim of this study compared codeine prescribing in publicly and privately 
insured children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after 
the 2013 FDA warning on codeine and tested the following hypothesis (H2): There is a difference 
in codeine prescribing (level and/or trend) between publicly and privately insured post-
tonsillectomy and/or adenoidectomy children at OHSU.  A multiple group ITS was performed to 
compare codeine prescribing publicly and privately insured children. Additional parameters were 
added to the model (b4 - b7) for group comparison: 
b4: Difference in level of the outcome between treatment and control group prior to intervention 
b5: Difference in slope of the outcome between treatment and controls prior to intervention 
b6: Difference between treatment and control groups in the level of the outcome immediately 
following the intervention 
b7: Difference between treatment and control groups in the slope of the outcome after the 
intervention, compared with the preintervention. 
Posttrend: Difference in postintervention treatment versus control (b5 + b7) 
 
A key assumption to a multiple group ITS is that the change in the level or trend in the 
outcome variable is presumed to be the same for both groups. Parameters b4 and b5 play an 
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important role in establishing balance between treatment and control groups; groups that have p-
values > 0.05 on both b4 and b5 can be used as controls in the model (Linden & Adams, 2015). 
As shown in Table 25, the initial mean level and slope difference between privately and publicly 
insured children were not significant (p = 0.602 and p = 0.762, respectively), indicating the 
groups were comparable on baseline level and trend. There was no significant difference in 
treatment effect (level change) during the first time period of the intervention (p = 0.664) and no 
significant difference in pre–post trends among groups (p = 0.383). The postintervention trends 
between groups did not differ (p = 0.198). Figure 14 depicts the time series graph for publicly 
versus privately insured children. These results do not support the hypothesis. There does not 
appear to be a difference in codeine prescribing between publicly and privately insured children 
as a result of the FDA warning. 
Table 25 
 
Regression Table for Codeine Prescribing in Publicly versus Privately Insured Children 
Variable Parameter Coefficient t-statistic P-value 95% 
Confidence 
Interval 
Codeine 
Prescribing 
[Public versus 
Private] 
b4 (Baseline level) -0.43 -0.52 0.602 -0.18, 0.45 
b5 (Baseline trend) 0.065 0.35 0.762 -0.31, 0.44 
b6 (Level difference) 0.67 0.44 0.664 -2.42, 3.76 
b7 (Slope difference) -0.18 -0.88 0.383 -0.61, 0.24 
b5 + b7 (Post-Slope 
difference) 
-0.12 -1.3 0.198 -0.3, 0.06 
*significance p £ 0.05 
 
H3: Other Opioid Prescribing in Publicly and Privately Insured Children  
 
The third aim of this study examined other opioid prescribing (oxycodone, hydrocodone) 
in publicly and privately insured children who underwent tonsillectomy at OHSU before and 
after the 2013 FDA warning on codeine and tested the following hypothesis (H3): In publicly and 
privately insured post-tonsillectomy and/or adenoidectomy children at OHSU, rates of other 
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opioid prescribing (level and/or trend) increased following the 2013 FDA warning on codeine. 
Separate single group ITS analyses were performed for codeine prescribing in publicly and 
privately insured children, as presented below. 
Other Opioid Prescribing in Publicly Insured Children 
 
 
Figure 15. Time Series Graph of Other Opioid Prescribing in Publicly Children 
 
As shown in Table 26, the starting level of other opioid prescribing in publicly insured 
children undergoing tonsillectomy and/or adenoidectomy was estimated at 99.5%. Other opioid 
prescribing did not change significantly in time periods prior to the FDA warning (p = 0.068). In 
the first time period of the FDA warning, there was a significant decrease in other opioid 
prescribing by 6.4% (p = 0.022, CI = [-11.7, -.1.0]). The difference between the pre-and post-
intervention slopes was not significant (p = 0.214). The postintervention trend was not 
significant (p = 0.306). Figure 15 represents the time series graph for other opioid prescribing in 
publicly insured children. 
These results suggest an abrupt (level) treatment effect on opioid prescribing in publicly 
insured children, where the FDA warning resulted in a significant and immediate reduction in 
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opioid prescribing. The postintervention trend did not continue downward after the initial 
reduction in other opioid prescribing, rather prescribing remained relatively flat.  
Other Opioid Prescribing in Privately Insured Children 
 
 
Figure 16. Time Series Graph of Other Opioid Prescribing in Privately Children 
 
The starting level of other opioid prescribing in privately insured children undergoing 
tonsillectomy and/or adenoidectomy was estimated at 97.6% (see Table 26). Other opioid 
prescribing did not significantly decrease in time periods prior to the FDA warning (p = 0.108). 
In the first time period of the FDA warning, there was not a significant decrease in other opioid 
prescribing (p = 0.210). The difference between the pre-and post-intervention slopes was 
significant (p = 0.036, CI = [-.93, -.03]. The postintervention trend was significant and negative 
(p = <0.001, CI = [-1.04, -0.5]). Figure 16 shows the time series graph of other opioid 
prescribing in privately insured children. 
These results indicate the FDA warning did not have an abrupt (level) change on other 
opioid prescribing in privately insured children. However, a treatment effect over time (slope 
change) in other opioid prescribing in privately insured children was demonstrated. After the 
FDA warning, other opioid prescribing fell each time period by 0.75%.  
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Table 26 
 
Regression Table for Other Opioid Prescribing in Publicly and Privately Insured Children 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Other Opioid 
Prescribing 
[Publicly 
Insured] 
b0 (Intercept) 99.5 100.63 0.000 97.5, -101.6 
b1 (Pre-Slope) -0.55 1.92 0.068 -1.14, 0.44 
b2 (Level change) -6.37 -2.47 0.022* -11.7, -1.02 
b3 (Slope change) 0.389 1.28 0.214 -0.24,1.01 
b1 + b3 (Post-Slope) -0.16 -1.05 0.306 -0.48, 0.16 
      
Other Opioid 
Prescribing 
[Privately 
Insured] 
b0 (Intercept) 97.64 0.476 0.000 96.65, 98.62 
b1 (Pre-Slope) -0.27 -1.68 0.108 -0.6, 0.06 
b2 (Level change) -2.59 -1.29 0.210 -6.8, 1.6 
b3 (Slope change) -0.48 -2.23 0.036* -0.93, -0.03 
b1 + b3 (Post-Slope) -0.75 -5.32 <0.001* -1.04, -0.45 
*significance p £ 0.05 
 
The hypothesis was not supported; rates of other opioid prescribing did not increase 
following the FDA warning. Rather, rates of other opioid prescribing decreased in both publicly 
and privately insured children after the FDA warning. Interestingly, publicly insured children 
saw an immediate (level) change whereas privately insured children saw a gradual (slope) 
change in other opioid prescribing. Still, both groups had a significant reduction in other opioid 
prescribing in the post-FDA warning period. 
H4: Other Opioid Prescribing in Publicly versus Privately Insured Children 
 
Figure 17. Time Series Graph of Other Opioid Prescribing in Publicly versus Privately Insured 
Children 
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The final aim of this study compared other opioid prescribing in publicly and privately 
insured children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after 
the FDA warning on codeine and tested the following hypothesis (H4): There is a difference in 
alternative opioid prescribing (level and/or trend) between publicly and privately insured post-
tonsillectomy and/or adenoidectomy children at OHSU.   
A multiple group ITS was performed to compare other opioid prescribing in publicly and 
privately insured children. As discussed above, additional parameters (b4 - b7) were added to the 
model and coefficients b4 and b5 were assessed to assure comparable baseline estimates between 
groups. As shown in Table 27, the initial level and slope difference between publicly and 
privately insured children were not significant (p = 0.271 and p = 0.898, respectively), indicating 
the groups were comparable on baseline level and trend. There was no significant difference in 
treatment effect (level change) during the first time period of the intervention (p = 0.103) and no 
significant difference in pre–post trends among groups (p = 0.088). The difference in the trend of 
the time series after the FDA warning was significant (p = 0.007, CI = [0.71, 1.1]). However, this 
can be explained by the manner in which other opioid prescribing decreased in each group. 
Publicly insured children demonstrated and immediate (level) change followed by a relatively 
flat trend, whereas privately insured children demonstrated a slower downward trend in other 
opioid prescribing. Figure 17 illustrates the time series graph for other opioid prescribing in 
publicly and privately insured children. 
The hypothesis was not supported. Though there was a difference in the manner in which 
opioid prescribing changed (level versus trend), other opioid prescribing decreased in both 
publicly and privately insured children after the FDA warning. 
 
 
 
 96 
Table 27 
 
Regression Table for Other Opioid Prescribing in Publicly versus Privately Insured Children 
Variable Parameter Coefficient t-statistic P-value 95% 
Confidence 
Interval 
Other Opioid 
Prescribing 
[Public and 
Private] 
b4 (Baseline level) 1.31 1.11 0.271 -1.1, 3.6 
b5 (Baseline trend) -0.04 -0.13 0.898 -0.69, 0.61 
b6 (Level difference) -5.37 -1.66 0.103 -11.9, 1.14 
b7 (Slope difference) 0.63 1.74 0.088 -0.1, 1.4 
b5 + b7 (Post-Slope 
difference) 
0.59 -2.8 0.007* 0.17, 1.1 
*significance p £ 0.05 
 
Additional Analyses: Age, Procedure Indication & Body Habitus 
 
Descriptive analysis suggested that age, procedure indication and body habitus may 
influence opioid prescribing in children undergoing tonsillectomy. Additional models were 
performed for each variable. Results are presented and discussed below.  
Opioid Prescribing Based on Age 
 
As shown in Table 28, pre-intervention rates of codeine prescribing in children age 0-4.9 
years was estimated at 2.4%. Codeine prescribing in children age 0-4.9 years decreased after the 
FDA warning, evidenced by a significant slope change in the post-intervention period when 
compared with the preintervention period (p = 0.012, CI = [-1.5, -0.23]). In the postintervention 
period, codeine prescribing in children age 0-4.9 years decreased by 0.53% with each time 
period following the FDA warning (p = 0.001, CI = [-0.8, -0.3]). However, codeine prescribing 
in children age 5-9.9 and 10-18 years did not significantly decrease after the FDA warning (no 
level or slope change). This is likely due to very low pre-intervention codeine prescribing rates in 
these age subgroups. Pre-intervention codeine prescribing rates were 0.41% in children 5-9.9 
years and nearly 0% in children 10-18 years.  
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Table 28 
 
Regression Table for Codeine Prescribing Based on Age 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Codeine  
[0-4.9 years] 
b0 (Intercept) 2.4 1.65 0.114 -0.63, 5.4 
b1 (Pre-Slope) 0.38 1.2 0.241 -0.28, 1.04 
b2 (Level change) 2.11 0.9 0.380 -2.8, 7.0 
b3 (Slope change) -0.91 -2.75 0.012* -1.5, -0.23 
b1 + b3 (Post-Slope) -0.53 -4.7 0.001* -0.8, -0.3 
      
Codeine  
[5-9.9 years] 
b0 (Intercept) 0.41 0.94 0.358 -0.49, 1.3 
b1 (Pre-Slope) -0.38 -0.54 0.521 -0.16, 0.08 
b2 (Level change) 0.86 1.79 0.088 -0.14, 1.85 
b3 (Slope change) -0.008 -0.12 0.908 -0.15, 0.13 
      
Codeine  
[10-18 years] 
b0 (Intercept) 0.002 0.68 0.507 -0.005, 0.009 
b1 (Pre-Slope) -0.001    -0.69 0.495 -0.005, 0.01    
b2 (Level change) 0.205 0.98 0.340 -0.23, 0.64 
b3 (Slope change) -0.009  -0.79 0.437 -0.033, 0.015 
*significance p £ 0.05 
 
Other opioid prescribing in children age 0-4.9 was estimated at 98.9% (see Table 29). 
Other opioid prescribing abruptly decreased (level change) by 11.9% after the FDA warning (p = 
0.03, CI = [-2.7, 1.04]). Other opioid prescribing in the preintervention period in children age 5-
9.9 was estimated at 97.9%. Other opioid prescribing in this age group (5-9.9 years) did not 
abruptly decrease after the FDA warning, but a significant slope change suggests a gradual 
decrease in other opioid prescribing in the post-FDA warning period (p = 0.017, CI = [-0.86, -
0.09].  Other opioid prescribing was estimated at 99.8% for children age 10-18 years. Children in 
this age group did not experience a significant level or slope change in other opioid prescribing 
in the post-FDA warning period.  
Overall, it appears that the FDA warning had the most profound effect on codeine and 
other opioid prescribing in the youngest children (0-4.9 years). Figure 18 shows the time series 
graphs (codeine and other opioids) for children age 0-4.9 years. Children age 5-9.9 demonstrated 
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gradual changes in other opioid prescribing, but no change in codeine prescribing. The oldest 
children (age 10-18) did not demonstrate changes in codeine or other opioid prescribing. 
Table 29 
 
Regression Table for Other Opioid Prescribing Based on Age 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Other Opioids 
[0-4.9 years] 
b0 (Intercept) 98.9 41.8 0.00 94.01, 103.8 
b1 (Pre-Slope) -1.19 -2.09 0.05* -2.34, -0.01 
b2 (Level change) -11.87 -2.27 0.03* -2.7, -1.04 
b3 (Slope change) 0.54 0.93 0.364 -0.66, 1.73 
      
Other Opioids 
[5-9.9 years] 
b0 (Intercept) 97.9 92.89 0.000 95.8, 100.2 
b1 (Pre-Slope) 0.085 0.51 0.618 -0.26, 0.43 
b2 (Level change) 2.06 -1.67 0.109 -4.6, -0.5 
b3 (Slope change) -0.47 -2.57 0.017* -0.85, -0.09 
      
Other Opioids 
[10-18 years] 
b0 (Intercept) 99.8 120.5 0.00 98,1, 101.5 
b1 (Pre-Slope) -0.14 -0.63 0.536 -0.58, 0.31 
b2 (Level change) -0.41 -0.22 0.829 -4.3, 3.5 
b3 (Slope change) -0.02 -0.10 0.925 -0.53, 0.48 
*significance p £ 0.05 
 
 
 
Figure 18. Time Series Graphs of Codeine and Other Opioid Prescribing in Children Age 0-4.9 
years 
 
Opioid Prescribing Based on Procedure Indication 
 
Codeine prescribing in children with OSA was estimated at 0.9% in the preintervention 
period (see Table 30). Codeine prescribing did not significantly decrease in the time periods 
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prior to the FDA warning (p = 0.086). After the FDA warning, there was not a significant level 
change (p = 0.099). However, a significant postintervention slope change (compared to the 
preintervention slope) indicated a gradual reduction in codeine prescribing after the FDA 
warning (p = 0.004, CI = [-0.68, -0.15]). Findings were similar for codeine prescribing in 
children without OSA, where the FDA warning did not appear to abruptly decrease codeine 
prescribing (p = 0.729), but a slope change indicated a gradual reduction in codeine prescribing 
in the post-FDA warning period (p = <0.05, CI = [-1.13, -0.12]. When children with and without 
OSA were compared, there were no differences in the level (p = 0.928), slope (p = 0.963) or 
postintervention trends (p = 0.847) of codeine prescribing.   
Table 30 
 
Regression Table for Codeine Prescribing Based Procedure Indication 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Codeine 
Prescribing 
[OSA] 
b0 (Intercept) 0.9 1.8 0.086 -0.13, 0.42 
b1 (Pre-Slope) 0.19 1.73 0.099 -0.38, 0.42 
b2 (Level change) 0.80 0.83 0.413 -1.2, 2.8 
b3 (Slope change) -0.41 1.8 0.004* -0.68, -0.15 
b1 + b3 (Post-Slope) -0.22 -3.69 0.0013* -0.35, -0.1 
      
Codeine 
Prescribing 
[No OSA] 
b0 (Intercept) 0.06 0.05 0.964 -2.4, 2.55 
b1 (Pre-Slope) 0.33 1.21 0.283 -0.23, 0.9 
b2 (Level change) 0.62 0.35 0.729 -3.04, 4.2 
b3 (Slope change) -0.57 -2.12 0.046* -1.13, -0.12 
b1 + b3 (Post-Slope) -0.24 -4.07 0.005* -0.36, -0.12 
      
Codeine 
Prescribing 
[OSA versus no 
OSA] 
b4 (Baseline level) 0.84 1.21 0.23 -0.22, 0.89 
b5 (Baseline trend) -0.14 -0.48 0.631 -0.74, 0.45 
b6 (Level difference) -0.18 0.09 0.928 -3.87, 4.2 
b7 (Slope difference) 0.16 0.05 0.963 -2.36, 2.48 
b5 + b7 (Post-Slope 
difference) 
0.016 0.195 0.847 -0.15, 0.18 
*significance p £ 0.05 
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Other opioid prescribing in the preintervention period in children with OSA was 
estimated at 98.4% (see Table 31). Other opioid prescribing did not decrease significantly in the 
pre-intervention period (p = 0.062). After the FDA warning, there was an abrupt decrease in 
other opioid prescribing by 6.2% in children with OSA (p = 0.016, CI = [-11.2, -1.3]. The 
postintervention trend (relative to the preintervention trend) was not significant (p = 0.273) 
These findings indicated an immediate treatment effect in other opioid prescribing in children 
with OSA. The postintervention trend estimate was not significant suggesting that after the 
immediate reduction in other opioid prescribing, prescribing remained relatively flat. 
In children without OSA, other opioid prescribing in the preintervention period was 
estimated at 99.5%. Other opioid prescribing decreased significantly each time period in the pre-
intervention period by 0.9% (p = 0.009, CI = [-1.6, -0.3]. After the FDA warning, there was not a 
significant level or slope change. However, the postintervention trend was significant and 
negative (p = 0.038, CI = [-1.9, -.42]. Other opioid prescribing in children without OSA 
decreased by 1.2% each time period after the FDA warning.  
When other opioid prescribing in children with and without OSA was compared (see 
Figure 19), there was no difference in the immediate treatment effect (level) or differences in the 
pre-and postintervention slopes. However, there was a significant difference in the post-
intervention estimates. Other opioid prescribing decreased in children with OSA by 0.12% in 
each time period after the FDA warning whereas other opioid prescribing in children without 
OSA decreased by 1.2% (p = 0.01, CI = [0.7, 1.8]). After the immediate reduction in other opioid 
prescribing in children with OSA, prescribing remained relatively flat whereas the time series 
trend after the intervention continued to decrease for children without OSA.  
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Figure 19. Time Series Graph of Other Opioid Prescribing in Children with and without OSA 
 
Table 31 
 
Regression Table for Other Opioid Prescribing Based on Procedure Indication 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Other Opioid 
Prescribing 
[OSA] 
b0 (Intercept) 98.4 153.3 0.00 97.1, 99.7 
b1 (Pre-Slope) -0.35 -1.97 0.062 -0.73, 0.02 
b2 (Level change) -6.2 -2.60 0.016* -11.2, -1.3 
b3 (Slope change) 0.24 1.12 0.273 -0.2, 0.68 
b1 + b3 (Post-Slope) -0.11 -0.71 0.483 -0.45, 0.22 
      
Other Opioid 
Prescribing [no 
OSA] 
b0 (Intercept) 99.5 93.43 0.00 97.3, 101.7 
b1 (Pre-Slope) -0.93 -2.87 0.009* -1.6, -0.3 
b2 (Level change) -3.16 -0.85 0.403 -10.9, 4.5 
b3 (Slope change) -0.44 -1.21 0.238 -1.2, 0.31 
b1 + b3 (Post-Slope) -1.18 -3.23 0.004* -1.9, -0.42 
      
Other Opioid 
Prescribing 
[OSA versus no 
OSA] 
b4 (Baseline level) -1.09 -0.88 0.385 -3.6, 1.4 
b5 (Baseline trend) 0.57 1.54 0.130 -0.18, 1.3 
b6 (Level difference) -3.83 -0.7 0.489 -11.9, 5.8 
b7 (Slope difference) 0.68 1.62 0.113 -0.16, 1.5 
b5 + b7 (Post-Slope 
difference) 
1.06 2.67 0.01* 0.26, 1.8  
*significance p £ 0.05 
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Opioid Prescribing Based on Body Habitus 
 
Codeine prescribing in children with normal body habitus was estimated at 0.72% in the 
preintervention period (see Table 32). Codeine prescribing did not appear to decrease 
significantly in the preintervention period (p = 0.341), nor did it abruptly decrease after the FDA 
warning (p = 0.157). However, a significant slope change in codeine prescribing indicated a 
gradual reduction in codeine prescribing in the post-FDA warning period (p = 0.018, CI = [-0.89, 
-.0.1]). Findings were similar in children with non-normal body habitus. Codeine prescribing in 
children with non-normal body habitus was estimated at 1.1% in the preintervention period. 
Codeine prescribing did not decrease significantly in the preintervention period, nor did it 
abruptly decrease after the FDA warning. However, a significant slope change in codeine 
prescribing indicated a gradual reduction in codeine prescribing in the post-FDA warning period 
(p = 0.001, CI = [-0.48, -.1.62]).  
When codeine prescribing was compared in children with normal versus non-normal 
body habitus, there was no difference in the level (p = 0.949), slopes (p = 0.382) or 
postintervention trend estimates (p = 0.678). Codeine prescribing did not appear to differ in 
children with normal versus non-normal body habitus. 
Table 32 
 
Regression Table for Codeine Prescribing Based on Body Habitus 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Codeine 
Prescribing 
[Normal BMI] 
b0 (Intercept) 0.72 0.97 0.341 -0.82, 2.26 
b1 (Pre-Slope) 0.26 1.47 0.157 -0.11, 0.64  
b2 (Level change) 0.78 0.61 0.551 -1.89, 3.45 
b3 (Slope change) -0.49 -2.55 0.018* -0.89, -0.1 
b1 + b3 (Post-Slope) -0.23 -3.52 0.002* -0.36, -0.1 
      
Codeine 
Prescribing 
b0 (Intercept) 1.1 3.83 0.001 0.48, 1.62 
b1 (Pre-Slope) 0.1 1.04 0.311 -0.10, 0.30 
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[Non-Normal 
BMI] 
b2 (Level change) 0.89 1.01 0.325 -0.94, 2.7 
b3 (Slope change) -0.3 -2.93 0.001* 0.48, 1.62 
b1 + b3 (Post-Slope) -0.2 -5.9 <0.001* -0.27, -0.13 
      
Codeine 
Prescribing 
[Normal versus 
Non-Normal 
BMI] 
b4 (Baseline level) -0.33 -0.42 0.306 -0.09, 0.29 
b5 (Baseline trend) 0.16 0.80 0.427 -0.25, 0.57 
b6 (Level difference) -0.3 1.56 0.949 -3.2, 3.0 
b7 (Slope difference) -0.19 -0.88 0.382 -0.63, 0.25 
b5 + b7 (Post-Slope 
difference) 
-0.03 -0.41 0.687 -0.17, 0.12 
*significance p £ 0.05 
 
Other opioid prescribing in children with normal body habitus was estimated at 99.7% 
(see Table 33). Other opioid prescribing decreased by 0.8% in each time period in prior to the 
FDA warning (p = 0.028, CI = [-1.49, -0.1]. There was not a significant level or slope change, 
however the trend of the time series after the intervention shows a significant reduction in other 
opioid prescribing by 0.5% in each time period after the FDA warning (p = 0.003, CI = [-0.76, -
0.26]). In children with non-normal body habitus, other opioid prescribing was estimated at 
97.2% in the preintervention period and did not appear to change significantly in the time periods 
prior to the FDA warning (p =0.202). After the FDA warning, other opioid prescribing abruptly 
decreased (level change) by 6.88% (p = 0.022, CI = [-12.6, -1.1]). The postintervention slope, 
when compared with the preintervention slope, was not significant (p = 0.894). These results 
indicate an immediate rather than a delayed treatment effect in other opioid prescribing in 
children with non-normal body habitus. 
Other opioid prescribing did not appear to differ in children with normal versus non-
normal body habitus, however because of differences in baseline level (b4) and slope (b5) group 
comparisons may be biased and are not adequate for comparison. 
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Table 33 
 
Regression Table for Other Opioid Prescribing Based on Body Habitus 
Variable Parameter Coefficient t-statistic P-value 95% Confidence 
Interval 
Other Opioid 
Prescribing 
[Normal BMI] 
b0 (Intercept) 99.74 87.83 0.000 97.38, 102.1 
b1 (Pre-Slope) -0.8 -2.35 0.028* -1.49, -0.1 
b2 (Level change) -5.12 -1.95 0.063 -10.55, 0.31 
b3 (Slope change) 0.28 0.82 0.422 -0.43, 0.99 
b1 + b3 (Post-Slope) -0.51 -4.23 0.003* -0.76, -0.26 
      
Other Opioid 
Prescribing 
[Non-Normal 
BMI] 
b0 (Intercept) 97.2 244.7 0.000 96.4, 98 
b1 (Pre-Slope) -0.1 -1.32 0.202 -0.26, 0.06 
b2 (Level change) -6.88 -2.47 0.022* -12.64, -1.11 
b3 (Slope change) 0.03 0.14 0.894 -0.42, 0.48 
b1 + b3 (Post-Slope) -0.07 -0.31 0.76 -0.54, 0.4 
      
Other Opioid 
Prescribing 
[Normal versus 
Non-Normal 
BMI] 
b4 (Baseline level) 2.55 2.12 0.04* 0.12, 4.9 
b5 (Baseline trend) -0.69 -2.0 0.05* -1.39, 0.005 
b6 (Level difference) 1.75 0.46 0.648 -5.9, 9.45 
b7 (Slope difference) 0.25 0.62 0.541 -0.57, 1.1 
b5 + b7 (Post-Slope 
difference) 
-0.44 -1.72 0.09 -0.92 
*significance p £ 0.05 
 
Summary of Findings 
 
After the FDA warning, codeine and other opioid prescribing decreased in the entire 
sample. Interestingly, codeine prescribing gradually decreased over time whereas an immediate 
treatment effect was demonstrated in other opioid prescribing. Varying times of the treatment 
effect (immediate versus delayed) was commonly seen when analyzing subgroups. All subgroups 
demonstrating a reduction in codeine prescribing in the post-FDA warning period showed a 
gradual treatment effect. Other opioid prescribing decreased immediately in some subgroups, 
whereas it fell more gradually in others.  
Codeine and other opioid prescribing did not appear to be influenced by health insurance 
status. Both publicly and privately insured children demonstrated a reduction in codeine and 
 
 105 
other opioids after the FDA warning period. Decreases in codeine prescribing in both publicly 
and privately insured children were gradual and there were no differences in codeine prescribing 
when groups were compared. The timing of the treatment effect differed between groups when 
considering other opioid prescribing. An immediate change in other opioid prescribing was 
demonstrated in publicly insured children and a more gradual decrease in other opioid 
prescribing occurred in privately insured children.  
Age appeared to influence codeine and other opioid prescribing with the most notable 
impact on the youngest children in the sample. A gradual reduction in codeine prescribing and an 
immediate fall in other opioid prescribing were found in children age 0-4.9 years. Other opioid 
prescribing fell gradually in the post-FDA warning period in children age 5-9.9 years, but 
codeine prescribing did not change significantly in this age group. Neither codeine or other 
prescribing changed significantly in the oldest children in the sample (age 10-18 years). 
Children with a procedure indication of OSA or non-OSA demonstrated similar and 
gradual reductions in codeine prescribing after the FDA warning. Both groups saw a reduction in 
other opioid prescribing, but differed in terms of timing of the treatment effect. Children with 
OSA showed an immediate decrease in other opioid prescribing after the FDA warning; after this 
immediate reduction, other opioid prescribing remained relatively flat in the postintervention 
period. Children without OSA demonstrated a more gradual reduction in other opioid prescribing 
after the FDA warning; the post intervention trend in this group continued to decrease each time 
period after the FDA warning.  
Finally, children with normal or non-normal body habitus demonstrated similar and 
gradual reductions in codeine prescribing after the FDA warning. Again, both groups had a 
reduction in other opioid prescribing, but differed in terms of timing of the treatment effect. 
 
 106 
Other opioid prescribing fell gradually in children with normal body habitus, whereas children 
with non-normal body habitus demonstrated an immediate decrease in other opioid prescribing.  
Chapter Summary 
 
This chapter presented the descriptive and statistical analysis of the study. Using an ITS 
study design, patterns of opioid prescribing in children undergoing tonsillectomy and/or 
adenoidectomy were evaluated. The primary questions of this study sought to assess if health 
insurance status influenced opioid prescribing. Findings of this study revealed that both publicly 
and privately insured children saw significant reductions in codeine and/or other opioid 
prescribing after the FDA warning. Additional findings of interest included the effect of age, 
procedure indication and body habitus on opioid prescribing. Of these, young age appeared to 
influence prescribing to the greatest degree. Chapter Five will discuss the theoretical and 
practical implications of the results, limitations of the study and recommendations for future 
research.   
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Chapter 5: Discussion 
Chapter Introduction 
 
 This chapter reviews the study findings and explores the practical and theoretical 
implications of the findings. A brief synopsis of the study purpose, methodology and analyses 
are presented. Limitations are discussed and the chapter concludes with recommendations for 
future research.  
Summary and Overview of the Problem 
 
 Tonsillectomy, with or without adenoidectomy, is one of the most commonly performed 
pediatric surgeries in the U.S. (Baugh et al., 2011). The procedure and care of a child undergoing 
tonsillectomy and/or adenoidectomy is fairly routine – however, reports of deaths and near 
deaths highlight the significant complications that can occur in children undergoing the 
procedure. Many complications are related to medications that depress the respiratory drive, such 
as opioids. Opioids provide post-tonsillectomy analgesia, but they also lead to unwanted effects 
such as sedation and respiratory depression. Clinical and/or genetic risk factors further heighten 
the danger of post-tonsillectomy opioids. Obstructive sleep apnea (OSA) belongs to the 
continuum of sleep related breathing disorders and is a common indication for tonsillectomy 
and/or adenoidectomy. Children with OSA are sensitive to the respiratory depressant effects of 
opioids and experience a higher preponderance of perioperative adverse events (De Luca Canto 
et al., 2015; Goldman et al., 2013; Mitchell et al., 2019). Obesity, which increases the likelihood 
of developing OSA, also heightens a child’s risk of perioperative complications (Cote et al., 
2018; Patino et al., 2013). Additionally, it is well established that polymorphisms in the genes 
responsible for codeine metabolism contributed to several post-tonsillectomy and/or 
adenoidectomy deaths (Cote et al., 2014). As a result, the FDA contraindicated the use of 
codeine in all children undergoing the procedure by placing a Boxed Warning on the drug. The 
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2013 FDA warning advised health care professionals “to prescribe an alternative analgesic [to 
codeine] for postoperative pain control in children undergoing tonsillectomy and/or 
adenoidectomy” (U.S. FDA Drug Safety Communications, 2013).  
Recent analyses found a significant reduction in post-tonsillectomy and/or 
adenoidectomy codeine prescribing following the FDA warning, however these studies were 
conducted on a sample of children with private insurance (Chua et al., 2017; Van Cleve, 2017). It 
is unknown to what extent the FDA warning impacted codeine and alternative opioid prescribing 
rates in publicly insured children. Examining this problem in the context of an understudied 
population (publicly insured children) was important for two reasons. First, when compared to 
children with private insurance, rates of tonsillectomy and/or adenoidectomy are similar for 
children insured by Medicaid (Boss et al., 2012). Second, differences in opioid prescribing 
between publicly and privately insured children are documented (Donohue et al., 2019; 
Tomaszewski et al., 2018). Therefore, understanding prescribing behaviors in both publicly and 
privately insured children fills an important gap in the literature. 
Purpose of the Study and Research Questions 
 
 The purpose of this study was to investigate the relationship between the FDA warning 
and codeine/alternative opioid prescribing in publicly and privately insured children who 
underwent tonsillectomy and/or adenoidectomy at OHSU between 2010 – 2018. This study 
sought to answer two research questions: (1) What is the relationship between the FDA warning 
and codeine/alternative opioid prescribing in children who underwent tonsillectomy at Oregon 
Health and Science University (OHSU) between January 2010-December 2018? (2) Does the 
relationship between codeine and/or alternative opioid prescribing in pediatric post-tonsillectomy 
children who underwent tonsillectomy at OHSU between January 2010 and December 2018 vary 
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by health insurance status? Results of this study clarified the impact of the FDA warning on 
codeine/other opioid prescribing and compared prescribing between publicly and privately 
insured children.  
Review of Theory  
 
 The Donabedian model served as the framework for the study. Donabedian’s landmark 
article proposed three domains in which the quality of medical care can be assessed – structure, 
process and outcome (Donabedian, 1966/2005). The assumption of the model is that “good 
structure increases the likelihood of good processes, and good processes increase the likelihood 
of good outcomes” (Donabedian, 1988, p.1145). In this study, the structure arm of the triad was 
the FDA warning, the process arm was opioid prescribing practices and the outcome was the 
number of codeine/other opioid prescriptions prescribed before and after the FDA warning. 
Building on Donabedian’s theory, Coyle & Battles (1999) advocated that antecedent conditions, 
or personal and/or environmental factors that may influence the outcomes of care, be 
incorporated into the model. In this study, health insurance status was included as an antecedent 
condition that may influence opioid prescribing.     
Review of Methodology 
 
 A quasi-experimental, interrupted time series (ITS) study design was used to assess 
opioid prescribing before and after the FDA warning. This study included two time-series 
segments and one interruption. The pre-FDA warning period was the first time-series segment, 
the interruption was the FDA warning and the second time-series segment was the post-FDA 
warning period. The ITS methodology facilitated an understanding of prescribing patterns over 
time and evaluated the immediate and gradual effects of the FDA warning on codeine/other 
opioid prescribing. 
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Following IRB approval from VCU and OHSU, data was extracted from OHSU’s EHR 
(Epic Hyperspace®). The sample included children who underwent tonsillectomy and/or 
adenoidectomy at OHSU from 2010-2018. The data was cleaned, coded into categories (age, 
gender, race, insurance status, OSA status and body habitus) and prepared for analysis. 
Descriptive analysis was undertaken to provide basic information of the sample and to highlight 
potential relationships between variables. Statistical analysis addressed prescribing practices in 
all children and subgroups of interest, addressing all study hypotheses.  
Review of Study Findings and Application to the Literature 
 
Descriptive Findings  
 
 Several noteworthy findings during descriptive analysis were discovered.  First, the trend 
of opioid prescribing changed throughout the study years where a progressive decline in the 
percentage of children who received any opioid following tonsillectomy and/or adenoidectomy 
was demonstrated. A decrease in the percentage of children who were prescribed opioids 
occurred between 2013 and 2014, coinciding with the FDA warning; this will be further explored 
below. Additionally, the type of opioid prescribed changed over the study period. Hydrocodone 
was the most commonly prescribed opioid early in the study period (years 2010 and 2011) and 
prescribing continued modestly through 2013. Hydrocodone prescribing fell substantially in 
2014, corresponding with two events: (1) the U.S. Drug Enforcement Agency and Department of 
Justice’s rescheduling of hydrocodone products from Schedule III to Schedule II and (2) the 
FDA warning on codeine. Drug scheduling of opioids denotes their abuse potential (lowest abuse 
potential with Schedule IV and highest with Schedule I) – though scheduling also enables or 
prohibits providers to refill controlled substances (U.S. Department of Justice, 2014). The 
reduction in hydrocodone prescribing may be reflective of its scheduling change – however, 
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another plausible explanation exists. Like codeine, hydrocodone is a prodrug and requires 
substantial metabolism by the CYP2D6 enzyme to produce its active form (hydromorphone). 
Though there is insufficient information to understand whether different CYP2D6 phenotypes 
influence hydrocodone’s metabolism (and a dearth of case reports about pediatric 
overdose/toxicity with hydrocodone), it’s plausible that providers elected to avoid prescribing 
drugs that may demonstrate CYP2D6 phenotypic variability in drug metabolism. After 2014, 
oxycodone-containing products (which do not rely as substantially on CYP2D6 metabolism) 
became the most frequently prescribed opioid for pediatric post-tonsillectomy patients at OHSU. 
Interestingly, other studies found hydrocodone to be the opioid most frequently prescribed in the 
post-FDA warning era (Goldman et al., 2018; Chua et al., 2017; Van Cleve, 2017). These 
differences may be related to provider or institutional preferences. 
 Several demographic characteristics of the sample merit elaboration. First, the majority of 
the sample included children in the youngest or middle-age categories (age 0-4.9 and 5-9.9 years, 
respectively). This is consistent with prior studies (Boss et al., 2012) and logical when 
considering the incidence of OSA peaks between 2-8 years of age (Patino et al., 2013). Next, 
similar to other age-related studies, there was an incidental finding of an increase in OSA and 
non-normal body habitus over time. The percentage of children with OSA increased steadily 
from 2010-2018 and the percentage of children with a non-normal body habitus was greater in 
the post-FDA warning period. Finally, consistent with prior studies, this study demonstrated that 
tonsillectomy and/or adenoidectomy was performed at the same rate regardless of gender or 
insurer status (Boss et al., 2012). 
Statistical Analysis 
 
Opioid Prescribing in All Children  
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Before hypothesis testing, codeine/other opioid prescribing was analyzed in the entire 
sample. Other opioid prescribing fell abruptly after the FDA warning, yet codeine prescribing 
fell more gradually. This is in contrast to other similar studies, where codeine prescribing fell 
abruptly and other opioid prescribing slightly increased following the FDA warning (Chua et al., 
2017; Van Cleve, 2017). In this present study, codeine prescribing appeared to increase in the 
time periods preceding the FDA warning and remained unchanged or slightly higher in the time 
periods immediately following the FDA warning – thereafter, codeine prescribing began to fall. 
The reasons behind this are unclear and difficult to explain clinically or empirically. Observing 
changes in outcomes prior to a treatment is consistent with an “anticipation effect” (Malani & 
Reif, 2015) – however it would be assumed that providers would decrease (not increase) codeine 
prescribing in anticipation of the FDA warning. It is plausible that prescribing providers were 
unaware of the FDA warning – or were aware, yet initially disregarded the warning. Also, if 
providers did not observe codeine-related adverse events based on their prior experience with the 
drug, it is conceivable they were skeptical of the FDA warning. Gathering further evidence to 
substantiate the aforementioned was difficult. Given the study site was an academic health center 
in a large metropolitan area, it is likely information on the FDA warning was disseminated to 
prescribing providers. Thus, it is plausible that one or more providers did not initially change 
prescribing practices, explaining the slower decline in codeine prescribing following the FDA 
warning.  
Also, Chua et al. (2017) and Van Cleve (2017) found other opioid prescribing slightly 
increased following the FDA warning on codeine. In contrast, this present study found a 
significant decrease in other opioid prescribing in the post-FDA warning period. It’s conceivable 
that providers in this study reduced prescribing of other opioids (oxycodone and hydrocodone) 
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because they are stronger, higher-potency opioids with a greater perceived risk of adverse events. 
Also, rather than relying on opioids for post-tonsillectomy pain, providers may have responded 
to the FDA warning by incorporating non-opioid agents for post-tonsillectomy pain – resulting in 
a decrease in overall opioid prescribing. 
Opioid Prescribing Based on Insurance Status 
 
Following analyses of the health insurance subgroup, it was found that one of the four 
hypotheses was supported. Each hypothesis and its application to the literature will be discussed, 
below. 
H1: In publicly and privately insured post-tonsillectomy and/or adenoidectomy children at 
OHSU, rates of codeine prescribing (level and/or trend) decreased following the 2013 FDA 
warning on codeine.  
Rates of codeine prescribing decreased in both publicly and privately insured children after the 
FDA warning and therefore this hypothesis was supported. This present study observed a 
significant slope change in codeine prescribing in both groups, indicating a gradual decline in 
codeine prescribing in the post-FDA warning period. Prior studies showed a reduction in codeine 
prescribing after the FDA warning, yet evaluated prescribing in privately insured children only 
(Chua et al., 2017; Van Cleve, 2017). This study adds to the body of knowledge by 
demonstrating a reduction in codeine in both publicly and privately insured children. 
H2: There is a difference in codeine prescribing (level and/or trend) between publicly and 
privately insured post-tonsillectomy and/or adenoidectomy children at OHSU. 
Codeine prescribing did not differ between publicly and privately insured children and therefore 
this hypothesis was not supported. Literature pertaining to opioid prescribing practices in 
publicly versus privately insured children is scant and mixed. Some studies found children with 
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public insurance were more likely to receive an opioid (Donohue et al., 2019) while other studies 
found publicly insured children were less likely to receive an opioid (Tomaszewski et al., 2018). 
In this study, it was hypothesized that prescribing disparities may exist due to provider biases 
and/or clinical explanations. However, this study found equitable prescribing between public and 
privately insured children. These findings are encouraging, but add little clarity to the mixed 
evidence base.  
H3: In publicly and privately insured post-tonsillectomy and/or adenoidectomy children at 
OHSU, rates of other opioid prescribing (level and/or trend) increased following the 2013 FDA 
warning on codeine. 
Rates of other opioid prescribing decreased in both publicly and privately insured children and 
thus this hypothesis was not supported. Based on prior studies, it was hypothesized the FDA 
warning would result in an increase in other opioid prescribing as a result of substituting an 
alternative opioid for codeine (Chua et al., 2017; Van Cleve, 2017). However, a reduction in 
other opioid prescribing in privately and publicly insured children was found. In this current 
study, the FDA warning appeared to decrease prescribing of not only codeine, but also non-
codeine opioids. As discussed above, providers may have reduced other opioid prescribing in 
favor of non-opioid post-tonsillectomy analgesics.  
H4: There is a difference in alternative opioid prescribing (level and/or trend) between publicly 
and privately insured post-tonsillectomy and/or adenoidectomy children at OHSU.   
Other opioid prescribing did not differ significantly between publicly and privately insured 
children and therefore this hypothesis was not supported. Both groups demonstrated a reduction 
in other opioid prescribing in the post-FDA warning period, however the timing of the treatment 
effect differed. Publicly insured children saw an immediate and abrupt reduction in other opioid 
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prescribing compared to a more gradual reduction in privately insured children. This may be 
related to a higher baseline level of other opioid prescribing in publicly insured children (99.5%) 
when compared with privately insured children (97.6%). Also, publicly insured children in this   
study had a greater frequency of OSA (59.6% versus 40.4%) and a greater occurrence of a non-
normal body habitus (63.1% versus 39.6%) than did privately insured children – which may have 
prompted an abrupt treatment response in publicly insured children.  
Incidental Findings: Opioid Prescribing Based on Age, Procedure Indication and Body  
Habitus 
 
 Additional findings in various subgroups were of interest. The youngest children in the 
sample (0-4.9 years) had the highest starting level of codeine prescribing in the pre-FDA 
warning period (2.4%). Codeine, considered a relatively weak opioid, was initially thought to be 
safer than other stronger opioids. Prior to the FDA warning, the perceived safety profile of 
codeine may have given providers confidence to prescribe the drug to the youngest children. 
Codeine prescribing in children age 0-4.9 years decreased following the FDA warning, but 
prescribing did not change in children age 5-9.9 or 10-18 years. This is likely due to very low 
pre-intervention codeine prescribing rates in the latter age groups (0.41% and nearly 0%, 
respectively). Additionally, the youngest children saw a significant and immediate reduction in 
other opioid prescribing after the FDA warning whereas older children demonstrated a gradual or 
no reduction in other opioid prescribing. Two plausible explanations exist. First, younger 
children are higher risk for post-tonsillectomy respiratory compromise (Cote et al., 2015). Also, 
many of the post-tonsillectomy codeine-related deaths occurred in young children (2-10 years). 
These factors may have prompted providers to be more cautious in prescribing opioids to 
younger children. Next, it is documented that older children and adults report higher post-
tonsillectomy pain than younger children (Alm, Stalfors, Nerfeldt & Ericsson, 2017; Eriksson, 
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Nilsson, Bramhagen, Idvall & Ericsson, 2017), possibly explaining why other opioid prescribing 
was not reduced in children age 10-18 years. 
 Opioid prescribing based on procedure indication (OSA versus no-OSA) showed codeine 
prescribing fell gradually in both groups. Other opioid prescribing also fell in both groups, but 
the timing of the treatment effect differed. In children with OSA, an immediate reduction in 
other opioid prescribing occurred. This may be reflective of the heightened risk of perioperative 
adverse respiratory events in children with OSA. Canto et al. (2015) reported children with OSA 
have a 5-fold increase in the odds for perioperative respiratory events when compared to children 
without OSA. Also, studies reported unexpected post-tonsillectomy and/or adenoidectomy 
deaths and/or near deaths in children with suspected or confirmed sleep apnea (Coté et al., 2014; 
Goldman et al., 2013). Children without OSA also demonstrated a reduction in other opioid 
prescribing, though at a more gradual pace. Interestingly, the post-intervention slope of other 
opioid prescribing in children without OSA trended downward, but remained relatively flat in 
children with OSA. It is plausible that children without OSA underwent adenoidectomy only, 
which tends to be less painful and requires fewer opioid analgesics. Conversely, children with 
OSA likely underwent combined tonsillectomy and adenoidectomy, which is a more painful 
procedure – possibly explaining the relatively flat postintervention trend seen in this group.  
 Next, children with normal and non-normal body habitus experienced a decline in 
codeine and other opioid prescribing. Again, the timing of the treatment effect of other opioid 
prescribing differed. Children with non-normal body habitus showed an immediate reduction in 
other opioid prescribing whereas children with a normal body habitus demonstrated a more 
gradual decline. These findings may be explained given non-normal body habitus, particularly 
obesity, increases the risk for perioperative adverse respiratory events in children undergoing 
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tonsillectomy and/or adenoidectomy (Goldman et al., 2013; Mortensen et al., 2011). However, 
because of the distribution of the sample in this study, the non-normal body habitus category 
contained children who were underweight, overweight or obese. Therefore, it cannot be assumed 
that all children in the non-normal category were obese. Still, these findings illustrate that body 
habitus impacted the timing in which other opioid prescribing fell.  
Contribution to the Literature 
 
This study clarified the local impact of the FDA warning on codeine prescribing and 
added additional knowledge on codeine/other opioid prescribing in an understudied population. 
Prior studies evaluated pre-and post-FDA warning opioid prescribing in privately insured 
children only. This study expanded the knowledge base by including publicly insured children in 
the sample – and by comparing prescribing in publicly versus privately insured children. This 
study also illustrated opioid prescribing trends from 2010 – 2018 and provided information on 
the most commonly prescribed post-tonsillectomy opioids at OHSU. Additionally, this study 
evaluated opioids prescribed rather than opioids dispensed, which better assesses actual 
prescribing practices. Findings from this study are relevant both theoretically and practically, as 
discussed below. 
Study Implications   
 
Theoretical Implications 
 
 Quality of care was a central matter in this study. Using the Institute of Medicine’s 
conceptualizations of quality, this study defined quality in terms of safety (halting codeine 
prescribing) and equity of care (in all children, regardless of health insurance status). The 
Donabedian model served as a framework for how quality was measured in this study. Using the 
constructs of structure, process and outcome a linkage was made between the FDA warning 
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(structure), prescribing practices (processes) and number of opioid prescriptions (outcomes). 
Results of this study support the linkage where prescribing practices and the number of opioid 
prescriptions changed as a result of the FDA warning. This was evidenced by an immediate or 
gradual reduction in codeine and other opioid prescribing in the post-FDA warning period (main 
and subgroup analyses). However, differences in prescribing between publicly and privately 
insured children were not apparent – therefore health insurance status did not appear to be an 
antecedent factor that influenced outcomes. Still, Donabedian’s model served as a useful 
framework to evaluate the influence of structural and process-related factors on outcomes.  
Practical Implications 
 
 Results have practical implications for providers who prescribe opioids and care for 
children undergoing tonsillectomy and/or adenoidectomy. The FDA warning reduced both 
codeine and other opioid prescribing at OHSU. Rather than substituting other opioids for 
codeine, it appears the FDA warning prompted providers to prescribe less opioids, in general. 
This shift in prescribing is encouraging and aligns with recent recommendations to reduce opioid 
prescribing in pediatric tonsillectomy and/or adenoidectomy patients (Mitchell et al., 2019). 
Additionally, this current study revealed that oxycodone is now the most frequently prescribed 
opioid in pediatric tonsillectomy and/or adenoidectomy patients at the study site. This is an 
important finding as the knowledge base regarding the impact of pharmacogenetics on 
oxycodone metabolism in children develops. Though the CYP34A enzyme is the primary 
metabolic pathway of oxycodone, the enzyme CYP2D6 plays a partial role. Children with 
atypical CYP2D6 phenotypes (extensive metabolizers) appear to have higher exposure to 
oxycodone’s active metabolite, oxymorphone (Balyan et al., 2017). Oxycodone-related toxicity 
has not been reported in post-tonsillectomy children – however, providers should consider the 
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risks (clinical and genetic) of prescribing the drug. Also, results of this study offer an opportunity 
to reinforce the dangers of codeine prescribing in children undergoing tonsillectomy and/or 
adenoidectomy. Codeine prescribing in the latter study years was very low – however, there is 
evidence of some residual codeine prescribing (0.4% in 2018). This study serves as a useful 
reminder that codeine should be avoided in this population. Finally, this study illustrates that 
clinical risk factors appear to influence prescribing practices, at least to some extent. It should 
continue to be emphasized that young children, children with OSA or obese children are at 
greater risk for opioid-related adverse events.  
Limitations 
 
 This study has limitations. Although the ITS design is regarded as a strong quasi-
experimental research design, this study is observational and does not account for all factors that 
may influence opioid prescribing. Inherent to the ITS design, threats due to between or within-
group differences are minimized (Bernal et al., 2018; Kontopantelis et al., 2015). Still, 
demographic variables were collected and stratified analyses were conducted on groups that 
exhibited differences in the pre-and post-FDA warning periods. Next, an ITS design relies on 
equally spaced observation intervals and clear differentiation of the pre-and post-intervention 
periods. Because of inadequate sample size for monthly observation intervals, data were grouped 
into 4-month observation intervals. Fewer observation intervals may have resulted in loss of 
statistical power, however adequate observations at each observation interval likely offsets this. 
Finally, the pre-intervention trend of the variable codeine exhibited a somewhat irregular pattern. 
Violation of the assumption of linearity does not invalidate the analysis, but does weaken it. 
Attempts were made to transform the variable, but linearity was not markedly improved. 
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Retaining the variable in its original form allowed metrics of interpretation to be meaningful and 
consistent across groups.  
 Next, the EHR was used as the data collection tool in this study. The EHR is generally 
regarded as an unbiased data collection tool, however its accuracy relies on individual users who 
input the data. The BMI variable had considerable missing data due to missing height 
information from the EHR. The missing data was imputed from relevant variables (age, gender, 
weight) – still, this introduces bias into the variable. Also, the procedure indication variable 
(OSA versus no OSA) relies on CPT and/or ICD codes that tend to be more useful for billing 
purposes than clinical purposes. It is conceivable that some children who had evidence of a 
sleep-related breathing disorder – but did not have a formal sleep study – were not given a 
formal CPT and/or ICD diagnosis of OSA. Additionally, the non-OSA group in the post-
intervention period was small and estimates may be biased on account of small N. Age groups 
were uneven with the majority (>80%) of children in the 0-4.9- or 5-9.9-year categories, 
potentially introducing bias into the analyses of opioid prescribing in older children (10-18 
years).  Next, it was surprising that measurement error afflicted the opioid prescribing variable. 
As previously discussed, a plausible EHR technological fault led to a biased estimate of opioid 
prescribing in time period 25, necessitating data exclusion. However, a sensitivity analysis 
showed the data exclusion did not alter the analysis. Finally, the pharmacy informatics team was 
unable to extract the dose of opioid prescribed. The binary yes/no variable of opioid prescribing 
cannot account for possible opioid dose reductions that may have occurred in the post-FDA 
warning period. 
 The study site was a large, academic medical center and study findings may not 
generalize to other institutions or populations. Demographic characteristics of the sample, 
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surgical techniques and prescribing practices may differ across facilities. Also, this study 
included only children who underwent outpatient tonsillectomy and/or adenoidectomy. All 
children were assumed to be candidates for outpatient surgery, without major comorbidities. 
However, clinical characteristics were limited only to OSA status and body habitus; therefore, it 
cannot be determined if some children possessed additional comorbidities that may have 
influenced prescribing practices.  
 Combined procedures were intended to be excluded, though the data was not filtered for 
this exclusion. However, it was estimated by the otolaryngology team that only a small number 
of tonsillectomy and/or adenoidectomies were combined with other non-otolaryngology 
procedures. Further, data from OHSU’s perioperative patient registry (Multicenter Perioperative 
Outcomes Group e-system) showed < 5% of outpatient tonsillectomy and/or adenoidectomies 
were combined with other non-otolaryngology procedures. All opioids in the dataset were 
prescribed by otolaryngologists – which linked the opioid prescription to the tonsillectomy 
and/or adenoidectomy procedure. Still, combined procedures represent a potential confounder 
and limitation to the study. 
 Finally, no evidence of codeine, hydrocodone or oxycodone shortage were found via the 
U.S. FDA’s Drug Shortages Database. However, local shortages or supply chain disruptions 
cannot be excluded.  
Conclusions and Recommendations for Future Research  
 
 The 2013 FDA warning on codeine led to significant changes in codeine and other opioid 
prescribing in all children; insurance status did not appear to influence prescribing practices. 
Findings from this study are encouraging, but evidence regarding the medical treatment of 
publicly versus privately insured children remains mixed. Achieving equity in healthcare 
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delivery requires a comprehensive research agenda that considers all sociodemographic variables 
that may influence care, including health insurance status. Therefore, the influence of health 
insurance status on opioid prescribing should be further explored in future, larger-scale studies. 
These studies should be conducted in varied settings including perioperative, emergency 
department and primary care settings – in both academic and non-academic/community facilities. 
Additionally, qualitative or mixed-method studies may be beneficial to better understand 
possible implicit and/or explicit biases in prescribing practices and/or perceptions of regulatory 
drug warnings. Future studies should also consider variables not measured in this study, 
including surgical technique and dose of opioid prescribed. Next, further studies should ascertain 
the impact of genetic variation on oxycodone metabolism in children.  Finally, studies should 
examine whether non-opioid medications have been substituted for opioids. Tonsillectomy 
remains a painful procedure. Research should address the adequacy of analgesia as the opioid 
prescribing trend shifts downward.    
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Appendix A 
 
- ICD-9-CM codes:   
- 327.23 (OSA (pediatric)(adult)) 
- 780.57 (unspecified sleep apnea) 
- ICD-9-PCS codes: 
- 28.2 (tonsillectomy without adenoidectomy) 
- 28.3 (tonsillectomy with adenoidectomy) 
- 28.6 (adenoidectomy without tonsillectomy) 
- ICD-10-CM codes: 
- G47.33 (OSA (pediatric)(adult)) 
- G47.30 (unspecified sleep apnea)  
- ICD-10-PCS codes: 
- 0CTP0ZZ (resection of tonsils, open approach) 
- 0CTPXZZ (resection of tonsils, external approach) 
- 0CTQ0ZZ (resection of adenoids, open approach) 
- 0CTQXZZ (resection of adenoids, external approach) 
- 0C5P0ZZ (destruction of tonsils, open approach) 
- 0C5PXZZ (destruction of tonsils, external approach) 
- 0C5Q0ZZ (destruction of adenoids, open approach) 
- 0C5QXZZ (destruction of adenoids, external approach) 
- 0CBP0ZZ (excision of tonsils, open approach) 
- 0CBPXZZ (excision of tonsils, external approach) 
- 0CBQ0ZZ (excision of adenoids, open approach) 
- 0CBQXZZ (excision of adenoids, external approach) 
- CPT codes: 
- 42820, 42821, 42825, 42826, 42830, 42831, 42835, 42836 (Excision and 
Destruction Procedures on the Pharynx, Adenoids, and Tonsils) 
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Appendix B 
 
Time Period Months Intervention Period 
1 2-5 (Feb 2010 – May 2010) Pre 
2 6-9 (June 2010 – Sept 2010) Pre 
3 10-13 (Oct 2010 – Jan 2011) Pre 
4 14-17 (Feb 2011 – May 2011) Pre 
5 18-21 (June 2011 – Sept 2011) Pre 
6 22-25 (Oct 2011 – Jan 2012) Pre 
7 26-29 (Feb 2012 – May 2012) Pre 
8 30-33 (June 2012 – Sept 2012) Pre 
9 34-37 (Oct 2012 – Jan 2013) Pre 
10 40-43 (Apr 2013 – July 2013) Post 
11 44-47 (Aug 2013– Nov 2013) Post 
12 48-51 (Dec 2013 – Mar 2014) Post 
13 52-55 (Apr 2014 – July 2014) Post 
14 56-59 (Aug 2014 – Nov 2014) Post 
15 60-63 (Dec 2014 – Mar 2015)  Post 
16 64-67 (Apr 2015 – July 2015) Post 
17 68-71 (Aug 2015 – Nov 2015) Post 
18 72-75 (Dec 2015 – Mar 2016) Post 
19 76-79 (Apr 2016 – July 2016) Post 
20 80-83 (Aug 2016 – Nov 2016) Post 
21 84-87 (Dec 2016 – Mar 2017) Post 
22 88-91 (Apr 2017 – July 2017) Post 
23 92-95 (Aug 2017 – Nov 2017) Post 
24 99-99 (Dec 2017 – Mar 2018) Post 
25 100-103 (Apr 2018 – July 2018) Post 
26 104-107 (Aug 2018 – Nov 2018) Post 
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Appendix C 
 
Public Private 
AETNA DIRECT  
AETNA NETWORK AETNA NETWORK 
AETNA OHSU 250  
AETNA OHSU 60/50  
AETNA OHSU PPO 
ALLEGIANCE   
APWU 
ATRIO EXCHANGE 
BAY AREA HOSPITAL 
BC MEDADVANTAGE 
BCBS ILLINOIS 
BCBS MASSACHUSETTS 
BCBS MINNESOTA 
BCBS OUT OF STATE 
BEECH ST 
BLUE CROSS CALIFORNIA 
BLUE CROSS FEDERAL 
BRIDGESPAN EXCHANGE 
*CHAMPVA 
CIGNA 
CIGNA NETWORK 
COMMERCIAL GROUP 
CORESOURCE AETNA 
COVENTRY FIRST HEALTH 
FIRST CHOICE HEALTH 
GEHA 
GREAT WEST NETWORK 
GWH CIGNA 
HEALTH FUTURE MANAGED CARE 
HEALTHNET HMO/POS/EPO/CC 
HEALTHNET MEDICARE PPO 
HEALTHNET PPO 
HMA/RGA 
KAISER ADDED CHOICE 
KAISER PEDIATRIC 
LIFE TRAC TRANSPLANT 
LIFEWISE 
LIFEWISE IN NETWORK FIRST CHOICE 
LOOMIS COMPANY BENEFITS 
MERITAIN HEALTH 
MODA AFFINITY 
MODA BEACON 
MODA CONNEXUS 
MODA HEALTH ODS OHSU 250 
MODA HEALTH OHP ODS PLUS 
MODA MEDICARE PPO 
MODA OEBB CONNEXUS 
AGENCIES FEDERAL 
AMERIGROUP APPLE HEALTH 
CAREOREGON MEDICARE ADV 
CAWEM INPT 
CAWEM NON COV 
CCO ADVANCED HEALTH 
CCO ALLCARE HEALTH PLAN 
CCO CAREOR HEALTH SHARE 
CCO CASCADE HLTH ALLIANCE 
CCO COLUMBIA PACIFIC 
CCO EASTERN OR 
CCO FAMILYCARE INC 
CCO INTERCOMMUNITY HTLH 
CCO JACKSON CARE CONNECT 
CCO KAISER HEALTH SHARE 
CCO PACIFICSOURCE 
CCO PRIMARYHLTH JSPHN CTY 
CCO PROVIDENCE HLTH SHARE 
CCO TRILLIUM COMMUNITY 
CCO TUALITY HEALTH SHARE 
CCO UMPQUA HEALTH ALLIANCE 
CCO WILLAMETTE VALLEY COM HLTH 
CCO YAMHILL COMMUNITY 
CHPW APPLE HEALTH 
CHPW APPLE HEALTH 
CHPW CUP APPLE HEALTH 
COORD CARE APPLE HEALTH 
MEDICARE A & B 
CUP APPLE HEALTH 
IDAHO MEDICAID 
INDIAN HEALTH SERVICE 
MOLINA APPLE HEALTH 
MOLINA KAISER APPLE HEALTH 
OHP CAREOREGON PLUS 
OHP CAREOREGON STANDARD 
OHP CASCADE PLUS 
OHP DOCS PLUS 
OHP DOUGLAS PLUS 
OHP DOUGLAS STANDARD 
OHP FAMILY CARE PCO PLUS 
OHP FAMILY CARE PLUS 
OHP INTERCOMMUNITY PLUS 
OHP LANE PLUS 
OHP MARION POLK PLUS 
OHP MIDROGUE PLUS 
OHP PACIFICSOURCE PLUS 
OHP PACIFICSOURCE STANDARD 
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MODA OHSU PPO 
MODA PEBB 
MODA SUMMIT 
MODA SUMMIT PEBB 
MODA SYNERGY SUMMIT 
MULTIPLAN 
MULTIPLAN WRAP 
NALC 
PACIFICSOURCE 
PACIFICSOURCE HEALTHY KIDS 
ESSENTIALS/EXPLORER 
PHP OPEN IPCO 
PHP PEBB STATEWIDE 
PHP PERSONAL IPCO 
PREMERA OF WA ALASKA 
PRIVATE HEALTH CARE SYSTEMS 
PROV PREF DIRECT 
PROVIDENCE CHOICE PEBB 
PROVIDENCE EXCHANGE 
PROVIDENCE HEALTH 
PROVIDENCE HEALTH PERSONAL OPTION 
PROVIDENCE PREF 
REGENCE ACCESS 
REGENCE BC MEDADVANTAGE PPO 
REGENCE BCBS 
REGENCE BCBS OHSU PLUS 
REGENCE BCBS PAR 
SAMARITAN HEALTH  
SHRINERS 
*TRICARE 
*TRICARE WEST HEALTHNET 
TUALITY HEALTHCARE 
UMR UHC 
UNITED HEALTHCARE 
UNITED HEALTHCARE NETWORK 
UNITED HLTHCARE 
*VA COMMUNITY OUTSOURCE 
*VA TRIWEST 
OHP PCCM PLUS 
OHP PLUS OPEN CARD 
OHP PROV HEALTH PLUS 
OHP TUALITY HEALTHPLUS 
OMAP STANDARD 
OREGONS HEALTH CO OP 
PACIFICSOURCE MEDICARE 
PROJECT ACCESS NOW 
SAMARITAN HEALTHY KIDS 
SAMARITAN MEDICARE 
UHC WEST WA APPLE HEALTH 
WA COMM HEALTH 
WA MEDICAID CUP 
WA MEDICAID FEDERAL 
WARM SPRINGS MANAGED CARE 
*Health Insurance Coverage provided by the government to military personnel. Employment-
connected, not income based and therefore classified as private. 
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Appendix D 
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Appendix E 
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